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Abstract 
 
Takotsubo syndrome, also known as Takotsubo cardiomyopathy, broken heart syndrome 
and stress cardiomyopathy, is a form of acquired cardiac failure that typically occurs after a 
period of intense emotional or physical stress. Patients typically present with symptoms 
indicative of acute coronary syndrome, but angiography shows no culprit pathology. 
Ventricular imaging shows a hypokinetic apical, and often mid-LV, myocardium coupled with 
a hyperkinetic basal myocardium, although inverted Takotsubo variants with or without mid-
LV sparing have also been described. The majority of reported Takotsubo syndrome cases 
are in post-menopausal females, although it can occur in both males and females across a 
wide range of ages.  
 
Using a previously-described method of inducing transient apical dysfunction in male rats by 
administering IV high-dose adrenaline, ovariectomised females showed a far greater 
sensitivity to the same adrenaline dose than non-ovariectomised females, showing a higher 
mortality rate. 2-week estrogen replacement did ameliorate this increase in mortality, 
although vehicle-only minipumps also had some effect in reducing mortality in 
ovariectomised female rats. 2-week estrogen administration to male rats did not result in a 
significantly-different mortality rate.  
 
Attempts to recapitulate another Takotsubo syndrome model by administering IP high-dose 
isoprenaline demonstrated that choice of anaesthetic was crucial in allowing a necessary 
condition, hyperthermia, to occur, as maintenance of anaesthesia with isoflurane rather than 
ketamine-midazolam prevented this rise in body temperature caused by the administration of 
isoprenaline. Hyperthermia was found to be an essential condition for the induction of apical 
dysfunction in this model, although the removal of hyperthermia after the initiation of 
contractile dysfunction did not reverse the Takotsubo-like contractility pattern.  
 
Attempts to recreate the contractile dysfunction in the isolated heart were unsuccessful. 
However, imaging studies showed that adrenaline can induce a mitochondrial dysfunction in 
the isolated rat heart, with hyperthermia augmenting this effect.  
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1. Introduction 
 
1.1 Takotsubo syndrome: a primer 
 
Takotsubo syndrome (also known as Takotsubo cardiomyopathy, apical ballooning 
syndrome, ampulla cardiomyopathy, stress cardiomyopathy or broken-heart 
syndrome) is an acute and reversible form of heart failure that usually occurs after a 
period of intense emotional or physical stress (Tranter et al., 2013). Symptoms of 
Takotsubo syndrome (TTS) often mimic an acute myocardial infarction (AMI) and 
include chest pain and dyspnoea. An electrocardiogram (ECG) taken during the 
acute phase often exhibits ST-elevation, much like an AMI. However, upon 
diagnostic coronary angiography, no culprit coronary pathology can be found 
(although there have been a number of cases with bystander coronary artery 
disease).  
 
When an echocardiogram or contrast ventriculogram is performed, the typical TTS 
variant shows a hypokinetic/akinetic apical segment and hyperkinetic basal segment; 
the mid segment of the left ventricle (LV) is also often hypokinetic. Atypical variants 
include inverted TTS where the circumferential basal segments are hypokinetic, and 
mid-LV TTS, where both apex and base are spared from hypokinesia.  
 
TTS was first described in Japan in 1990, particularly when triggered by the anxiety 
of earthquakes (Satoh et al., 1990). Twenty five years later the exact mechanism of 
the myocardial stunning present in TTS is still unknown. A number of hypotheses 
have been proposed over the twenty five years, some of which have since been 
disproved, whereas others are still viable. Furthermore, although the association with 
intense stress is well understood, and plasma catecholamines are thought to be 
raised at the time of presentation (Wittstein et al., 2005), the link between circulating 
stress hormones and the clinical syndrome is disputed by some (Madias, 2015). 
Many commentators state that TTS is a benign disease, especially as it could be the 
better alternative to a catecholamine-induced arrhythmic death (Dastidar et al., 
2015). There is however a growing evidence to show that, at the time of 
presentation, patients with TTS are at a greater risk of arrhythmias, mostly through 
the prolonged QT interval and risk of torsade de pointes, but also increase there is 
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increased risk of mortality in the long-term (Redfors et al., 2015). However, this has 
yet to be confirmed beyond a single study.  
 
1.2 Clinical features of Takotsubo syndrome 
 
With a growing awareness of TTS since its first description in 1990, there have been 
great efforts to characterise the clinical condition. TTS symptoms initially mimic an 
AMI. Plasma catecholamines are elevated beyond those of an AMI patient (Wittstein 
et al., 2005) and remain elevated for a number of days, indicating a centrally-driven 
stress rather than an abrupt catecholamine surge.  
 
1.2.1 Electrocardiographic changes associated with TTS 
 
ST-segment elevation, T-wave inversion and QT-interval prolongation can develop in 
TTS patients (Wright et al., 2014), with the increased QT-interval often a risk factor 
for ventricular arrhythmias, including torsades de pointes (Ahn et al., 2011; 
Samuelov-Kinori et al., 2009). It has been proposed that some ECG changes, along 
with plasma biomarker levels, could form part of a panel of discriminators between 
an AMI and TTS, one of which is relative T-wave inversion in aVr (i.e. a positive T-
wave in aVr) (Kosuge et al., 2012). J-waves and fragmented QRS complexes have 
also been observed in a number of patients in the acute phase of TTS (Shimizu et 
al., 2014) 
 
The cause of these ECG changes have not yet been fully established, although ST-
segment elevation in the setting of an AMI is due to transmural repolarisation 
heterogeneity mediated by activation of ischaemia-sensitive KATP channels 
preferentially in the epicardium and the same mechanism may be true for TTS (R. A. 
Li et al., 2000; Sclarovsky and Nikus, 2010). Furthermore, the T-wave inversion seen 
in TTS may be due to repolarisation dispersion due to prolonged action potentials in 
the area of contractile dysfunction (Furushima et al., 2008).  
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1.2.2 Circulating plasma biomarkers of TTS 
 
Circulating plasma biomarkers in TTS, much like the initial symptoms, can mimic an 
AMI, although there are a number of important differences. Compared to both an ST-
segment elevation MI (STEMI) and a non-STEMI (NSTEMI), plasma N-terminus pro-
brain natriuretic peptide (NT-proBNP) is significantly raised to high levels in TTS at 
24 hours after presentation, whereas the plasma troponin T (TnT) level is only mildly 
increased (Fröhlich et al., 2012). Fröhlich and colleagues proposed that the NT-
proBNP/TnT ratio could form part of a diagnostic test to distinguish between STEMI 
or NSTEMI and TTS. They also found that creatine kinase (CK) and myoglobin were 
also not greatly raised in TTS. Plasma brain natriuretic peptide (BNP) levels have 
also been found to be raised in TTS compared to STEMI (Madhavan et al., 2009). 
Neuropeptide Y (NPY) has also been shown to be increased in TTS (Szardien et al., 
2011), indicating a raised level of emotional stress and sympathetic activity as it is 
co-released with noradrenaline (Haass et al., 1989).  
 
The absence of significantly raised levels of CK, TnT or myoglobin imply that there is 
not a high level of cardiomyocyte damage and myonecrosis as there is in an AMI 
(Madhavan et al., 2009), whereas the raised NT-proBNP and BNP indicate an 
increased level of ventricular wall stress and distension (Kinnunen et al., 1993), 
perhaps in the apex during a typical TTS episode.  
 
Some microRNAs (miRNAs) may also be higher in the blood of TTS patients 
compared to STEMI patients, with one study implicating raised levels of miR-16 and 
miR-26a in TTS patients compared to STEMI, and raised miR-133a in STEMI 
patients compared to TTS (Jaguszewski et al., 2014). Both miR-16 and miR-26a are 
linked to the physiological response to stress, with studies showing miR-16 is 
upregulated in the plasma of healthy students after an acute stressor (Katsuura et 
al., 2012) and miR-26a is upregulated in brain tissue of stressed mice (Rinaldi et al., 
2010). This miRNA pattern shows a clear link between TTS and the body’s response 
to stress. However, samples were not taken before the onset of TTS, and therefore it 
cannot be determined whether this particular miRNA profile is linked to chronic 
stress, a predisposition to stress, or a sudden stress in this patient group. 
Furthermore, the source of the circulating miRNAs in TTS is not currently known.  
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There was also an increase in miR-1 in TTS patients (Jaguszewski et al., 2014), 
which is strongly linked to chronic heart failure (Karakikes et al., 2013), potentially 
showing a link between TTS and chronic heart failure that has yet to be determined.  
 
1.2.3 Molecular changes of the myocardium in TTS 
 
A number of molecular and structural changes in the heart occur in TTS, with most of 
the information regarding these from a series endomyocardial biopsy studies carried 
out by Nef and colleagues. Superoxide levels in biopsies taken from acute phase 
TTS (within 12 hours of presentation) showed increased superoxide levels compared 
to controls, and compared to samples taken 21 days later after the contractility deficit 
had resolved (Nef et al., 2008). This was associated with an increase in Nrf2-
mediated gene transcription. Decreases in mRNA levels for glucose and glycogen 
metabolism-associated proteins were also observed, indicating a shift from glucose 
and towards fatty acids as the main respiratory substrate of the myocardium. This is 
in contrast with the shift towards glucose metabolism in decompensated heart failure 
(HF) (Osorio et al., 2002), and may be part of the cardioprotective mechanism of 
TTS. Positron emission tomography imaging has shown a decrease in glucose 
uptake in the hypokinetic segment during acute TTS, perhaps indicating a metabolic 
stunning (Bonnemeier et al., 2006; Kurowski et al., 2007). Intracellular lipid 
accumulation has also been observed in acute TTS (Shao et al., 2013b): although its 
role in TTS pathophysiology is currently unknown, lipid accumulation is linked to 
increased oxidative stress, mitochondrial dysfunction and cardiac failure (Chiu et al., 
2001; Sharma et al., 2004).  
 
Akt-1 activation has been shown to be increased in 12 hour endomyocardial 
samples, which also returns to baseline levels after functional recovery has occurred 
(Nef et al., 2009a). This is also a cardioprotective mechanism: Akt-1 activation is 
linked to physiological hypertrophy, and a reduction in the Akt/mTOR pathway has 
been associated with pathological hypertrophy that occurs in the compensation 
phase of HF (Kemi et al., 2008). The mechanism of Akt-1 activation in TTS is 
unknown, but it has been reported that β2AR signalling, which is thought to be critical 
in TTS induction (see below), can modulate the PI3K/Akt pathway (Chesley et al., 
2000; Zhang et al., 2011).   
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Sarcoplasmic Ca2+-ATPase 2a (SERCA2a) expression has been shown to be 
reduced in acute TTS samples, the phospholamban/SERCA2a ratio was increased, 
and phospholamban (PLB) phosphorylation was decreased (Nef et al., 2009b). PLB, 
when dephosphorylated, inhibits SERCA2a function, decreasing the amount of Ca2+ 
that is taken back up into the sarcoplasmic reticulum (SR). PLB is phosphorylated on 
the serine-16 residue by protein kinase A (PKA), activated by the β-adrenoceptor 
signalling cascade. A reduced PLB phosphorylation level may indicate that β-
adrenoceptor signalling is in some way impaired in TTS (see below).  
 
1.2.4 Macroscopic structural changes of the myocardium in TTS 
 
Alongside the molecular changes that occur during TTS, there are a number 
macroscopic structural changes that the myocardium undergoes during acute TTS. 
These include contraction band necrosis, neutrophil infiltration, and fibrosis (Akashi 
et al., 2008). Although echocardiography has been invaluable in the characterisation, 
it has limited use in detecting subtle changes in the myocardium. With the increased 
use of cardiac magnetic resonance (CMR) imaging, a more precise calculation of left 
ventricular function can be made and, importantly to the characterisation of the 
disease, parameters such as myocardial oedema and late gadolinium enhancement 
(LGE) can be evaluated and correlated with other TTS parameters, such as ECG 
changes. 
 
Myocardial oedema is known to be present in TTS and correlates well with the 
region of hypocontractility (Perazzolo Marra et al., 2013). This oedema resolves fully 
within six months of the first presentation and does not leave scarring or any 
functional deficit. Whereas oedema is thought to be universal in TTS, the presence 
of LGE is controversial, often as LGE in TTS when present is subtle (Avegliano et 
al., 2011).  
 
In one study, LGE was present in five out of 15 patients; the LGE resolved within 15 
days of the initial CMR. Comparing endomyocardial samples from the LGE-positive 
patients with the LGE-negative patients, it was shown that collagen-1 levels are 
higher in LGE-positive patients (Rolf et al., 2009). The mechanism of LGE in TTS is 
not understood, but as the LGE has been shown to reverse in TTS, it could be due to 
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the delayed washout of gadolinium from the myocardium due to the transient 
increase in interstitial water content, rather than necrosis and irreversible fibrosis 
(Dastidar et al., 2015; Inoue et al., 1999). 
 
1.3 Proposed mechanisms of Takotsubo syndrome 
 
A great number of mechanisms for TTS have been proposed, and can be 
approximately categorised as being either vascular (e.g. vasospasm) or myocardial 
(e.g. direct catecholamine toxicity) in nature. None have been categorically proven to 
be the sole mechanism, and many may be at play simultaneously, or in different 
patients to give a final common disease pathway of TTS.  
 
1.3.1 Aborted myocardial infarction 
 
An aborted myocardial infarction (MI) is typically caused by the rupture of an 
atherosclerotic plaque and its necrotic core into the lumen of a coronary vessel, 
causing a thrombus to form that occludes the vessel, which then spontaneously and 
without medical intervention recanalises. There is no doubt that a brief period of 
ischaemia can, and does, cause a form of myocardial stunning. However, in typical 
TTS the area of hypokinesia (i.e. apex and often mid-LV) is greater than the area 
supplied by any one coronary vessel. Therefore, a single aborted MI could not cause 
the whole apex and mid-LV to be affected. Multi-vessel involvement is certainly a 
possibility (see below) but multi-vessel aborted MI is probably unlikely (note that no 
culprit coronary pathology can be noted with percutaneous coronary intervention 
(PCI) for a diagnosis of TTS to be made). 
 
Furthermore, the changes seen on the ECG during acute TTS remain during 
angiography (note that TTS and AMI patients should, on average, receive 
angiography at the same time after symptoms of an AMI have been reported) and do 
not mimic the ECG changes seen after mechanical or pharmacological 
recanalisation.  
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1.3.2 Multivessel vasospasm 
 
Unlike aborted MI, multivessel vasospasm is a potential candidate for a mechanism 
of TTS, and a number of multivessel vasospasm case reports have been published. 
In order for multivessel vasospasm to be the mechanism, all of the major coronary 
arteries would need to be spastic at a similar time. This phenomenon has been 
observed on a number of occasions, with one report showing 10% of 30 TTS 
patients exhibited spontaneous multivessel vasospasm and 43% of patients in 
response to ergonovine or acetylcholine. Another series of cases reported only 10% 
of multivessel vasospasm in response to acetylcholine.  
 
Multivessel vasospasm may certainly be the cause, or one of the causes, in a subset 
of TTS patients. However, many of the iatrogenic triggers, such as dobutamine 
stress echocardiography, are by nature vasodilators, and together with the fact that 
only a minority, albeit a significant minority, show multivessel vasospasm, the theory 
that vasospasm is the dominant cause of TTS is unsubstantiated. Nevertheless, in 
patients whose TTS does appear to be caused by multivessel vasospasm, this could 
have important implications for their management and should be noted.  
 
1.3.3 Microvascular dysfunction 
 
Of the vascular hypotheses, microvascular dysfunction is perhaps the most 
convincing. A number of studies have shown signs of microvascular dysfunction, 
such as reduced myocardial perfusion without macrovascular dysfunction, the 
presence of myocardial oedema, and the observation of late gadolinium 
enhancement (LGE) on MRI during TTS. Furthermore, microvascular dysfunction is 
associated with other conditions that predominate in the postmenopausal female 
(e.g. Syndrome X) and therefore it is tempting to involve it in this disease as well. 
However, as stated by myself and colleagues in a recent review, “microvascular 
dysfunction may be the result of apical dysfunction and its precipitants rather than its 
cause. Endothelial dysfunction is likely to be present after catecholamine surges with 
associated increases in shear stress without this necessarily being the primary 
cause of myocardial dysfunction. In addition, changes in muscle function may affect 
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blood flow, particularly in the microvasculature, which would be expected in TTC and 
has been well documented in other causes of LV dysfunction” (Tranter et al., 2013).  
 
1.3.4 Left ventricular outflow obstruction  
 
Left ventricular outflow obstruction (LVOTO) has been observed in a number of TTS 
cases, manifesting as a pressure gradient across the left ventricular outflow tract 
(LVOT). In four of these cases, the pressure gradient was recreated by dobutamine 
stress echocardiography (Merli et al., 2006). People who are predisposed to LVOTO, 
other than hypertrophic obstructive cardiomyopathy patients, may fit well with the 
typical TTS patient: an older woman (i.e. post-menopausal) with a smaller heart and 
prominent septal bulge that, during high levels of catecholamine stimulation, develop 
a dynamic LV obstruction in the midcavity.  
 
If this did occur, and there is evidence to suggest it does, the LV would be 
functionally divided into two chambers: the apical chamber under a high level of wall 
stress; and the basal chamber, under a normal or low level of wall stress. This high 
level of wall stress in the apex could be caused by an initially hypercontracting apex. 
As the wall stress increases, subendocardial ischaemia would occur, causing apical 
ischaemia. However, this ischaemia would be self-limiting as the reduction in apical 
blood flow would be reduced by apical dysfunction as the wall stress would also 
reduce.  
 
Only a minority of TTS patients show LVOTO in the acute phase, with a large study 
showing LVOTO in 25% of TTS patients. Therefore, LVOTO is unlikely to be the 
causative factor in the majority of cases. However, it could act as a modifier of TTS 
to result in a more severe disease phenotype.  
 
1.3.5 Direct catecholamine-mediated myocardial stunning  
 
A number of pharmacological agents can have a direct deleterious effect on 
cardiomyocyte function. Some of these agents, such as acetylcholine or carbachol (a 
stable acetylcholine analogue) act to reduce inotropy by activating their canonical 
pharmacological pathways.  
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However, there are endogenous pharmacological agents that can act in a non-
canonical way. Adrenaline and noradrenaline are the primary catecholamines 
secreted by the adrenal gland and sympathetic nerves, respectively, and act to 
increase cardiac chronotropy, inotropy, lusitropy and dromotropy: they increase 
cardiac output. However, a high and sustained level of catecholamines can be toxic, 
precipitating arrhythmias, apoptosis and necrosis.  
 
TTS is often associated with emotional or physical stress immediately prior to the 
start of symptoms, and patients have been shown to have greatly increased 
circulating catecholamine levels. Evolutionarily it would be advantageous to have a 
mechanism in place to prevent such a surge from having a fatal effect, either 
immediately due to a tachyarrhythmia or from non-reversible heart failure as a result 
of cardiomyocyte death. By activating an inhibitory pathway that would limit 
catecholamine activity, many of these deleterious effects could be avoided.  
 
1.4 Stimulus trafficking as the putative mechanism of Takotsubo syndrome 
 
1.4.1 Myocardial β-adrenoceptor pharmacology 
 
It has been hypothesised that TTS could be the result of a direct effect of 
catehcolamines on the β-adrenoceptors in the myocardium (Lyon et al., 2008): In the 
myocardium, both β1 and β2 adrenoceptors (ARs) are present, each with their 
specific affinities for different pharmacological agents, and both of which can 
desensitise in response to agonist stimulation (Freedman et al., 1995; Gong et al., 
2000). However, unlike the β1AR, which only couples to the stimulatory Gs protein, 
the β2AR is pleiotropic and can couple to both the stimulatory Gs protein and the 
inhibitory Gi protein, which can go on to activate a number of enzymatic pathways.  
 
Activation of either the β1AR or β2AR when coupled to the Gs protein activates 
adenylyl cyclase, generating cyclic adenosine monophosphate (cAMP). cAMP can 
have a wide range of cellular signalling functions; in the context of TTS we are 
primarily interested in its ability to activate PKA. PKA when activated by cAMP can 
phosphorylate a number of proteins to increase cardiac function. However, under 
high catecholamine stimulation of both βARs, PKA-mediated phosphorylation of the 
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β2AR can occur. Phosphorylation of the receptor by PKA and the G-protein receptor 
kinases (GRKs), particularly GRK2 and GRK5, can initiate stimulus trafficking, 
whereby the β2AR’s coupling is changed from Gs to Gi after being internalised and 
subsequently retrafficked to the sarcolemma.  
 
This internalisation and retrafficking of the β2AR starts, as previously mentioned, with 
the phosphorylation of serine and threonine residues in the intracellular loops of the 
receptor that can occur, through the actions of PKA and GRKs when the receptor is 
bound to an agonist (Krasel et al., 2005). When the internal phosphorylation sites are 
phosphorylated, β-arrestins can then bind to the intracellular loops of the receptor, 
uncoupling the receptor from its G-proteins. This can then target the receptor to 
clathrin-coated pits to internalise the receptor to an endosome to then be 
dephosphorylated and recycled back to the membrane (Krueger et al., 1997), but 
coupled to Gi proteins rather than Gs. Interestingly, this recycling back to the 
membrane does not occur with noradrenaline, but does with isoprenaline and 
adrenaline, and is the reason for the agonist-specificity seen in stimulus trafficking 
(Liu et al., 2009).  
 
The β2AR Gi signalling that occurs after stimulus trafficking is cardioprotective 
(although negatively inotropic) and may be essential in preventing irreversible 
catecholamine cardiotoxicity. This pathway has been shown to be essential in 
ischaemic preconditioning in the isolated heart (Tong et al., 2005), and there is now 
strong evidence from animal models that this pathway is critical in the induction of 
TTS like cardiac contractility in the rat (Paur et al., 2012). One mechanism of Gi’s 
cardioprotection and negative inotropy is through the antagonism of adenylyl cyclase 
activity by the Gαi subunit (Zhu et al., 2005). However, the primary mechanism of 
cardioprotection appears to be via the Giβγ subunit that activates the PI3K-Akt cell 
survival pathway (Zhu et al., 2001), which has been shown to inhibit cardiomyocyte 
apoptosis induced by both hypoxia and oxidative stress (Chesley et al., 2000). 
Although it could be tempting to say that β2AR Gi signalling is wholly 
cardioprotective, there is evidence to show that that excessive β2AR phosphorylation 
by GRKs and Gi signalling can result in severe contractile dysfunction and the 
maladaptive cardiac remodelling associated with the failing heart (Zhu et al., 2012), 
and in fact GRK2 inhibition could be a potential therapy for cardiac failure 
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(Lymperopoulos et al., 2012). Whether or not β2AR Gi signalling is cardioprotective 
or cardio-deleterious could depend on a balance of both Gs and Gi signalling, and 
the balance between cardioprotection and negative inotropy, with too much 
cardioprotection paradoxically causing dysfunction due to excessive negative 
inotropy (Zhu et al., 2005).  
 
1.4.2 Predisposition of the apical myocardium to catecholamine-induced hypokinesia 
 
If the proposed mechanism of stimulus trafficking is correct (Lyon et al., 2008), the 
predisposition of the apical myocardium to hypokinesia must be explained. In the 
heart there are a number of axes: apex-base and epicardium-endocardium are two 
such axes. Along these axes there are gradients of physiological function: for 
instance, action potentials are longer in the base than the apex (Efimov et al., 1994; 
Laurita et al., 1996), and longest in the mid-myocardium in the epicardium-
endocardium axis due to the presence of the putative M-cells (Antzelevitch et al., 
1991).  
 
There is a gradient of βAR density along the apex-base axis, where there is a higher 
density of βARs in the apex compared to the base (Lathers et al., 1986). Although 
the evolutionary reason for this gradient is unclear, it would ensure that under 
catecholamine stimulation the apex would respond more than the base. If the 
opposite was true and the base responded to catecholamines more than the apex, 
an LVOTO could occur (Tranter et al., 2013).  
 
There is also a gradient of the ratio of the relative numbers of β2ARs to β1ARs, with a 
higher β2ARs/β1ARs ratio present in the apex compared to the base (Lyon et al., 
2008). Izumi and colleagues have reported mRNA levels of ADRB2 (β2AR gene) in 
the apex to be double of that found in the base (Izumi et al., 2009), and radioligand 
binding has confirmed this gradient is present in receptors present in the 
sarcolemma (Paur et al., 2012). 
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1.4.3 Atypical Takotsubo syndrome variants 
 
Although the majority of TTS is of the typical (i.e. apical hypocontractility) variant, up 
to a quarter of TTS cases may be atypical, such as predominant basal 
hypocontractility (Hsu et al., 2010). The cause of an atypical TTS versus a typical 
TTS is unknown, although there is a greater sympathetic innervation of the basal 
myocardium than the apical myocardium (Kawano et al., 2003), whereas the apex 
would be more sensitive to circulating catecholamines. Therefore, TTS with a 
neurologic trigger that may not trigger adrenaline release as much as sympathetic 
neurone release, perhaps a subarachnoid haemorrhage, may predispose the patient 
to an atypical contractility pattern, although this has yet to be proven. 
 
Animal models of TTS assessing the role of afterload on the disease has shown that 
positive inotropes that cause low afterload (e.g. isoprenaline) favour typical TTS, 
whereas those that increase afterload (e.g. noradrenaline) favour atypical TTS. 
Further work is needed to determine whether this role of afterload is also true for 
human TTS.  
 
1.5 Animal models of Takotsubo syndrome 
 
Animal models can be an essential tool in the delineation of human disease 
pathophysiology, as well as a test bed for potential therapeutic strategies. Although 
an animal model will never fully recapitulate the human disease, much of the 
physiology will be the same. Therefore, although not the studies are not directly 
translatable, they can give important insights into disease pathophysiology. Broadly, 
animal models can be divided into two categories based on the method of inducing a 
stress response: psychogenic stress models, of which there are relatively few 
studies, and exogenous pharmacological stress models, which has been the primary 
model to study animal models of TTS.  
 
1.5.1 Psychogenic stress models of TTS 
 
In the majority of TTS cases in humans, the stress response is from within the body, 
i.e. the brain and sympathetic nervous system, rather than from an exogenously-
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administered pharmacological agent (e.g. adrenaline from an EpiPen). The 
endogenous stress response involves many elements from both the nervous and 
humoral systems: the neurohumoural stress response, which includes adrenaline 
and noradrenaline (amongst other catecholamines-associated substances), and the 
hypothalamic-pituitary-adrenal axis. Therefore, any psychogenic stress model that 
generates TTS will be non-specific for the particular causative agent or agents. It 
does however give a platform to test possible treatment strategies and potential 
preventative measures that an at-risk patient could employ.  
 
The first major psychogenic model of TTS was by Ueyama and colleagues from 
Wakayama Medical University (Ueyama et al., 2002). They used the stress 
associated with 30 minutes of dorsal recumbency restraint without general 
anaesthesia to induce a “transient left ventricular apical ballooning” in female Wistar 
rats that was completely inhibited by amosulalol, a non-specific αAR and βAR 
antagonist, indicating the essential role of catecholamines in the induction of TTS-
like contractility. This work was followed up by the same team in 2003 in which they 
demonstrated the role of estrogen supplementation in preventing left ventricular 
dysfunction in response to a similar, albeit shorter (20 minutes), period of dorsal 
restraint in ovariectomised rats (Ueyama et al., 2003).  
 
In a continuation of their 2003 paper, Ueyama and colleagues further tested the 
effects of estrogen supplementation in the dorsal recumbency stress model in 
ovariectomised rats (Ueyama et al., 2007). They found that estrogen 
supplementation continued to protect against stress-induced left ventricular 
dysfunction, and this was associated with a decrease in c-fos mRNA expression in 
the paraventricular hypothalamic nucleus, adrenal gland and left ventricle, 
suggesting an attenuation of sympathetic outflow from the brain after estrogen 
supplementation and a reduction in chromaffin cells excitation (Ueyama et al., 2006). 
Heat shock protein 70 and ANP levels were significantly increase in the hearts of 
estrogen-supplemented rats, indicating a cardioprotective phenotype induced by the 
estrogen.  
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1.5.2 Exogenous pharmacological TTS models 
 
The use of a psychogenic model of stress in rodents is ethically controversial, 
especially one that is as extreme as dorsal restraint, which in a number of countries 
may not be allowed due to the severity of the procedure. The use of pharmacological 
models of stress, where an exogenous agent is administered to the animal, may be 
far more ethical as the animal is often anaesthetised and less of a centrally-driven, 
and therefore emotive, stress response is provoked.  
 
Izumi and colleagues showed that two infusions of adrenaline at a rate of 
10μg.kg−1.min−1 resulted in a reduced ejection fraction with a TTS-like apical 
hypocontractility, tachycardia and hypertension in cynomolgus monkeys (Izumi et al., 
2009). This reduction in ejection fraction could be marginally improved with 
metoprolol infusion, which improved the apical dysfunction. Interestingly, the 
researchers found decreases in mRNA transcript levels of the ryanodine receptor-2 
(RYR2) gene in both the apex and base after adrenaline infusion, and a decrease in 
the apex and an increase in the base of SERCA2a mRNA transcript levels compared 
to control monkeys.  
 
TTS-like contractility can also be induced in rats using a single intravenous bolus of 
adrenaline delivered via the jugular vein (Paur et al., 2012). This apical dysfunction, 
with some reduction in basal contractility also (although never below baseline 
contractility), was maximal at 20 minutes after adrenaline bolus and reversed within 
60 minutes. Unlike previous TTS models, Paur et al. (2012) showed a possible 
mechanism, providing strong evidence for the hypothesis made by the same group 
four years previously (Lyon et al., 2008).  
 
A bolus of noradrenaline had no hypokinetic effect, and the hypokinesia associated 
with adrenaline bolus was completely inhibited by pertussis toxin treatment, both of 
which together indicate that the TTS-like contractility in this animal model is 
dependent on Gi signalling via the β2AR: Stimulus trafficking cannot occur with 
noradrenaline but can with adrenaline (Wang et al., 2008); pertussis toxin inhibits Gi, 
the pathway activated by stimulus trafficking at the β2AR (Xiao et al., 1995). 
Therapies that inhibited either the β2AR (ICI-118,551) or p38-MAPK (SB203580), a 
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downstream effector of the Gi pathway, worsened mortality, indicating a 
cardioprotective effect of β2AR Gi signalling. However, further augmentation of Gi 
signalling worsened the negative inotropic effect. A possible reversal/prevention 
agent was also trialled: levisomendan, a calcium myofilament sensitiser and 
phosphodiesterase inhibitor (Greenberg et al., 2003; Sorsa et al., 2004), prevented 
apical dysfunction and improved mortality.  
 
Soon after we published the adrenaline bolus model (Paur et al., 2012), another 
single-dose catecholamine induced TTS animal model was published by a group 
from the University of Gothenburg, Sweden. An intraperitoneal injection of 
isoprenaline at a dose of 50mg.kg-1 resulted in a clear and sustained hypokinesia 
(predominantly apical but sometimes inverted) that occurred within 100 minutes and 
resolved within ten days, making this the first rodent model of TTS in which the time 
course was more human in nature (Shao et al., 2013b). Much like in the single 
adrenaline bolus model, attempts to block β2AR Gi signalling resulted in increased 
mortality, although improved cardiac contractility was seen in the animals that 
survived the study. ST-segment elevation manifested after isoprenaline injection, 
and fibrosis was seen in the hypokinetic region ten days post-isoprenaline.  
 
A novel aspect of this study was the detection of lipid accumulation in the hypokinetic 
myocardial segments during the acute phase, as has been demonstrated in human 
endomyocardial biopsies during acute TTS; lipids were undetectable after recovery 
had occurred. Interestingly, this was associated with a decrease in intracellular 
glycogen content during the acute phase that also reversed after recovery and 
correlates with human studies showing decrease glucose uptake in the hypokinetic 
myocardial segments during acute phase TTS (Bonnemeier et al., 2006; Kurowski et 
al., 2007). A similar effect in a mouse model of TTS, albeit with a much higher dose 
of isoprenaline (400mg.kg-1), has also been demonstrated (Shao et al., 2013c).  
 
The effects of haemodynamics has been investigated by the Gothenburg group by 
utilising different catecholamines that have differing effects on peripheral resistance, 
namely dopamine, adrenaline, noradrenaline and phenylephrine as pressors, and 
isoprenaline as an anti-pressor. They found that isoprenaline, which resulted in an 
initial hypotension, only caused apical akinesia, whereas adrenaline, causing a 
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sustained hypertension, only caused basal akinesia (i.e. inverted TTS). The other 
pressors also favoured basal akinesia (Redfors et al., 2014a). Furthermore, when 
pressor catecholamines were combined with a hypotensive agent (nitroprusside or 
hydralazine), their predisposition to cause basal akinesia was switched to apical 
akinesia. When isoprenaline was combined with phenylephrine, no akinetic areas 
were observed.  
 
This study makes the inference that afterload is essential in determining which 
“route” on the apparent TTS dichotomy the heart takes when challenged with a TTS-
inducing level of catecholamines: high afterload predisposes to basal/inverted TTS; 
low afterload predisposes to apical/normal TTS. They propose that changes in 
haemodynamics in the whole organism alters the regionality of wall stress in the left 
ventricle, so a low afterload in the presence of excessive positive inotropic drive 
causes an increase in apical wall stress and tension. This could reach a point where 
it becomes disproportionally high and the cardiomyocytes in that region become 
unable from a metabolic perspective to generate the required force. Therefore, in 
order to prevent an energy deficit, the cardiomyocytes enter a state of metabolic 
hibernation, manifesting as a hypokinetic/akinetic myocardial segment (Redfors et 
al., 2013). Although the group are quick to dismiss the β2AR Gi hypothesis of TTS, 
this could still play a key role in mediating this cardioprotective metabolic switch as 
β2AR signalling is known to act to reduce force, and therefore energy used (Xu et al., 
2010).  
 
The isoprenaline-induced animal model of TTS (Shao et al., 2013b) has been used 
to test the commonly-used general anaesthetic isoflurane on its effect on TTS 
induction. They found that isoflurane at a dose of 0.75% and 1.5% in O2 reduced 
apical dysfunction in a dose-dependent manner when given 15 minutes before 
isoprenaline in combination with their standard anaesthetic protocol (ketamine-
midazolam) (Redfors et al., 2014b). Pre-treatment with isoflurane in combination with 
ketamine-midazolam did not affect arterial pH, respiratory rate or heart rate. 
However, it caused a decrease at baseline in systolic and diastolic blood pressure, 
as well as a very modest reduction in body temperature (38.4 ± 0.17 vs. 38.2 ± 0.16) 
(see Chapter 5). As noted in their previous studies, isoprenaline caused a reduction 
in blood pressure that recovered in control animals, whereas in isoflurane-treated 
 43 
rats the hypotension remained. One proposed mechanism of isoflurane’s action was 
to activate the KATPm channel on the mitochondria as this is one mechanism by which 
isoflurane is cardioprotective against ischaemia (Landoni et al., 2008). However, use 
of the KATPm blocker glyburide had no effect on isoflurane’s inhibition of TTS-like 
contractility. One proposed hypothesis was through the activation of adenosine A1 
receptors by isoflurane, which would reduce intracellular cAMP and could then 
prevent stimulus trafficking, as well as preventing cardiac damage (Kersten et al., 
1997). Alternatively, it could be that isoflurane is inhibiting endogenous sympathetic 
activity that is normally augmented by ketamine anaesthesia, and therefore the 
overall sympathetic activity in the rat is not great enough to cause TTS-like 
contractility (Peña and Wolska, 2004).  
 
Although isoflurane could prevent the induction of TTS, no attempt was made by the 
group to use isoflurane as a therapeutic intervention: very few people with their first 
episode of TTS can be identified to be ‘at-risk’, and therefore prevention of TTS may 
not be better than cure, especially as it is a relatively uncommon cardiac disease. 
Nevertheless, the fact that isoflurane can inhibit TTS in animal models was of great 
use in the interpretation of my own results.  
 
Although not identical to TTS models, animal models of catecholamine 
cardiomyopathy, a similar yet distinct disease, can also yield important insights into 
cardiac responses to catecholamines. For instance, in an animal model of 
catecholamine cardiomyopathy, isoprenaline minipumps were implanted into rats for 
7 days, it was primarily the apex that was affected, with reduced contractility and 
increased fibrosis present in this region alongside a left ventricular free wall thinning 
that was most present in the apex (Heather et al., 2009). Therefore, in diseases of 
catecholamine excess, the apex, versus the base, appears to be most sensitive to 
damage and/or dysfunction.  
 
1.5.3 Summary of animal models of TTS 
 
Animal models of TTS have contributed a great amount of information about the 
disease: the importance of catecholamines in the induction phase; the role of β2AR 
Gi signalling as a cardioprotective factor during TTS; and the appreciation that TTS 
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is perhaps not a disease solely of the cardiomyocyte, but rather a combination of the 
heart with the whole body response to stress that requires a multi-level integrative 
approach to study it. Further animal models should better delineate the mechanisms 
of this disease and attempt to unequivocally determine the link between stress and 
cardiodepression. Promising results from endomyocardial biopsies show that rat, 
mouse and human TTS-like contractility have a great deal in common, and therefore 
animal modelling of this disease is a valid way to study this fascinating phenomenon.  
 
1.6 Gender, the cardiovascular system, and Takotsubo Syndrome 
 
Gender plays a key role in many different diseases, with the full complement of each 
gender’s sex hormones interacting with pathological processes to either worsen or 
improve the person’s condition. For instance, women are more sensitive to torsade 
de pointes arrhythmias due to their predisposition to a longer QT interval (Abi-
Gerges et al., 2004); develop coronary artery disease at a later age than men 
(Regitz-Zagrosek and Seeland, 2011); and are more sensitive to coronary artery 
disease as a result of diabetes mellitus (Barrett-Connor et al., 1991). Women are 
also more protected against left ventricular hypertrophy (Carroll et al., 1992), 
although men have a higher rate of survival once the hypertrophy has been 
established (Y. Liao et al., 1995). Gender and cardiovascular disease has a complex 
pattern that is in no way fully satisfied by the general assertion that females, relative 
to males, are protected against cardiovascular disease, and the effect of gender and 
the associated hormones varies according to the disease in question.  
 
1.6.1 Pharmacology of estrogens 
 
Estrogens, including 17β-estradiol (E2), estrone (E1), and estriol (E3), are C18 steroid 
hormones produced from cholesterol by a number of cell types in both the male and 
female (Gruber et al., 2002). E2, the primary estrogen in females, is produced by the 
theca and granulosa cells of the ovaries (Lieberman, 1996), whereas E1 and E3 are 
primary produced by the liver as breakdown products of E2 (Tsuchiya et al., 2005). 
Aromatisation, the final step in estrogen formation, can also occur in the Leydig cells 
of the testes (Brodie and Inkster, 1993), adipose tissue (Miller, 1991) and skeletal 
muscle (Matsumine et al., 1986). After the menopause, E2 levels fall with most 
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circulating E2 is made via the conversion of testosterone by extragondal tissues; in 
this state E1 becomes the predominant circulating estrogen (Gruber et al., 2002).  
 
Estrogens (primarily E2, which will hereafter be referred to as “estrogen” unless 
stated otherwise) can exert their pharmacological actions through two primary 
pathways: the genomic pathway, and the non-genomic pathway (Marino et al., 
2006). The genomic pathway consists of estrogen entering the nucleus to interact 
with DNA to effect changes in gene transcription, whereas the non-genomic pathway 
is mediated by extracellular and intracellular estrogen binding to G-protein coupled 
receptors.  
 
1.6.2 Genomic actions of estrogen 
 
As a steroid hormone, and therefore non-polar, estrogen can diffuse through a cell 
membrane to enter the cytoplasm without the need for a carrier protein. In the 
cytoplasm estrogen can bind to one of the estrogen receptors (ER): ER-α and ER-β. 
The action of estrogen binding to an ER causes a conformational change and 
dissociation from its cytoplasmic chaperones (Hall et al., 2001; Nilsson et al., 2001). 
The estrogen-ER complex then translocates to the nucleus, stimulated through the 
interaction with cytosolic caveolin-1 (Schlegel et al., 1999). ERs then dimerise, 
forming either heterodimers or homodimers (Cowley et al., 1997) with other nuclear 
estrogen-ER complexes. These estrogen-ER complex dimers can then interact with 
DNA to effect transcriptional changes. The canonical pathway of ER’s genomic 
control involves the binding of dimeric estrogen-ER complexes to estrogen response 
elements (EREs): sequences of DNA that are specific inverted palindromic base 
sequences in or near to the promoter region of a gene (Klinge, 2001). The ER-β 
receptor has been shown to localise in the mitochondria where it may mediate 
mitochondrial DNA gene transcription (Simpkins et al., 2008). 
 
The two ER subtypes, ER-α and ER-β, can have different effects on gene 
transcription in the same tissue: for instance, ER-β upregulated inducible nitric oxide 
synthase (iNOS) in vascular smooth muscle cells, whereas ER-α downregulates it 
expression (Tsutsumi et al., 2008). On the other hand, in ovariectomised mice 
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treated for estrogen for one week, 90% of genes that showed a decrease in 
response to estrogen was mediated via the ER-β subtype (O’Lone et al., 2007).  
 
There is also a non-canonical pathway for the estrogen-ER complex to cause 
changes in gene expression when the gene in question does not have an ERE in or 
near to its promoter region. In this non-canonical pathway, the estrogen-ER complex 
can bind to another DNA-binding transcription factor in a process called 
transcriptional cross-talk (Göttlicher et al., 1998); approximately one-third of genes 
that are responsive to estrogen receive the estrogen signal via this method (O’Lone 
et al., 2004). One such mediator is stimulating protein-1, which when bound with an 
estrogen-ER complex, change expression of genes as diverse as endothelial nitric 
oxide synthase (eNOS), cyclin D1, c-fos, and the low-density lipoprotein (LDL) 
receptor (Castro-Rivera et al., 2001; Chambliss and Shaul, 2002; Duan et al., 1998; 
Li et al., 2001). Estrogen-ER (particularly ER-α) complexes can also inhibit nuclear 
factor-κB (NF-κB) activity by binding to the c-rel subunit, preventing its usual binding 
to the promoter of the IL-6 gene and mediating part of estrogen’s anti-inflammatory 
effects (Kalaitzidis and Gilmore, 2005).  
 
In the heart, estrogen can upregulate the expression of the Na+-Ca2+ exchanger 
(NCX) and downregulate the L-type Ca2+ channel (LTCC), and potassium channel 
subunits Kv1.5 and Kv4.3 (Chen et al., 2011; Johnson et al., 1997; Saito et al., 
2009). Estrogen treatment can upregulate the expression of both iNOS and eNOS in 
cardiomyocytes (Nuedling et al., 1999), and eNOS in endothelial cells (MacRitchie et 
al., 1997). Cardiomyocyte ANP expression may also be increased by estrogen, 
which can then go on to mediate anti-hypertrophic effects (Horio et al., 2000). Loss 
of estrogen can facilitate the upregulation of β1ARs, which could predispose the 
heart to catecholamine-induced arrhythmias and cell death (Chu et al., 2006).  
 
The genomic effects on the renin-angiotensin system are complex: although 
estrogen can inhibit the action of angiotensin-converting enzyme (ACE), estrogen 
can upregulate the expression of angiotensinogen and plasma levels of renin 
(Brosnihan et al., 1997; Gordon et al., 1992). It appears though that, overall, 
angiotensin-II activity is not increased due to the estrogen’s ACE inhibition and 
angiotensin-II receptor subtype 1 (AT1) downregulation; estrogen deficiency has 
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been shown to upregulate AT1 expression in spontaneously hypertensive rats 
(Wassmann et al., 2001).  
 
1.6.3 Non-genomic actions of estrogen 
 
The classical steroid effects of estrogen can take hours to manifest as changes in 
protein synthesis are required (Gruber et al., 2002). Some effects of estrogen can 
occur much more rapidly than this, and these effects are mediated via the non-
genomic estrogen signalling pathways. Although some ER-α has been reported to 
be present at the cell membrane (Pedram et al., 2006), much of the rapid, non-
genomic effects of estrogen are mediated via G-protein receptor 30 (GPR30), also 
known as G protein-coupled estrogen receptor (GPER) (Filardo and Thomas, 2012), 
an estrogen-specific membrane receptor (Thomas et al., 2005). GPER is thought to 
be primarily an intracellular receptor, so the estrogen must diffuse into the cell before 
it can activate the G-protein, whereas a classical G-protein coupled receptor would 
have its agonist binding domain on the extracellular aspect of the cell (Meyer et al., 
2014).  
 
GPER activation can generate cAMP through Gs coupling (Filardo et al., 2002), 
inhibit (Deschamps et al., 2010) or stimulate (Ho and Liao, 2002) the Akt pathway, 
and mobilise intracellular calcium stores and generate phosphatidylinositol 3,4,5-
trisphosphate in the nucleus (Revankar et al., 2005). Alternatively, it can reduce Ca2+ 
sensitivity in vascular smooth muscle cells and inhibit endothelin-1-mediated 
vasoconstriction. GPER has also been shown to couple to Gi proteins, attenuating 
cAMP reduction when it forms a plasma membrane complex with Membrane-
associated Guanylate Kinases (MAGUKs) and Protein Kinase A-anchoring Protein 5 
(AKAP5) (Broselid et al., 2014). Overall, GPER exhibits pleiotropy, depending on 
what the receptor is coupled to intracellularly.  
 
In cardiomyocytes, activation of GPER appears to be predominantly 
cardioprotective: in both male and female rats GPER activation reduced ischaemia-
reperfusion injury (Deschamps and Murphy, 2009); GPER activation reduced left 
ventricular remodelling and diastolic dysfunction in an ovariectomised rat model of 
heart failure (Wang et al., 2012); and can inhibit cardiomyocyte apoptosis (Li et al., 
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2015). GPER is present in both male and female hearts, with GPER activation in 
isolated male hearts resulting in a decrease in contractility that is associated with 
ERK and eNOS phosphorylation (Filice et al., 2009). If expression of GPER is 
knocked down, male mice exhibits systolic and diastolic dysfunction whereas 
females appear to remain protected by their remaining estrogen receptors (Delbeck 
et al., 2011).  
 
1.6.4 Estrogen, gender and the autonomic nervous system 
 
Estrogen exerts a potent sympatholytic influence, reducing the effect of both 
endogenous and exogenous catecholamines. For instance, estrogen can reduce 
isoprenaline-augmented cAMP production and L-type Ca2+ currents in isolated rat 
cardiomyocyte, and reduced isoprenaline-induced tachycardia and arrhythmias in 
the isolated rat heart (H. Y. Li et al., 2000). Application of estrogen to rat atrial 
cardiomyocytes reduced automaticity, which in the intact atrial syncytium could result 
in arrhythmias (Nakajima et al., 1999).  
 
At rest, males have a higher level of sympathetic nerve activity to muscles (Ng et al., 
1993), although plasma noradrenaline levels are higher in women and plasma 
adrenaline levels higher in men (Davidson et al., 1984). At the level of the heart, 
women seem to have a lower sympathetic activity and higher Vagal activity 
compared to men as demonstrated by a lower low frequency to high frequency ratio 
in heart rate variability measurements (D. Liao et al., 1995; Ramaekers et al., 1998). 
In response to behavioural stressors, men show a higher systolic blood pressure 
increase, with a slower recovery to baseline than women (Light et al., 1993). Men 
also show a greater systolic blood pressure response to range of exercise types 
(Gleim et al., 1991); women exhibit a lower sympathetic nerve firing rate in response 
to repeated hand grip exercise, to which the authors conclude is due to a blunted 
metaboreflex (Ettinger et al., 1996). Women also have a lower sympathetic response 
to hypoglycaemia that is attributed to a lower central drive in response to the 
hypoglycaemia (Davis et al., 2000).  
 
The effects of the sex hormones on autonomic nervous system function, particularly 
estrogen, can be mediated either centrally, in the autonomic nervous system, or 
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peripherally, by acting on neurones and target tissues. Centrally, intracerebral 
infusion of estrogen increased Vagal tone (Saleh and Connell, 1999), and injection of 
estrogen into the nucleus tractus solitarius, intrathecal space and rostral 
venterolateral medulla supressed sympathetic outflow, as measured in the efferent 
renal sympathetic nerve (Saleh et al., 2000). Male brains show fewer noradrenaline 
uptake-1 transporters than female brains (Vathy et al., 1997), which could act to 
increase the noradrenaline concentration in synapses.  
 
Peripherally, Vagus nerves in females release more acetylcholine in response to a 
similar stimulus in males (Du et al., 1994), and sympathetic neurons in females have 
a higher activity of the inhibitory α2AR on the pre-synaptic membrane, inhibiting 
noradrenaline release (Du et al., 1991); this difference was reduced after 
ovariectomy. As mentioned previously, estrogen can increase NOS expression, 
which may be further inhibiting noradrenaline release from the pre-synaptic bouton 
(Fei et al., 1997). As a further sympatholytic effect estrogen can increase the 
catalytic activity of catechol-O-methyltransferase (COMT) and monoamine oxidase 
(MAO), enzymes that catalyse the breakdown of catecholamines (Fernández-Ruiz et 
al., 1988).  
 
Overall, estrogen appears to act to not only inhibit the effects of the sympathetic 
nervous system, but change the balance between the two arms of the autonomic 
nervous system towards to parasympathetic nervous system, which will give an 
additional indirect sympatholytic effect. Therefore, females are well protected against 
catecholamine-mediated diseases, of which TTS is one. As this protection is 
somewhat lost after the menopause, this could give an important insight into the role 
of sex hormones on the disease’s pathophysiology.  
 
1.6.5 Gender and Takotsubo syndrome: the TTS Goldilocks hypothesis 
 
Takotsubo syndrome primarily occurs in post-menopausal females, with on average 
90% of cases being in females and the mean reported age between 62 and 76 years 
of age (Schneider et al., 2013a). Chest pain is more common in female sufferers, 
whereas males have a higher rate of out-of-hospital cardiogenic shock or cardiac 
arrest associated with TTS (Schneider et al., 2013b). This point is further confirmed 
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by a study that showed stress-related acute cardiac dysfunction was the most likely 
cause of death in 19.8% of men who died from sudden cardiac death (Owada et al., 
1999). QTc duration appears to be longer in women on the day of presentation 
(Schneider et al., 2013b). Plasma creatine kinase and cardiac troponin may be 
higher in men than women, implying a increased level of cardiac damage in that 
gender. No differences in in-hospital complications were found between men and 
women.  
 
As the primary patient of TTS is a post-menopausal female (Templin et al., 2015), it 
may be the case that the withdrawal of estrogen after the menopause leaves the 
individual in a particularly vulnerable state: more sensitive to catecholamines than 
the pre-menopausal female, in whom circulating estrogen can exert a sympatholytic 
effect, as demonstrated in numerous animal models (Tanaka et al., 2013; Ueyama et 
al., 2003), but less sensitive than males, who tend to be higher responders to 
catecholamines (Gratas-Delamarche et al., 1994). Therefore, adrenaline can exert 
enough of an effect via the βARs to induce stimulus trafficking of the β2AR, but not 
high enough to cause sudden cardiac death or catecholamine cardiomyopathy 
(Kassim et al., 2008): when men receive this same plasma concentration of 
catecholamines, they may simply die of a sudden cardiac death before any TTS 
could manifest.  
 
1.6.6 Hormone replacement therapy and cardiovascular disease 
 
As females become less protected after the menopause, many thought that hormone 
replacement therapy (HRT) could reverse this loss of protection (Murphy, 2011). 
However, this has failed to materialise in clinical trials (Rossouw et al., 2002; Shlipak 
et al., 2003). There are a number of theories as to why this is the case, and a 
consensus has yet to be reached. As the distribution of TTS cases is heavily 
weighted towards post-menopausal females (Schneider et al., 2013a), and a number 
of animal studies have shown estrogen replacement (i.e. HRT) in ovariectomised 
rats can prevent or attenuate cardiac dysfunction after a TTS-inducing stimulus (Cao 
et al., 2015; Ueyama et al., 2007), it could be expected that HRT would reduce the 
risk for this particular cardiac disease.  
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In an initial study of 16 cases of TTS in post-menopausal females, none were found 
to be receiving HRT at the time of presentation (Kuo et al., 2010). However, this was 
not found in a larger study of 200 TTS cases in females aged over 50 years of age 
(mean age was 71.7 years). Of these 200 patients, 15 were receiving HRT; those 
receiving HRT were less like to require mechanical haemodynamic support or 
ventilator support compared to females over 50 years of age who were not receiving 
HRT (Patel et al., 2013). Therefore, HRT does not completely prevent TTS, and 
prospective studies are required to determine what, if any, TTS risk reduction occurs 
in women who receive HRT. However, it does appear to improve prognosis, perhaps 
reducing the severity of the cardiac dysfunction and co-morbidities surrounding this 
dysfunction that result in the patient requiring further medical support.  
 
One important aspect of any cardiac disease is the metabolic disturbance that can 
accompany it and worsen its prognosis. TTS endomyocardial biopsies show clear 
metabolic changes, both through increases in superoxide levels and a change in 
respiratory substrate preference (Nef et al., 2008), and estrogen can protect against 
mitochondrial dysfunction (Borrás et al., 2010; Razmara et al., 2008): The 
mitochondria could be a source of either protection or dysfunction, or both, in this 
complex, multifaceted disease.   
 
1.7 Mitochondrial function in the heart 
 
The heart is a very metabolically active organ, and as a result requires large 
amounts of ATP to maintain cellular homeostasis and generate sufficient contractile 
force: each day the heart synthesises approximately 30kg of ATP (Lemieux and 
Hoppel, 2009). Mitochondria do not solely synthesise ATP: they also function as a 
Ca2+ store, buffering cytoplasmic Ca2+. Mitochondria in cardiomyocytes, as in almost 
all other mammalian cells, can also act as cell death regulators and generators of 
cytotoxic reactive oxygen species (ROS). Therefore, mitochondrial dysfunction can 
impede cellular respiration and ATP levels, and initiate apoptotic pathways 
(Gustafsson and Gottlieb, 2008).  
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1.7.1 ATP generation by mitochondria 
 
The mitochondria are commonly referred to as the “powerhouse of the cell” 
(Siekevitz, 1957): they are the site of the Krebs cycle, fatty acid oxidation, and 
oxidative phosphorylation, primary sources of ATP for a cell. NADH and FADH2 
donate electrons to the proteins of the electron transport chain (ETC), namely 
Complex I, II, III and IV. The ETC can then move protons from the mitochondrial 
matrix into the intermembrane space to generate a proton diffusion gradient; this 
proton gradient can then generate ATP by diffusing through the ATP synthase 
protein (complex V), turning it in the process to drive phosphorylation of ADP to ATP 
(Nunnari and Suomalainen, 2012). 
 
1.7.2 Reactive oxygen species in health and disease 
 
Complexes I and III generate ROS during their normal function: as much as 2% of 
O2 used by mitochondria during respiration is converted into superoxide by 
complexes I and III (Gustafsson and Gottlieb, 2008). In health, this generated 
superoxide is detoxified by a number of antioxidant enzymes found in the 
mitochondria (Giordano, 2005). For instance, superoxide is catalysed to hydrogen 
peroxide by manganese superoxide dismutase (MnSOD), which is further detoxified 
by catalase.  
 
In disease states, increased ROS formation by mitochondria occurs in the failing 
heart after myocardial infarction, and can cause cellular damage through 
mitochondrial DNA damage, lipid peroxidation and protein modification (Ide et al., 
2001). Heart failure also reduces the mitochondrial capacity for detoxification of the 
ROS that is generated: MnSOD activity was shown to be reduced in a guinea pig 
transaortic constriction model of heart failure (Dhalla and Singal, 1994), and catalase 
activity was reduced after a rat model of myocardial infarction, with the left ventricle 
showing a reduction in antioxidant capacity before the right ventricle (Hill and Singal, 
1997).  
 
ROS generated by the mitochondria can lead to a positive feedback loop where 
more ROS is formed in a process known as ROS-induced ROS release (RIRR): the 
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initial generation of ROS opens the mitochondrial permeability transition pore 
(mPTP), a pore that when opened permeabilises the inner mitochondrial membrane 
to water, ions and molecules up to 1.5 kDa in size (Zoratti and Szabò, 1995). The 
opening of the mPTP causes a depolarisation in the mitochondrial membrane 
potential (Ψm), which in turn causes a burst of ROS formation by the ETC. RIRR can 
also occur through ROS-induced opening of an anion channel also found in the inner 
mitochondrial membrane, the inner membrane anion channel (Aon et al., 2003). If 
Ψm collapses, destabilisation of the action potential, including action potential 
shortening and membrane inexcitability, can occur, resulting in lethal arrhythmias 
(Akar et al., 2005). Inhibitors of mPTP opening have been demonstrated to be 
cardioprotective (Nazareth et al., 1991). Changes in Ψm (ΔΨm) can be measured 
using a number of fluorescent dyes and are indicative of the health of the cell (Lyon 
et al., 2010; Matsumoto-Ida et al., 2006; Scaduto and Grotyohann, 1999). 
 
1.7.3 Mitochondria as mediators of cell death 
 
Cellular apoptosis requires the activation of caspase enzymes, which can then 
catalyse the breakdown of the cell into apoptotic blebs (Suen et al., 2008). One such 
mediator of caspase activation is through the release of cytochrome c release from 
the mitochondria into the cytoplasm, where it can bind APAF1 and activate caspase-
9 via the formation of an apoptosome (Bao and Shi, 2007).  
 
The Bcl-2 protein family regulate apoptosis via the release of cytochrome c from 
mitochondria, with Bcl-2, Bcl-xl and Mcl-1 acting as apoptosis inhibitors and Bax and 
Bak as apoptosis activators (Chipuk and Green, 2008). It is thought that Bcl-2 
prevents the permeabilisation of the outer mitochondrial membrane by inhibiting the 
activation of Bax and Bak (Gustafsson and Gottlieb, 2007). When Bax and Bak are 
activated, they are able to interact with lipids and Bid in the mitochondrial outer 
membrane to make very large pores that are permeable to molecules are large as 
2,000 kDa (Kuwana et al., 2002).  
 
Although depolarisation of Ψm and opening of the mPTP are known to be associated 
with apoptosis, the link is unclear. One proposed hypothesis states that when the 
mPTP opens, leading to the collapse of Ψm, ions can equilibrate between the 
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intermembrane space and the matrix. This leads to movement of water into the 
matrix through osmosis and subsequent swelling that can be so profound as to 
interfere with the outer mitochondrial membrane’s integrity (Green and Kroemer, 
2004). 
 
There are a number of pathways that can interact with mitochondria to inhibit 
dysfunction and apoptosis induction. The KATPm channel is present in the inner 
mitochondrial membrane and is composed of inward rectifier-like and sulfonylurea 
receptor-like components, albeit smaller than those found on cell surface 
membranes (Bajgar et al., 2001). Opening of the KATPm channel inhibits mPTP 
opening and prevents cytochrome c release (Korge et al., 2002), and its activity is 
thought to be critical in ischaemic preconditioning in both cardiac (Otani, 2004) and 
neuronal (Sun et al., 2015) tissues. The opening of the KATPm can be effected by a 
number of mediators either endogenous, such as PKCε (Fryer et al., 2001; Jabůrek 
et al., 2006), or exogenous, such as isoflurane (Redfors et al., 2014b). The PI-3/Akt 
signalling pathway has also been shown to be cardioprotective in part by acting via 
the mitochondria: Akt activation can inhibit cytochrome c release by mitochondria 
(Uchiyama et al., 2004) and prevent the translocation of Bax to the mitochondria 
(Tsuruta et al., 2002). Activation of Akt by estrogen signalling and β2AR Gi signalling 
could mediate part of the cardioprotective effects of these two pathways (Ciccarelli et 
al., 2007; Guo et al., 2006).  
 
1.7.4 Mitochondria and Takotsubo syndrome 
 
Little is known about mitochondrial function during TTS, although a study of 
endomyocardial biopsies noted increased levels of superoxide in acute TTS (Nef et 
al., 2008) and a decrease in glucose uptake (Bonnemeier et al., 2006; Kurowski et 
al., 2007), so metabolic changes must be taking place during the acute phase. 
Intracellular lipid accumulation has been demonstrated in both animal models and 
human TTS (Shao et al., 2013b), which can also lead to superoxide formation and 
subsequent mitochondrial dysfunction (Chiu et al., 2001; Sharma et al., 2004). On 
the other hand, Akt-1 activation has been demonstrated in acute TTS 
endomyocardial biopsy samples (Nef et al., 2009a), which could be acting to prevent 
mitochondrial dysfunction. Excessive nitrosative stress has also been observed in 
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TTS patients’ hearts, which can also cause mitochondrial dysfunction via the action 
of poly(ADP-ribose) polymerase 1 (PARP-1) (Surikow et al., 2015).  
 
High levels of catecholamines are known to generate ROS both through the 
stimulation of mitochondrial respiration (Bovo and Zima, 2012) and the direct 
oxidation of catecholamines to unstable catecholamines-O-quinones, which can 
subsequently degrade to release superoxide (Izem-Meziane et al., 2012). It could be 
hypothesised that mitochondria must be protected in some part by Akt signalling in 
order to withstand and survive a number of oxidative stress sources without 
cardiomyocytes succumbing to mitochondria-mediated apoptosis.  
 
1.8 Summary 
 
Takotsubo syndrome is an acute and reversible form of cardiac failure that typically 
occurs in post-menopausal females, but can occur in younger females and men. Its 
pathophysiology is not fully understood, but a central part of the disease process 
appears to be raised sympathetic activity. A number of animal models have alluded 
to the β2AR Gi pathway to be at least partly involved in the negative inotropy that is 
present in TTS, as well as the apparent cardioprotection the disease appears to 
confer compared to diseases with a similarly-dire initial presentation. As the disease 
is most prevalent in post-menopausal females, understanding the role of estrogen 
withdrawal is of particular importance in elucidating TTS pathophysiology. Animal 
models have shown that ovariectomised animals are more sensitive to 
catecholamines and stress, and estrogen replacement can somewhat ameliorate 
this. This has not fully translated to the clinic and HRT, at the current clinical dose, 
does not preclude the development of TTS, but may reduce its severity. There are 
clear metabolic and oxidative stress disturbances in the acute phase of the disease, 
implying mitochondrial dysfunction could also be present. Further animal and clinical 
studies are clearly needed to better understand this intriguing clinical phenomenon.  
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1.9 Aims 
 
1. To test the effects of estrogen and gender on catecholamine responsiveness, 
with reference to contractility, arrhythmia severity and mortality, using the 
adrenaline bolus TTS model.  
 
2. To further develop in vivo TTS models in order to inform in vitro and ex vivo 
studies of the disease.  
 
3. To use putative ex vivo models of TTS to establish potential mechanisms for 
the contractile dysfunction seen in vivo.  
 
4. To understand the link between catecholamine excess and sudden cardiac 
death, using both in vivo and ex vivo models of catecholamine 
overstimulation.  
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2. Materials and methods 
 
2.1 Animals 
 
All procedures were carried out in accordance with Animals (Scientific Procedures) 
Act (1986) and European Directive 2010/63/EU.  
 
2.1.1 Sprague Dawley rats 
 
The Sprague Dawley rat is an outbred strain of the brown rat (Rattus norvegicus) 
bred specifically for laboratory studies. All rats were obtained from Charles River 
Laboratories (UK) and housed in cages of four or fewer in a room on a 12-hour 
light/dark cycle maintained at 21oC. Standard rat chow and water were available ad 
libitum. Male and female rats used typically weighed 200-350g and 190-250g, 
respectively. Some larger male rats (<500g) were used for optical mapping studies 
and cardiomyocyte isolation.  
 
2.1.2 Ovariectomised female rats 
 
Ovariectomised rats were obtained from Charles River Laboratories (UK), where the 
ovariectomy procedure was carried out by their own veterinary surgeons. Briefly, 
ovaries were exteriorised through bilateral dorsal incisions halfway between the 
caudal edge of the ribcage and the proximal tail. The oviduct was ligated, after which 
the ovary was removed with a cut to the oviduct. Remaining tissue was replaced and 
the wound closed using either sutures or wound clips. Post-operative analgesia was 
administered as necessary. Upon receipt of the ovariectomised rats, no wound was 
visible and fur over the surgical incision had fully regrown.  
 
2.2 Solutions and reagents 
 
All reagents were obtained from Sigma-Aldrich (UK) unless otherwise stated.  
 
Krebs-Henseleit (KH) solution (mM): NaCl (119), KCl (4.7), MgSO4 (0.94), CaCl2 
(1mM for isolated cardiomyocyte studies; 1.85mM for whole-heart studies), KH2PO4 
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(1.2), NaHCO3 (25), glucose (11.5), ascorbic acid (80µM for isolated heart 
experiments only); pH equilibrated with 95% O2, 5% CO2.  
 
Low-calcium solution (mM): CaCl2 (12-15 µM), NaCl (120), KCl (5.4), MgSO4 (5), 
pyruvate (5), glucose (20), taurine (20), HEPES (10), nitrilotriacetic acid (5); bubbled 
with 100% O2. 
 
Enzyme solution: NaCl (120), KCl (5.4), CaCl2 (150µM) MgSO4 (5), pyruvate (5), 
glucose (20), taurine (20), HEPES (10); bubbled with 100% O2. 
 
0.9% normal saline (mM): NaCl (154). 
 
2.3 Isolated heart studies 
 
For all isolated heart studies, hearts were excluded from analysis according to the 
following criteria, as assessed five minutes after reestablishment of coronary 
perfusion: <200bpm after reestablishment of coronary perfusion; >5min-1 premature 
ventricular contractions; evidence of heart block; clear region of infarction.  
 
2.3.1 Heart extraction 
 
Rats were killed by cervical dislocation, with or without subsequent decapitation, 
after a brief period of isoflurane anaesthesia delivered to an anaesthetic chamber 
(5% in 100% O2) to prevent distress during restraint. After confirmation of death, a 
large cut was made inferiorly to the xiphisternum to enter the peritoneal cavity. The 
xiphisternum was gripped with a pair of tissue forceps and the diaphragm was cut 
open to visualise the heart. Cuts were made bilaterally to the lateral aspects of the 
ribcage, followed by a cut to the superior aspect of the ribcage. The heart, lungs and 
thymus were gently gripped and the chest contents were removed by cutting 
posteriorly to the heart and lungs, severing the great vessels and trachea. The 
excised organs were immediately placed into ice-cold KH solution with heparin 
sodium (2 units.ml-1). The lungs and thymus were dissected away in a petri dish filled 
with ice-cold KH solution and the ascending aorta was exposed. The aorta was held 
with two Dumont 7 forceps (Fine Scientific Tools, UK) and lifted onto a cannula and 
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secured with an artery clip and 2-0 silk suture. After confirmation that the suture is 
securely holding the heart, the artery clip was removed and a further suture was tied 
as required. The pulmonary artery was cut to prevent the build-up of perfusate in the 
right ventricle.   
 
2.3.2 Sonomicrometry studies 
 
The heart was perfused with KH (37oC) in a pressure-driven water-jacketed 
Langendorff system at a pressure of 90-100cm.H2O. The Langendorff system was 
maintained at 37oC using a thermal circulator (Techne Inc., USA). An ECG was 
taken, with the cathode attached to the metal cannula using a crocodile clip and the 
anode inserted into the right ventricle using a needle electrode (Grass Technologies, 
USA). The anode and cathode were connected to a BioAmp (AD Instruments, USA).  
 
Piezoelectric crystals (1mm, Sonometrics Inc., Canada) were affixed to the left 
ventricular free wall, perpendicular to the interventricular groove and directly 
inferiorly to the left atrial appendage, using cyanoacrylate glue. Wires from the 
crystals were loosely secured to the water jacket around the heart to improve 
signals. Crystals were connected to an Ultrasound Dimension Gauge Analogue 
Sonomicrometer (Sonometrics Inc.). Outputs from the BioAmp and the 
sonomicrometry device were digitised by a PowerLab (AD Instruments) at a rate of 
1000Hz, low-pass filtered (50Hz) and monitored and recorded using LabChart 6 on a 
MacBook Pro (Apple Inc., USA). Contraction was analysed using the Cyclic 
Measurements function of LabChart 6. All values for contraction are reported as a 
percentage shortening of the distance between the crystals during diastole.  
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Figure 2.1: A representative isolated heart with sonomicrometry crystals (front) and an ECG 
electrode (right) 
 
 
 
Figure 2.2: A photo of the optical mapping system with the cameras (right) and microscope 
objective lens (left) 
 
2.3.3 Optical mapping studies 
 
Hearts were perfused with KH (37oC) at a constant flow rate (15-17ml.min-1), 
maintained by a peristaltic pump (Thermo Scientific, USA). Perfusate was kept in a 
water-jacketed reservoir and passed through water-jacket tubing and three water-
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jacketed bubble traps (Radnoti, USA) before reaching the cannula. The heated water 
jacket was kept at a constant temperature by a thermal circulator set to 40.5oC 
(Thermo Scientific). The heart was chambered inside a KH-filled Perspex box with a 
quartz window (Cairn Research, UK), through which optical recordings could be 
taken. Quartz was used as it shows little fluorescence. An ECG was taken using a 
setup similar (BioAmp to PowerLab: AD Instruments) to that used for 
sonomicrometry, although in this case the anode was free in the KH-filled chamber 
rather than inserted into the myocardium.  
 
Optical images were taken through a modified microscope (Olympus, Japan) fitted 
with a 1x lens and a 10x body zoom, giving an overall magnification of 10x. Light 
from the objective was passed through a dichroic mirror (610nm longpass) (Chroma 
Technology, USA) to split the beam, which then passes through an optical filter 
(either 565-605nm bandpass or 620nm longpass) (Chroma Technology) to reach 
one of two charge-coupled device cameras (SciMeasure, USA). The heart was 
illuminated with 530nm light emitted from four LED light sets (Cairn Research). 
Signals from the cameras were inputted to a computer via a custom-made 
acquisition system (Redshirt Imaging, USA). All images were acquired using the 
Cardioplex software (Redshirt Imaging) at a rate of 1000fps. For calcium and voltage 
dyes, data was taken at baseline and at 5 minute intervals after the intervention had 
started; for Ψm, data was taken every 30 seconds.  
 
After focusing the heart onto the cameras, dyes were loaded into the heart. Rhod-2 
is a calcium-sensitive dye that increases its fluorescence when bound to Ca2+. Rhod-
2 acetoxymethyl ester (AM) (Thermo Fisher Scientific, USA) was used as it is able to 
enter the cardiomyocyte, where it can be de-esterified to form the active Rhod-2 dye. 
150µg of Rhod-2 AM was mixed with 150µl of 10% w/v Pluronic F-127 (Sigma-
Aldrich) and warmed slightly by holding the vials for two minutes. 1200µl of room 
temperature KH was added to the 300µl of Rhod-2 AM and Pluronic F-127 and the 
1500µl was injected via an injection port directly before the final bubble trap over 5 
minutes. Signals were acquired 30 minutes after Rhod-2 was infused.  
 
RH237 (Thermo Fisher Scientific) is a voltage sensitive dye that decreases in 
fluorescence during cellular depolarisation. 1.05ml of injectable RH237 was made up 
 63 
from a 1.25mg.ml-1 (100% v/v DMSO) stock by adding 50µl stock RH237 to 1ml of 
room temperature KH, which was then infused via a needle port over 5 minutes. 
Signals were acquirable immediately and RH237 was infused as near to the time of 
experimentation as possible due to the gradual washout of the RH237 from cells 
over time.  
 
Tetramethylrhodamine Methyl Ester (TMRM) is a Ψm-sensitive dye that reduces in 
fluorescence when Ψm is less polarised, indicating a degree of mitochondrial 
dysfunction. 25mg of TMRM (Thermo Fisher Scientific) was added to 10ml of DMSO 
and mixed. 20µl of this TMRM stock was added to 50ml of room temperature KH to 
give a final TMRM concentration of 2µM. This was infused for 20 minutes at 10% of 
the infusion rate (i.e. 1.5-1.8ml.min-1) through an injection port directly before the 
final bubble trap by an Aladdin syringe pump (World Precision Instruments, Inc., 
USA), during which the pump’s contribution to cardiac perfusion was reduced to 
~90% of the original. This was followed by a 20 minute washout period during which 
the extracellular TMRM dye could leave the heart and the surrounding chamber. 
Satisfactory TMRM infusion was validated by a uniform signal across the heart, 
tested using the real-time function on the Cardioplex software. Experimental 
interventions were then carried out. For the in vitro determination of the effect of 
hyperthermia on TMRM fluorescence, a 2µM solution of TMRM in KH was 
equilibrated for 15 minutes at the desired temperature, after which fluorescence 
measurements were taken in triplicate using a previously described fluorometer 
(Manning et al., 2008). Laser pulses at 530nm were used to excite the fluorophore, 
and emission was measured at 585nm.  
 
For experiments where cardiac paralysis was required (calcium and voltage 
recordings), blebbistatin was used as an excitation-contraction uncoupler, which acts 
by preventing the release of phosphate from the myosin head, keeping the 
myofilaments in a detached state (Kovács et al., 2004); it is thought to have few 
effects on the action potential, making it a useful tool to remove motion artefact from 
these sensitive recordings (Fedorov et al., 2007). 5mg of blebbistatin (Cayman 
Chemical, USA) was added to 1.72ml of DMSO and mixed. 500µl of this stock 
solution was added to 50ml of room temperature KH and infused via an injection port 
directly before the final bubble trap by an Aladdin syringe pump (World Precision 
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Instruments, Inc.) at 30% of the flow rate (i.e. ~4.8ml.min-1), during which the pump 
was reduced by the same amount. When the heart was paralysed the flow rate for 
blebbistatin was reduced to 10% of the original pump flow rate (i.e. 1.5-1.8ml.min-1) 
and the pump rate was increased to 90% of the original pump flow rate. A baseline 
recording was taken once the heart rate had reached a steady state (mild 
bradycardia was often seen due to mild hypothermia), after which the experimental 
intervention was started.  
 
In the case of adrenaline being the experimental intervention, a stock solution of 
10mM (-)-adrenaline (Sigma-Aldrich) was diluted to 100µM in room temperature KH. 
This was then infused by an Aladdin syringe pump (World Precision Instruments, 
Inc.) at the required percentage of the infusion rate to give the desired final 
concentration. When hyperthermia pre-treatment was part of the experimental 
intervention, the thermal circulator was increased from a set temperature of 40.5oC 
to 44.5oC and allowed to equilibrate for 30 minutes before any further experimental 
interventions were implemented. This corresponded to a temperature at the level of 
the heart of 41oC.  
 
Data was analysed using Matlab R2014b (Mathworks, USA) using code written by Dr 
Jennifer Simonotto (see Appendix for full code). Briefly, voltage and calcium 
transients were detected using a second-order differential method and their 
durations to 15%, 25%, 50%, 75% 90% were calculated and a mean was taken for 
all the transients for each measurement. For TMRM analysis, the background was 
masked out of the analysis and a baseline (i.e. before TMRM infusion) fluorescence 
count was measured for the heart and subtracted from all other measurements to 
give a true baseline above which is the TMRM signal. After the washout period a 
measurement was taken for each pixel and taken to be ‘1’, to which all changes in 
TMRM after the end of the washout were normalised. The median value for all the 
pixels across the heart was reported for each time point.  
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2.4 Isolated cardiomyocyte studies 
 
2.4.1 Isolation of adult rat ventricular cardiomyocytes 
 
Hearts were extracted and dissected as previously stated (Section 2.3.1). The heart 
was then hung by the ascending aorta from a cannula, through which flowed (6-
8ml.min-1.g-1) warmed (37oC) KH to perfuse the heart via the coronary arteries. After 
the heart was clear of blood, the perfusate was rapidly switched to low-calcium 
solution: adequate perfusion was validated by a rapid cessation of contraction upon 
low-calcium perfusion. Low-calcium solution was perfused for 5 minutes, after which 
the perfusate was switched to enzyme solution containing 1mg.ml-1 collagenase type 
II (Worthington, UK) and 0.6mg.ml-1 hyaluronidase (Sigma-Aldrich, UK). Enzymatic 
digestion on the Langendorff apparatus continued for 10 minutes, after which the 
heart was removed and the left ventricle dissected away and minced into small 
pieces. These were transferred into a Falcon tube containing the same enzymatic 
digestion solution and shook in a 37oC water bath for 5 minutes. After 5 minutes the 
solution was filtered and left ventricle pieces were transferred to a new Falcon tube 
with the same solution present. After 30 minutes of shaking in a 37oC water bath, the 
solution was filtered through gauze and spun for 1 minute at 700rpm. The pellet was 
then resuspended in enzyme solution (without enzyme) and kept at room 
temperature until the time of the experiment.  
 
2.4.2 Hyperthermia pre-treatment of isolated cardiomyocytes 
 
Cardiomyocytes that were used in hyperthermia experiments were subjected to a 
hyperthermia pre-treatment protocol. ~0.5ml of the cardiomyocyte suspension was 
transferred to a 1.5ml centrifuge tube and heated in a water bath at either 37oC or 
41oC for one hour. After one hour, the centrifuge tube was removed and cells were 
immediately transferred to the cell bath for contractility experiments.  
 
2.4.3 Isolated cardiomyocyte contractility experiments 
 
For all cell shortening experiments, a Nikon TE-200 inverted microscope was used in 
conjunction with an IonOptix MyoCam conected to the side-port (IonOptix Corp., 
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USA). This was then connected to a PC and data was acquired and analysed using 
the IonWizard software (IonOptix Corp.).  
 
A drop of cardiomyocyte suspension was placed into a cell bath and allowed to settle 
for 5 minutes. After 5 minutes the pump superfused the cells with KH solution (37oC, 
2ml.min-1) and the stimulator was started (50V, 1ms pulse width, 0.5Hz). After a 
further 5 minutes a suitable cardiomyocyte was orientated in the viewfinder of the 
IonWizard software and the edges of the cell were tracked using the edge-detection 
system. For inclusion, cardiomyocytes must be rod shaped with clear striations, only 
contracting in response to the stimulator, and have a cell shortening of 2-8% at 
baseline.  
 
For population studies, cells were chosen at random and ~30 seconds of contraction 
was measured before moving onto the next cell. Cells must have been rod shaped 
with clear striations; cells were included even if they were not in the 2-8% cell 
shortening range.  
 
For catecholamine response studies, cells were recorded for a 10 minute baseline 
period, followed by 1µM isoprenaline for 10 minutes, and then a 25 minute perfusion 
of KH without any pharmacological agent present. Finally, a repeat stimulation with 
1µM isoprenaline was carried out in the presence of CGP-20712A, a β1-
adrenoceptor antagonist. All measurements were taken at the end of each epoch, 
unless otherwise stated, and are the mean of >10 contractions. After each 
experiment, lines were rinsed with ~60ml of distilled H2O.  
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Figure 2.3: A representative isolated cardiomyocyte during IonOptix recording (edge detection 
trace below).  
 
 
 
 
Figure 2.4: Representative contractions from an isolated cardiomyocyte stimulated at 0.5Hz.  
 
2.5 In vivo studies 
 
2.5.1 Anaesthesia protocols 
 
Isoflurane anaesthesia: Animals were transferred to an anaesthetic chamber and 
isoflurane (5% in 100% O2) was delivered until the animal was anaesthetised, as 
determined by a loss of the righting reflex. Anaesthesia was maintained outside of 
the anaesthetic chamber using a Bain co-axial tube (2-2.5% isoflurane in 100% O2, 
1.5L.min-1), with anaesthetic gases removed using a Fluovac scavenger (Harvard 
Instruments, USA). Anaesthesia was adjusted according to the depth of anaesthesia 
observed, with an isoflurane concentration of 3% used if required to obtain a surgical 
plane of anaesthesia. 
Ketamine-midazolam anaesthesia: Animals were restrained and a mixture of 
ketamine and midazolam was injected intraperitoneally on the right side at a level 
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just cranial to the level of the knees using a 26G needle at a dose of 50mg.kg-1 and 
5mg.kg-1, respectively. Just prior to injection, a small amount of negative pressure 
was applied to the syringe: the presence of blood, urine or faeces in the syringe or 
needle dead-space resulted in the immediate withdrawal of the needle and fresh 
solutions to be used. After a brief period of excitability, animals lost their righting 
reflex and were in a state of humane restraint. However, some muscle rigidity and 
sensitivity to pain remained, and for this reason no surgical procedures were carried 
out under this anaesthesia regimen; no pain response was observed to 
intraperitoneal administration of solutions. Anaesthesia was augmented at a dose of 
25mg.kg-1 and 2.5mg.kg-1 of ketamine and midazolam, respectively, each time a 
lightening of anaesthesia was noted, as determined by small co-ordinated muscular 
movements. Due to excessive salivary secretions under this anaesthetic protocol, a 
piece of gauze was place into the mouth of the rats to drain away saliva and prevent 
aspiration.  
 
2.5.2 Echocardiography protocol 
 
The thorax of the rat was shaved using an electric hair trimmer after which the 
animal was transferred to a heated ultrasound table (Visualsonics, Canada). The rat 
was secured using surgical tape and their body temperature was monitored using a 
rectal thermometer connected to a homeothermic temperature monitor (Harvard 
Apparatus). The homeothermic monitor outputted to a heated blanket (Harvard 
Apparatus, USA), the temperature of which was adjusted according to the animal’s 
body temperature. Hair depilatory cream (Church and Dwight, USA) was applied to 
the thorax for 5 minutes, after which the cream was gently scraped off and the chest 
washed with a damp tissue to remove any remaining cream. Ultrasound gel (Henleys 
Medical Supplies, UK) was applied to the thorax and the ultrasound probe (RMV-
716, Visualsonics) was lowered onto the thorax with the axis of the probe parallel to 
the cranial-caudal axis of the rat.  
 
The ultrasound probe was translated around the chest until the heart was visualised 
on the B-mode image on the Vevo 770 ultrasound system (Visualsonics). When the 
heart was visualised, the probe was translated laterally to determine where the best 
view of the apex and of the ascending aorta were. The probe was then moved to the 
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approximate mid-point of these two locations and rotated towards the axis of the 
right forelimb and left hindlimb until an ‘on-axis’ parasternal long axis view of the left 
ventricle was obtained. This was defined as a view that clearly showed the left 
ventricular cavity with a clear line of sight between the apex and the ascending aorta 
and the left atrial annulus visible. M-mode images were taken in the apical and basal 
regions of the left ventricle, defined as such as the apical third and the basal third of 
the left ventricle. Contractility was measured using the left ventricular internal 
dimensions tool, which was part of the Vevo 770 software. A minimum of five beats 
were used, from which a mean was calculated. Fractional shortening was defined as 
the percentage of the reduction in internal diameter of the left ventricle relative to the 
diameter during diastole. Heart rate was measured using the ECG. No attempt to 
measure ejection fraction was made due to the over-reliance on assumptions about 
LV cavity shape the measurements make, which during a disease model of regional 
contractility changes may not be accurate. Rats were killed at the end of the 
experiment by cervical dislocation and their heart frozen in liquid nitrogen after 
dissecting the left ventricle into apex, middle and base.  
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Figure 2.5: A representative ‘on-axis’ parasternal long axis B-mode image at baseline.   
 
 
 
Figure 2.6: A representative M-mode trace with analysis.  
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2.5.3 Adrenaline bolus protocol 
 
After the rat was depilated and a satisfactory echocardiographic parasternal long-
axis image was obtained, a lateral incision cranial to the left clavicle was made using 
a size 20 scalpel and pressure was applied using a sterile swab to promote 
haemostasis. When capillary bleeding had ceased, the skin was blunt dissected 
away from the underlying fascia, through which a small cut was made to expose the 
muscle layer. Further dissection was made cranio-medially until the left external 
jugular vein was exposed. If this vein was collapsed upon visualisation, the same 
procedure was performed on the right side. In this event a piece of sterile gauze was 
placed over the wound on the left side.  
 
After visualisation of a suitable external jugular vein and the acquisition of baseline 
echocardiographic images, a 30G needle was inserted into the vein. Successful 
insertion into the vein was judged by a small amount of blood entering the dead-
space of the needle. Adrenaline (Hameln, UK) at a dose of 4.28×10-7mol.kg-1 was 
injected over a period of ~10 seconds. Proper intravenous administration was 
determined by the absence of local infiltration from the injection and a reduction in 
blood content in the vein due to be displaced by a clear fluid; bradycardia on the 
ECG was also indicative of an intravenous adrenaline dose. Animals were 
maintained between 37-38oC using the homeothermic heated blanket.  
 
2.5.4 Intraperitoneal isoprenaline protocols 
 
Consciously-administered isoprenaline: Rats were restrained and isoprenaline was 
injected intraperitoneally on the right side of the abdomen using a 26G needle. Rats 
were returned to their cage and monitored for 15 minutes after injection. Rats 
typically showed reduced locomotor activity at rest and normal movement during 
handling. Rats were anaesthetised with isoflurane before imaging as described 
above.  
 
Isoprenaline under anaesthesia: After a satisfactory echocardiographic image was 
obtained and a baseline measurement taken, a solution of (-)-isoprenaline (Sigma-
Aldrich, UK) was injected intraperitoneally on the right side of the abdomen at the 
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level of the knees. Just prior to injection, a small amount of negative pressure was 
applied: blood, urine or faeces in the syringe or needle dead-space resulted in the 
withdrawal of the needle and fresh isoprenaline to be used. Body temperature was 
maintained between 37-38oC for initial experiments.  
 
2.5.5 Tail-cuff plethysmography  
 
After acquisition of a satisfactory echocardiographic image, an inflatable pressure 
cuff (AD Instruments) was put onto the proximal aspect of the tail and a pulse 
transducer (AD Instruments) was attached distal to the cuff. These were connected 
to a non-invasive blood pressure system (AD Instruments), which was connected to 
a PowerLab (AD Instruments). The cuff was inflated to 200mmHg and deflated over 
20 seconds. Systolic blood pressure was taken to be the pressure level in the tail 
cuff at the time of restoration of pulsatile blood flow as determined by the pulse 
transducer.  
 
2.5.6 Body temperature manipulation protocols 
 
Hyperthermia after isoprenaline: After isoprenaline administration under ketamine-
midazolam anaesthesia, rats became naturally hyperthermic, with temperatures of 
>39oC seen. In hyperthermia experiments, the homeothermic blanket was used as a 
standard heated blanket and left on the animal’s abdomen until a rectal temperature 
of 41oC was reached, when the blanket was removed and the heated ultrasound 
table turned off. The blanket was replaced and the heated table switched on when 
the rectal temperature reached 40.7oC.  
 
Active cooling after TTS induction: Nitrile gloves were filled with ice and placed on 
the abdomen of the rat, and small pieces of compacted ice were placed around the 
rat and on the rat’s superior thorax; all heating apparatus was turned off and 
removed. The heated ultrasound table and heated blanket were replaced when the 
rat reached 37oC and the rat was dried with paper towelling; some animals continued 
to cool for a brief period after the restoration of heating.  
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2.5.7 Minipump implantation 
 
17β-estradiol was dissolved at a concentration of 80mg.ml-1 in DMSO by vortexing. 
When fully dissolved, this was mixed in a 1:1 ratio with glycerol to give a final 17β-
estradiol concentration of 40mg.ml-1. All solutions were filtered with a Millex-GV 
0.22µM syringe-end filter (Millipore, USA) to ensure sterility of the solutions. Alzet 
2004 osmotic minipumps (Durect Corp., USA) were filled with either 1:1 
DMSO/glycerol or DMSO/glycerol with 17β-estradiol using a blunt needle in a tissue 
culture hood; care was taken to remove any air bubbles from the minipump to ensure 
optimum infusion after implantation. After filling, the flow moderator was inserted and 
the minipumps were once again inspected for air bubbles. Filled minipumps were left 
overnight at 37oC in 0.9% normal saline to prime.  
 
Rats were anaesthetised in an anaesthetic chamber with isoflurane (as per protocol 
above); when anaesthetised, the scruff of the animal was shaved with an electric hair 
trimmer and the rat was transferred to a heated pad (Beurer, Germany). A surgical 
plane of anaesthesia was maintained using a Bain co-axial nosecone. 10% povidone 
iodine was applied liberally to the shaved scruff and a sterile drape was put over the 
animal with a hole cut for the scruff. 30µg buprenorphine hydrochloride (Ceva Animal 
Health, USA) was administered subcutaneously in the right flank prior to the first 
incision. An aseptic surgical technique was used throughout the procedure: all non-
disposable equipment was sterilised by autoclaving; all disposable equipment was 
packaged sterile. 70% v/v ethanol was used to sterilise gloves if a non-sterile surface 
was touched during the procedure. After confirmation of a surgical plane of 
anaesthesia by observing a negative pedal reflex response to a painful stimulus 
applied to a hind-paw, a lateral ~3cm incision was made just caudal of the vertebra 
prominens using a size 20 disposable scalpel (Swann-Morton, UK). Pressure was 
applied to the wound with sterile gauze to stem any capillary bleeding. The skin was 
blunt dissected away from the underlying fascia, after which a cut was made through 
the fascia to the subfascial space. A large pocket was opened caudally to the 
incision through blunt dissection, into which the minipump was inserted with the flow 
moderator pointing away from the wound.  
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The fascia was sutured with one or two interrupted sutures (3-0 Ethibond Excel, 
Ethicon, USA), depending on the size of the opening after blunt dissection. 3-0 
Ethibond Excel was then used to close the skin wound, typically using 5-7 
interrupted sutures depending on the size of the wound. Rats were left to recover in 
a heated box (~41oC) for 15 minutes, after which they were transferred to individual 
housing; rats were monitored daily. After a week of being house individually, rats 
were transferred back to a grouped cage of four. Animals were experimented on 14 
days after implantation.  
 
2.5.8 Silastic capsule implantation 
 
Silastic capsules are another method of estrogen replacement that have been 
described previously (Ingberg et al., 2012; Ström et al., 2013, 2012, 2010). 
HelixMark silicone tubing with dimensions 3.18mm external diameter and 1.58 
internal diameter (Helix Medical, USA) was cut into 3cm lengths and autoclaved 
alongside 5mm lengths of wooden applicator sticks. A mixture of sesame oil and 
17β-estradiol (180μg.ml-1) was warmed to 37oC in a water bath for 1 hour to aid its 
dissolving. A stirrer bar was then added to the container and stirred at a high speed 
until all 17β-estradiol was dissolved. Silastic capsules were plugged at both ends 
with a length of applicator stick and the capsule was filled with either 17β-estradiol in 
sesame oil or sesame oil alone with a 30G needle inserted between the tubing and 
the wooden plug until the capsule was filled and oil was being forced out of the 
wooden plugs. Capsules were left overnight in either 17β-estradiol and sesame oil or 
sesame oil alone, depending on their contents, and were implanted the following 
day. The implantation procedure was identical to the procedure used for osmotic 
minipumps (see above). Animals were experimented on 14 days after implantation. 
 
2.6 Statistics 
 
All statistical analysis of data was carried out using Prism 6 (GraphPad Software, 
USA), with the exception of 2x2 contingency table analysis, which was carried out 
using Matlab R2014b (Mathworks). All continuous data was tested for normality 
using a Komogorov-Smirnov test, and if shown to follow a Gaussian distribution, the 
presence of difference was tested for using a parametric test; otherwise, where 
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appropriate a non-parametric equivalent was used. Significance was taken to be at a 
level of 0.05.  
 
2.6.1 Comparison of two groups of data 
 
A Student’s t-test was used to compare the means of two groups of normally 
distributed data, where a significant P-value (i.e. P<0.05) showed that there was a 
significant difference between the two groups and they were likely to be from two 
separate distributions, rather than from two parts of the same distribution. A Mann-
Whitney U test was used if the data was not normally distributed, which compares 
the medians of the groups instead of the means. Paired tests were used when 
appropriate (i.e. before and after treatment on the same cell, heart or animal).  
 
2.6.2 Comparison of three or more groups of data 
 
A one-way ANOVA with Sidak’s post-hoc test was used to compare more than two 
groups of data with each other. A Kruskal-Wallis test with Dunn’s post-hoc test was 
used if the data was not normally distributed.  
 
2.6.3 Comparison of data with two independent variables 
 
Data with two independent variables was any study where a number of time points 
were taken alongside more than one region or treatment (i.e. apex and base over 
time after adrenaline). A two-way repeated-measures ANOVA was used to analyse 
this data to assess the effects on the dependent variable of time and the other 
dependent variable. Tukey’s post-hoc test was used to compare the effects between 
regions or treatments over the whole course of the experiment, whereas a Dunnett’s 
post-hoc test was used to compare individual time-points between regions or 
treatments. 
 
2.6.4 Comparison of mortality  
 
Mortality was compared using a 2x2 contingency table with a Bernard’s exact test. 
The Barnard’s test is more powerful than a Fisher’s exact test for a 2x2 contingency 
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table, although this diminishes as the table increases in size (Ludbrook, 2008; Mehta 
and Hilton, 1993). Bernard’s exact test was ran on a 2x2 matrix using Matlab 
R2014b (Mathworks) (see Appendix for full code).  
 
2.6.5 Comparison of survival curves 
 
Survival curves were analysed using the log-rank test to assess for any difference in 
survival between treatments.  
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3. The effects of gender on catecholamine responsiveness and Takotsubo 
syndrome 
 
3.1 Introduction 
 
Gender and the hormonal differences associated with the respective genders at 
different stages of life play a key role in modulating catecholamine responsiveness 
and TTS pathophysiology. For instance, estrogen-competent females are relatively 
protected against stress compared to males (Lindheim et al., 1992), and pre-
menopausal females are protected compared to males against sudden cardiac death 
(Kannel and Schatzkin, 1985). With particular reference to the effects of sex 
hormones in TTS, the disease appears to pre-dominate in post-menopausal females, 
in whom due to a reduction in ovarian function, there are only very low levels of 
circulating estrogen (Schneider et al., 2013b); relatively few cases of TTS are in 
males (also very little estrogen) or females (estrogen-competent). Therefore, it 
appears that it is not the absence of estrogen, but the withdrawal of estrogen after a 
sustained period of estrogen cycling that may cause a predisposition to TTS.  
 
Estrogen in both genders can have potent sympatholytic and anti-arrhythmic effects 
(H. Y. Li et al., 2000; Nakajima et al., 1999), and during the post-menopausal period 
females are at an increased risk of cardiovascular disease compared to pre-
menopausal females of a similar age (Kannel et al., 1976). Furthermore, post-
menopausal females have been shown to have a hyper-responsive sympathetic 
nervous system in response to a stressful environmental stimulus (Lindheim et al., 
1992). By understanding how the magnitude of catecholamine release in response to 
TTS-inducing events (i.e. stressful events) and the heart’s response to such 
catecholamines are affected by the menopause could give a key insight into the 
mechanisms of TTS. As rats do not experience a menopause, animal models of 
menopause have been created surgically by removing the ovaries of the rat; this 
animal model is most commonly used in osteoporosis (Kalu, 1991), although is also 
amenable to use in cardiovascular studies.  
 
To date, there is only one published model of TTS in a ‘post-menopausal’ animal, 
tested in a number of papers by the group from Wakayama Medical University 
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(Ueyama et al., 2007, 2003). This model used dorsal recumbency restraint to induce 
a stress response in the animal, which subsequently resulted in a dysfunctional left 
ventricle, somewhat ameliorated by chronic (2 week) estrogen replacement. As this 
is a psychogenic model of stress that leads to TTS-like dysfunction, ovariectomy 
could be affecting both the central neurophysiological response to the stressful 
stimulus and the heart’s response to the released catecholamines. This was shown 
to be true by Ueyama et al. (2007), where an increase in stress-induced cardiac 
dysfunction was observed in the ovariectomised group.  
 
We developed a model of TTS in male rats, in which a single adrenaline bolus 
caused a transient apical dysfunction that peaked at 20 minutes post-bolus and 
returned to baseline within 1 hour (Paur et al., 2012). As TTS is a syndrome primarily 
of the post-menopausal female, I set out to determine the effects of gender and 
estrogen status on the cardiac response to a single adrenaline bolus that resulted in 
TTS-like contractility in Sprague Dawley male rats.  
 
3.2 Materials and methods 
 
3.2.1 Reagents 
 
Isoflurane was obtained from Abbot Laboratories (UK). Adrenaline was obtained 
from Hameln (UK). Sesame oil, DMSO (100% v/v), glycerol (100% v/v) and 17β-
estradiol were obtained from Sigma-Aldrich (UK). Buprenorphine was obtained from 
Ceva Animal Health (USA).  
 
3.2.2 Animals 
 
All animal procedures were performed in accordance with Animals (Scientific 
Procedures) Act 1986 and under a personal and project Home Office licence. 
Animals were housed in groups of four and experienced a 12 hour light/dark cycle. 
Sprague Dawley rats were obtained from Charles River Laboratories (UK). Male rats 
typically weighed between 200-350g, whereas female rats weighed between 190-
250g. Ovariectomised rats were purchased from Charles River Laboratories, who 
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carried out all ovariectomy procedures in-house. All animals were killed by a 
Schedule 1 method (cervical dislocation) at the end of the experiment.  
 
3.2.3 Minipump implantation 
 
Alzet 2004 osmotic minipumps (Durect Corp., USA) containing 17β-estradiol 
(40mg.ml-1 in 50/50 DMSO/glycerol) or vehicle alone (50/50 DMSO/glycerol were 
implanted subfascially in the scruff of ovariectomised rats under isoflurane 
anaesthesia with peri-operative buprenorphine (30µg) given additionally. Rats were 
studied 14 days after implantation.  
 
3.2.4 Silastic capsule implantation 
 
Silastic capsules (3cm lengths of HelixMark silicone tubing (3.18mm external 
diameter, 1.58 internal diameter) (Helix Medical, USA) plugged with applicator sticks) 
were filled with 17β-estradiol (180μg.ml-1 in sesame oil) or sesame oil alone and 
incubated overnight at room temperature in sesame oil or 180μg.ml-1 17β-estradiol n 
sesame oil and implanted the next day in exactly the same protocol as for 
minipumps. Rats were studied 14 days after implantation. 
 
3.2.5 Echocardiography protocol 
 
Animals were anaesthetised in an anaesthetic box (5% isoflurane in 100% O2, Abbot 
Laboratories, UK) until a loss of righting reflex was observed. The rat was removed 
and its thorax shaved. The rat was then transferred to a heated ultrasound table 
(Visualsonics, Canada) and anaesthesia was maintained using a Bain co-axial 
nosecone (2.5% isoflurane in 100% O2). A rectal thermometer connected to a 
homeothermic blanket system (Harvard Apparatus, USA) was used to maintain body 
temperature between 37-38oC. Hair removal cream (Charles and Dwight, USA) was 
applied to the thorax for 5 minutes before being wiped off. The RMV-716 ultrasound 
probe, connected to the Vevo 700 ultrasound system (Visualsonics), was lowered 
onto the thorax and moved until an ‘on-axis’ parasternal long axis echocardiographic 
image was acquired. M-mode images from apical and basal left ventricular regions 
were taken at baseline and at 5 minute intervals after adrenaline bolus. After the 
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experiment was completed, rats were killed by cervical dislocation and their hearts 
frozen in liquid nitrogen.  
 
3.2.7 Adrenaline bolus administration 
 
A lateral incision was made just cranial to the clavicle and the skin was blunt 
dissected away from the underlying fascia. A small cut was made to the fascia to 
expose the muscle layer. This cut was then further dissected cranio-medially to 
expose the external jugular vein. Adrenaline (Hameln, UK) at a dose of 4.28×10-
7mol.kg-1 was injected via a 30G needle over a period of ~10 seconds. Correct 
placement of the needle was confirmed by the clearing of blood in the vein during 
injection and instantaneous bradycardia.   
 
3.2.8 Arrhythmia analysis 
 
Arrhythmias were scored in a hierarchical  using a modified version of the Lambeth 
convention (Walker et al., 1988): 0 = 0-49 ventricular ectopics; 1 = 50-499 ventricular 
ectopics; 2 = >500 ventricular ectopics or one brief period of non-sustained 
ventricular tachycardia; 3 = <1 min of ventricular tachycardia; 4 = >1 min of 
ventricular tachycardia; 5 = non-terminating VF. Scores were applied in a 
hierarchical way, so that if an animal had 500 ventricular ectopics and 2 minutes of 
ventricular tachycardia, the score would be 4, not 2+4.  
 
3.2.9 Statistical analysis 
 
Unless otherwise stated, all echocardiographic data was analysed using two-way 
repeated measures ANOVA calculations with either Tukey’s (for whole experiment 
analysis) or Dunnett’s (individual time-point analysis) post-hoc tests. Mortality 
comparisons were made using Bernard’s exact test.  
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3.3 Results 
 
With the exception of male, female and ovariectomised rats without any estrogen 
treatment, and ovariectomised rats with acute estrogen, all data presented in this 
chapter was acquired solely by myself during my PhD studies. Male and female rat 
studies without estrogen treatment was acquired jointly by myself and Peter Wright 
and is presented in part in his PhD thesis and an MRes thesis authored by myself; 
ovariectomised rats with or without acute estrogen treatment was also acquired 
jointly by myself and Peter Wright and is presented in Peter Wright’s PhD thesis. 
Therefore, these animals will be referenced to, but no figures derived from those 
experiments will be presented apart from mortality comparisons. QTc analysis was 
not presented in Peter Wright’s thesis and was solely analysed by myself during my 
PhD: therefore, this will be presented in this chapter.  
 
3.3.1 Mortality in male, female and ovariectomised rats after adrenaline bolus 
 
After adrenaline bolus, male animals exhibited a transient apical ballooning that 
peaked at ~20 minutes post-bolus and resolved within 60 minutes post-bolus (Paur 
et al., 2012). Out of 13 male animals tested, 46% died within 60 minutes: 5 animals 
died in the acute phase (i.e. within ~5 minutes of adrenaline bolus) due to the 
development of tachyarrhythmias and subsequent ventricular fibrillation (VF); one 
died due to heart block 33 minutes after adrenaline bolus. Females were significantly 
protected against mortality, with only 6.25% showing mortality (1 of 16 animals 
tested); this mortality was due to VF in the acute phase. Females were also 
protected against cardiac dysfunction after adrenaline bolus.  
 
Ovariectomised rats showed a high (75%) level of mortality after adrenaline bolus 
(12 tested), with 5 rats dying due to VF and 4 due to a severe acute heart failure 
manifesting as profound bradycardia and cardiac dysfunction 20-30 minutes after 
adrenaline bolus. Acute treatment with estrogen (600ng 17β-estradiol infused for 10 
minutes directly before adrenaline bolus) did not significantly reduce mortality: 50% 
mortality was observed, all due to VF (12 animals tested).  
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3.3.2 Acute estrogen infusion had no effect on QTc duration in ovariectomised rats 
 
Acute estrogen infusion (600ng 17β-estradiol) was administered over 10 minutes, 
with adrenaline bolus given after the infusion had finished. Experiments were carried 
out jointly with Peter Wright, and contraction and mortality data appears in his PhD 
thesis. QTc was measured immediately before estrogen infusion and between the 
completion of the estrogen infusion and the start of the adrenaline bolus. No 
significant difference was found after estrogen infusion (P=0.72, n=6, paired t-test; 6 
animals were excluded from analysis due to an undetectable t-wave endpoint) (figure 
3.1) 
 
 
Figure 3.1: Acute estrogen infusion did not significantly alter the QTc duration in 
ovariectomised rats (P=0.72, n=6, paired t-test (6 animals were excluded from analysis due to 
an undetectable t-wave endpoint). Mean±SEM shown.  
 
3.3.3 Chronic estrogen supplementation reduced mortality after adrenaline bolus in 
ovariectomised rats 
 
Supplementing ovariectomised rats with 17β-estradiol (238µg.day-1) has been shown 
to ameliorate cardiac dysfunction caused by high levels of emotional stress (Ueyama 
et al., 2007). As we observed very high levels of mortality in the ovariectomised rats 
compared to female rats, it was hypothesised that replacement of estrogen in these 
estrogen-deficit animals could somewhat prevent the high mortality rate. Osmotic 
minipumps were implanted that delivered the same dose (238µg.day-1) of 17β-
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estradiol, dissolved in a 50/50 DMSO/glycerol solution. The reason behind this 
solvent choice was based on the insolubility of 17β-estradiol in most solvents that 
are compatible with the osmotic minipump. 100% (v/v) DMSO is not compatible 
either, so after 17β-estradiol was dissolved in DMSO, the DMSO-17β-estradiol 
mixture was then diluted to 50% DMSO (v/v) to allow it to be delivered from a 
minipump.  
 
Compared to ovariectomised animals without estrogen treatment, implantation of a 
minipump containing 17β-estradiol (238µg.day-1 infusion rate) for 2 weeks 
significantly reduced mortality after adrenaline bolus (10% vs. 75%, n=10 with 
minipump, 12 without minipump; P<0.01, Bernard’s exact test). There was also a 
reduction in mortality in the vehicle minipump group compared to no minipump, 
although this was not significant (40% vs. 75%, n=10 with minipump, 12 without 
minipump; P=0.15, Bernard’s exact test) (figure 3.2). The one estrogen minipump 
implanted rat that died was due to VF; three vehicle minipump animals died from VF 
and one from bradycardic acute heart failure. Although 22 animals were implanted 
with minipumps (11 per group), one from each group were excluded from analysis 
due to uncertain jugular vein injection efficiency. No difference in median arrhythmia 
score (estrogen=1.5, vehicle=3) was seen between the two minipump groups 
(P=0.34, Mann-Whitney U test), and unlike the isoprenaline TTS model, no ECG 
changes of note were observed.  
 
3.3.4 Chronic estrogen supplementation shortened baseline QTc in ovariectomised 
rats 
 
Unfortunately, the ECG quality from the non-ovariectomised female animals was 
such that an accurate QT interval could not be measured during the adrenaline bolus 
model. Therefore, no comparison between non-ovariectomised and ovariectomised 
rats’ QT interval can be made. However, in humans, an increase in the risk for 
syncope and sudden cardiac death has been reported in females after the 
menopause with congenital long QT type 2 (hERG loss-of-function mutation) (Buber 
et al., 2011). Women with premature ovarian failure, perhaps a human disease that 
is closer to the artificial ovariectomy used in rats to simulate the menopause, did 
show a prolonged QT interval compared to healthy controls (Canpolat et al., 2013), 
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and yet females studied 20-25 days post-bilateral oophorectomy did not show 
significant changes in ventricular repolarisation (De Leo et al., 2000). Human studies 
on hormone replacement therapy for post-menopausal females have shown that 
estrogen hormone replacement can increase the QT interval (Gökçe et al., 2005), 
whereas progesterone hormone replacement did not, probably due to progesterone’s 
differing actions on cellular repolarisation (Nakamura et al., 2007).  
 
Here, 2-week 17β-estradiol minipump treatment at a level able to reduce mortality in 
ovariectomised rats reduced the QTc at baseline (i.e. before adrenaline bolus), as 
did vehicle treatment; no different in QTc at baseline was seen between the two 
minipump groups (P<0.001 OVX vs. OVX-E, P<0.01 OVX vs. OVX-V; n=12 per 
group, one-way ANOVA) (figure 3.4).  
 
 
 
Figure 3.2: A significant decrease in mortality after estrogen minipump implantation was seen, 
returning it to a similar level seen in estrogen-competent females. OVX: ovariectomised; OVX-
E: ovariectomised with estrogen minipump; OVX-V: ovariectomised with vehicle minipump. **: 
P<0.01; ***: P<0.001, Bernard’s exact test. n= 13, 16, 12, 10 & 10, respectively. Male, female and 
OVX mortality experiments carried out in conjunction with Peter Wright.  
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Figure 3.3: No difference in median arrhythmia score was seen between the two minipump 
groups (Mann-Whitney U test).  
 
 
Figure 3.4: Both estrogen and vehicle minipump treatment shortened QTc interval at baseline 
(pre-adrenaline bolus) compared to ovariectomised rats without minipump (**: P<0.01, ***: 
P<0.001; n=12 per group, one-way ANOVA). Mean±SEM shown.  
 
3.3.5 Estrogen minipump vs. vehicle showed no difference in contractility response 
to adrenaline bolus 
 
Neither vehicle- nor estrogen-treated animals showed a clear negative inotropic 
response (i.e. TTS contractility response) to an adrenaline bolus. Rather, a mild 
initial positive inotropic response was seen (figure 3.5). No significant differences 
were found between the apical contractility changes or the basal contractility 
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changes (n=9 estrogen, 6 vehicle; two-way repeated measures ANOVA). Time 
points 30 minutes and 35 minutes were removed from statistical analysis due to poor 
quality M-mode images for the base of one animal at these time points.  
 
 
Figure 3.5: Both estrogen and vehicle minipump groups showed a similar positive inotropic 
response to adrenaline bolus (n=9 estrogen, 6 vehicle; two-way repeated measures ANOVA). 
FS: fractional shortening. Mean±SEM shown.  
 
3.3.6 Chronic estrogen administration in male rats – effect on body weight 
 
As estrogen administration to ovariectomised rats resulted in a reduction in mortality, 
although not clearly over vehicle (see section 3.4), the effect of 2-week estrogen 
treatment was tested on male rats. Male rats were implanted for two weeks with 
sesame oil-filled silastic capsules, into which estrogen (180μg.ml-1) was dissolved; a 
vehicle group (sesame oil without estrogen) was used as a control group. This 
method has been used previously to produce physiological levels of plasma 17β-
estradiol in ovariectomised rats (10-140ng.ml-1) (Ström et al., 2012). However, this 
method has not been used in male rats, so is not validated.  
 
When administered to male rats, estrogen has been shown to reduce their growth 
rate (Kawai et al., 1982). Therefore, an analysis of the growth rate of the rats 
implanted with estrogen silastic capsules, compared with control, could help to 
ascertain whether the males were actually receiving the estrogen dissolved in the 
sesame oil. Compared to vehicle, there does appear to be trend in the fold change 
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from baseline in body weight at 1-week post implant (P=0.057, two-way repeated 
measures ANOVA with Sidak’s post-hoc test) (figure 3.6). Therefore, estrogen may 
be present in the plasma, at least in the first week, and could be having some 
physiological effect.  
 
 
Figure 3.6: Estrogen treatment in males did not have a significant effect on growth rate 
compared to vehicle. Body weight fold change is fold change relative to baseline (body weight 
before implantation) (n=8 per group, two-way repeated measures ANOVA). Mean±SEM shown.  
 
3.3.7 Both vehicle and estrogen silastic capsule implantation reduced QT interval 
 
As shown above, the implantation of an osmotic minipump containing either 
DMSO/glycerol (50/50) or DMSO/glycerol with 17β-estradiol reduced the QT interval 
in ovariectomised females compared with no implantation. That was a confusing 
result as we did not expect vehicle to also have an effect, and for estrogen to prolong 
the QT interval as shown in HRT recipients (Gökçe et al., 2005). Using the same 
protocol as for the ovariectomised animals, a QT interval measurement was taken 
just prior to the adrenaline bolus.  
 
It was found that, much like in ovariectomised animals, the presence of either 
capsule, 17β-estradiol or vehicle alone, shortened the QT interval compared to male 
rats without any capsule implantation (estrogen (n=8) vs. no implant (n=11): P<0.05; 
vehicle (n=8) vs. no implant (n=11): P<0.05. One-way ANOVA with Sidak’s post-hoc 
test) (figure 3.7). No difference was found between the two silastic capsule groups. 
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QT intervals for no-implant males were taken from a set of male rats anaesthetised 
under an identical protocol to the one used here but used for a different study set.  
 
 
Figure 3.7: Both silastic capsule implant groups showed a reduction in QTc compared to male 
rats without implant (n=11, 8 & 8). *: P<0.05, one-way ANOVA with Sidak’s post-hoc test. 
Mean±SEM shown.  
 
3.3.8 Silastic capsule implantation did not reduce mortality after adrenaline bolus 
 
I hypothesised that the addition of estrogen to males would reduce their sensitivity to 
adrenaline as it did in ovariectomised females, as demonstrated through the 
reduction in mortality in the estrogen minipump group. Of the 8 animals implanted in 
each group, two estrogen animals and one vehicle animal were excluded from 
contractility and mortality calculations due to uncertain jugular vein injection 
accuracy. With male animals, no significant change in mortality was observed with 
either silastic capsule groups compared to males without capsule implantation, or 
between the two capsule groups. Compared to the 46% mortality rate described 
above for male animals without silastic capsule, estrogen silastic capsule animals 
showed 66.7% mortality (n=6) and vehicle silastic capsule animals showed 42.9% 
mortality (n=7) (figure 3.8). With regard to the modes of death, in the estrogen group 
two animals died from VF and two animals died from acute heart failure; in the 
vehicle group one died from VF and one died from acute heart failure.  
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Figure 3.8: No significant difference was seen in mortality rate between estrogen (n=6) and 
vehicle (n=7) silastic capsule groups (Barnard’s exact test).  
 
3.3.9 Effects of adrenaline bolus on contractility in the silastic capsule groups 
 
Males without any capsule implantation show a clear apical dysfunction 20 minutes 
after adrenaline bolus that resolves within 60 minutes (Paur et al., 2012). As females 
appear to be somewhat protected against apical dysfunction, the implantation of an 
estrogen-secreting silastic capsule could have a similar effect. Of the six rats with 
estrogen capsules with a confirmed intravenous adrenaline bolus, only two survived 
for the full 60 minute echocardiography protocol; four of the seven vehicle capsule 
rats survived for the full 60 minutes. Of these two rats, one rat showed mild 
dysfunction in the basal myocardium (~80% of baseline fractional shortening) with a 
eukinetic apical myocardium, whilst the other showed more severe dysfunction in 
both apical and basal myocardial segments (figure 3.9).  
 
Rats implanted with a silastic capsule containing only vehicle showed a marked 
positive inotropic response (P<0.0001 compared to baseline, two-way repeated 
measures ANOVA) five minutes after adrenaline bolus that quickly subsided. After 
this there was a mild, and non-significant, depression in both measured regions of 
the heart. At 60 minutes post-bolus there was a significant positive inotropic 
response (P<0.05, two-way repeated measures ANOVA) in the basal myocardium 
(figure 3.10).  
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Figure 3.9: Fractional shortening (FS) changes relative to baseline after adrenaline bolus for 
two male rats implanted with estrogen silastic capsules.  
 
 
Figure 3.10: Fractional shortening (FS) after adrenaline bolus of male rats implanted with 
estrogen silastic capsules (#: P<0.05 base vs. baseline; ####: P<0.0001 base vs. baseline; ****: 
P<0.0001 apex vs. baseline; two-way repeated measures ANOVA; n=4). Mean±SEM shown.  
 
3.4 Discussion 
 
TTS is primarily a disease of the post-menopausal female (Schneider et al., 2013b), 
hypothesised to be the case due to the loss of estrogen’s sympatholytic effects. As 
males also have low levels of estrogen, it was hypothesised that males and 
ovariectomised females would have a similar level of mortality, and perhaps 
ovariectomised females would be somewhat protected compared to males as they 
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have had high levels of estrogen present throughout their lifetime up to the point of 
ovariectomy. This was not the case, and ovariectomised females showed the highest 
mortality level of all the animal groups we tested, showing that the sudden 
withdrawal of estrogen is worse than having no estrogen at all.  
 
In consensus with other studies of acute catecholamine toxicity in ovariectomised 
animals (Ueyama et al., 2007, 2003), estrogen replacement for two weeks reversed 
their propensity for adrenaline-induced mortality, although the vehicle that was used 
also appeared to have an effect on mortality; in contrast, an acute infusion of 
estrogen immediately before adrenaline bolus did not have a significant effect on 
mortality.  
 
Unlike in ovariectomised animals, estrogen treatment for the same length of time, 
albeit with a different vehicle and infusion method, did not reduce mortality in male 
rats, and too few animals survived to draw definite conclusions about contractility 
changes after the adrenaline bolus. However, both vehicle and estrogen groups 
appeared to show some contractile dysfunction after the adrenaline bolus, in line 
with our previous studies (Paur et al., 2012).  
 
3.4.1 Mechanism of mortality reduction with estrogen in ovariectomised rats 
 
As previously stated, this is not the first time chronic (as opposed to acute) estrogen 
replacement has reduced the severity of an animal model of TTS (Ueyama et al., 
2007, 2003). However, there is one important difference between the studies 
presented here in previously in the literature: whilst in the published reports the 
stressor was psychogenic in nature, here the catecholamine source is purely, at 
least in the initial phase, exogenous. When the source of stress was psychogenic 
(dorsal restraint), estrogen supplementation reduced the increase in heart rate and 
blood pressure, and reduced the amount of contractile dysfunction seen (Ueyama et 
al., 2007). The group observed a reduction in c-fos mRNA expression in the 
paraventricular hypothalamic nucleus, the adrenal gland and the left ventricle in the 
ovariectomised rats treated with estrogen compared to sham after the stressor. As c-
fos is an indicator of cellular activation, they propose that the estrogen 
supplementation reduced these cells’ response to dorsal restraint. This would mean 
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that there was a lower emotional response to the stressor, less adrenaline was 
released from chromaffin cells in response to an emotional stress, and the heart 
responded less to whatever catecholamines were released. Therefore, estrogen 
could be acting to reduce the activity of all three cell types, just the emotional 
response (or central nervous system’s response thereof), or a combination of two: a 
reduction in emotional response would naturally lead to a reduction in adrenal gland 
activation, which would in turn lead to a lower activation of the heart. The same 
group has shown that estrogen supplementation in ovariectomised rats reduces the 
reactivity of sympathoadrenal-projecting central neurons, decreasing the overall 
sympathetic outflow from nucleus tractus solitarius (Ueyama et al., 2006).  
 
As this TTS model is based on an anaesthetised animal given an exogenous 
catecholamine, we expect there to be no emotional response, although there could 
be autonomic responses to changes in haemodynamics. Estrogen appeared to 
reduce both arrhythmic death and death from acute heart failure. These two modes 
of death are distinct, although the mechanisms by which estrogen attenuates them 
could be similar.  
 
Ventricular fibrillation is a result of the formation of a stable rotor in the ventricles, 
preventing the normal activation pattern of the ventricles as would occur in sinus 
rhythm (Jalife, 2000). When catecholamines bind to βARs, increases in intracellular 
cAMP increase the amount of Ca2+ stored in the sarcoplasmic reticulum (SR), 
thereby increasing the amount available during the next contraction (Bers, 2008). If 
this level of Ca2+ in the SR is too high, spontaneous Ca2+ releases can occur, 
resulting in an increase in intracellular Ca2+. This can then activate the electrogenic 
sodium-calcium exchanger (NCX), driving an inward current to depolarise the 
cardiomyocyte. If this depolarisation reaches the threshold potential, an ectopic beat 
can occur (Pogwizd and Bers, 2002). Increases in ectopics can result in ventricular 
tachycardia, often due to an “R-on-T” event (ectopic beat during ventricular 
repolarisation), which may degrade into ventricular fibrillation.  
 
Ovariectomised animals have been shown to have increased levels of β1ARs in 
cardiac tissue, which could be reduced by in vivo estrogen supplementation 
(Thawornkaiwong et al., 2003). Furthermore, in the isolated heart, acute estrogen 
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can reduce the propensity for isoprenaline-induced tachycardia and ischaemia-
reperfusion arrhythmias (H. Y. Li et al., 2000). Therefore, in these ovariectomised 
animals treated with estrogen for two weeks, not only may it decrease the heart’s 
response to the injected catecholamines by reducing the expression of the 
arrhythmic β1AR, it could also be further inhibiting the activity of the remaining 
receptors during the adrenaline bolus, thereby having a double effect to reduce 
cAMP increases in cardiomyocytes.  
 
The development of cardiac dysfunction after a stressor, either pharmacological or 
psychogenic, has been shown to be caused, at least in part, by the activation of the 
β2-Gi signalling pathway, whereby the β2AR changes its coupling from the positively-
inotropic Gs pathway to the negatively-inotropic Gi pathway (Paur et al., 2012; Shao 
et al., 2013b). This switching is dependent on a robust βAR activation and 
subsequent cAMP signal in order to cause the phosphorylation of the β2AR that is 
required for stimulus trafficking (Paur et al., 2012). By decreasing the number and 
activity of the βARs, the threshold for stimulus trafficking may not be met, and 
therefore the acute heart failure will be avoided. Furthermore, it has been shown that 
acute estrogen can prevent the β2AR Gs to Gi switch, which could also reduce the 
likelihood of acute heart failure (Cao et al., 2015). This could explain the lack of 
acute heart failure seen in the acute estrogen ovariectomised group, although no 
definite conclusions can be drawn from that study due to it being underpowered for a 
mode of mortality analysis.  
 
3.4.2 Effect of vehicle in ovariectomised rats 
 
Although there was not a significant difference between vehicle-treated and non-
treated ovariectomised rats, or between vehicle-treated and estrogen-treated 
ovariectomised rats, the mortality rate of the vehicle-treated animals was between 
the very high mortality of the non-treated and the very low mortality rate of the 
estrogen treated. A 50%:50% v/v DMSO:glycerol vehicle was chosen as this was the 
only suitable vehicle to dissolve the required amount of 17β-estradiol in, whilst 
remaining compatible with the minipump.  
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Both DMSO and glycerol can act as antioxidants (Santos et al., 2003; Zhou et al., 
2008), and cardiac dysfunction in response to isoprenaline in ovariectomised 
animals can be ameliorated by treating with carvedilol, where treatment with 
carvedilol reduced superoxide formation and NAPDH oxidase activity (Ribeiro et al., 
2013). As carvedilol is known to act as an antioxidant, as well as a beta-blocker 
(Zhuang et al., 2009), it could be acting to reduce ROS either directly on a molecular 
level, or pharmacologically thorough its actions on the βARs. However, it is not 
possible to delineate this further with this study as beta blocker activity acts to 
reduce oxidative stress in itself by reducing βAR activity (Andersson et al., 2011). 
Nevertheless, the reduction in ROS is associated with a reduction in contractile 
dysfunction. Interestingly, the pressor response (a sympathetic action) in 
ovariectomised animals to a psychogenic stimulus (cage-switch stress) is partially 
inhibited by estrogen treatment, acting by decreasing superoxide formation and 
increasing the availability of nitric oxide (Morimoto et al., 2008). Therefore, there 
appears to be a ROS-mediated dysfunction that is perhaps more significant in 
ovariectomised animals than estrogen-competent animals.  
 
I hypothesise that, with respect to mortality after adrenaline bolus, there is an 
additive effect between vehicle and estrogen in the ovariectomised groups: both act 
to reduce oxidative stress, and therefore cellular dysfunction, but the estrogen can 
additionally modulate βARs expression and activity, further protecting the heart from 
catecholamine toxicity, and also prevent stimulus trafficking, protecting the heart 
from severe acute decompensation. Clinically, HRT does appear to protect against a 
worse TTS prognosis, with a study 200 TTS patients showing that those in receipt of 
HRT at the time of TTS onset were relatively protected against requiring mechanical 
support or ventilator support compared to those not in receipt of HRT (Patel et al., 
2013).  
 
3.4.3 Effect of minipump implantation on ventricular repolarisation 
 
Both estrogen and vehicle minipumps in ovariectomised rats caused a significant 
reduction in QTc compared to no minipump ovariectomised rats. As acute estrogen 
had no effect on QTc, any effect that estrogen or vehicle had are likely to be 
genomic, rather than non-genomic. For instance, mice deficient in estrogen 
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receptors do show a prolonged QT interval due to increased L-type Ca2+ currents in 
the ventricle (Johnson et al., 1997). Therefore, replacement of estrogen in an 
estrogen-deficient animal could reduce the L-type current. However, the reduction in 
QT interval may not be directly via the estrogen receptors, and could, as previously 
stated, be through a reduction in oxidative stress and increase in nitric oxide 
availability (Morimoto et al., 2008). Increased oxidative stress has been linked to 
slow ventricular repolarisation in human studies (Baja et al., 2010), and decreased 
nitric oxide availability may also increase the QT interval (Chang et al., 2006; 
Lehtinen et al., 2008). Therefore, the QT interval in ovariectomised rats may be 
being maximally reduced by the action of ROS scavenging, with little additional effect 
of the estrogen. Although an effect of surgery itself cannot be ruled out, post-surgical 
QT intervals tend to increase, rather than decrease (Nagele et al., 2012), and drugs 
given at the time of surgery (isoflurane and buprenorphine), will have been fully 
excreted two weeks later, although isoflurane has been shown to increase QT 
interval acutely (Yildirim et al., 2004).  
 
3.4.4 Lack of mortality reduction in male animals after estrogen treatment 
 
Despite estrogen’s powerful effect to reduce mortality in ovariectomised rats, 
estrogen in male rats did not seem to have any effect and the previously found 46% 
mortality rate after adrenaline bolus in male rats was not improved upon: 66.7% in 
the estrogen capsule group and 42.9% in the vehicle capsule group.  
 
The use of silastic capsules to replace estrogen in ovariectomised murine species is 
somewhat validated (Ingberg et al., 2012; Ström et al., 2013, 2012), and has been 
shown in rats to initially cause a large spike in plasma estradiol concentration 
(~1000pg.ml-1), which then falls to between 10pg.ml-1 and 40pg.ml-1 for 35 days post-
implantation (Ström et al., 2012). The choice to use the silastic capsules in the male 
animals, rather than minipumps, was made on the basis that silastic capsules would 
avoid the apparent effect of the DMSO vehicle present in the ovariectomised 
animals. Furthermore, silastic capsules, vs. pellets, give a more physiological level of 
estrogen: pellets have been shown to give plasma estradiol concentrations an order 
of magnitude greater than the physiological range, which then rapidly decreases 
after two weeks (Ström et al., 2008);  
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Firstly, it is not certain that the male animals received any estrogen from the silastic 
capsule: in hindsight, an estradiol ELISA test on plasma taken at the end of the 
echocardiographic study would give an indication of the estrogen status of the male 
rat; this is planned for the next set of studies. However, there did appear to be a 
stunting of growth in the animals receiving estrogen compared to the animals 
receiving vehicle alone, at least after the first week post-implantation. Estrogen has 
been shown to reduce the growth rate of male rats (Kawai et al., 1982), and 
therefore this could be an indirect indication that some estrogen activity is present.  
 
Secondly, male rats have been shown to require acute levels of estrogen an order of 
magnitude higher than female rats in order to have a similar anti-arrhythmic effect: 
researchers tested the effect of acute estrogen infusion at the same dose used in the 
acute estrogen studies to test its effect on arrhythmia severity after coronary artery 
occlusion, finding that a ten-fold higher dose was needed to have a similar effect in 
male rats compared to female rats (Philp et al., 2006). This can be at least partly 
explained by the fact that a ten-fold higher dose of estrogen was required in the male 
rats, compared to females, to achieve a change in plasma estradiol above the level 
found with vehicle. Sadly, no mechanism for this was proposed by the study’s 
authors, and could be due to a number of factors, such as differences in sex 
hormone binding globulin levels, or increased metabolism of estrogen in males. 
However, in vitro studies showed that the EC50 of estradiol to inhibit the L-type Ca2+ 
current was also approximately ten-fold higher in cardiomyocytes isolated from male 
rats compared to female rats, showing that there was also a change in cellular 
sensitivity to estradiol between the genders. As this is an rapid effect of estrogen, it 
is likely to be mediated by GPER: GPER is present in both male and female hearts 
as activation of GPER can both limit ischaemia-reperfusion injury (Deschamps and 
Murphy, 2009) and decrease contractility via eNOS activation and nitric oxide 
generation (Filice et al., 2009), a known inhibition pathway of L-type Ca2+ channels 
(Han et al., 1998, 1994).  
 
However, the activity of the genomic estrogen receptors may be lower in males: in 
GPER knockout mice, male mice can exhibit signs of systolic and diastolic 
dysfunction, whereas female mice are relatively protected, perhaps due to higher 
activity of other estrogen receptors (Delbeck et al., 2011). Perhaps in the studies 
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presented in this chapter, the dose of estrogen, although suitable for the female 
animals (albeit ovariectomised), is not sufficient to significantly reduce arrhythmias 
through the aforementioned mechanisms, nor is it sufficient to prevent the acute 
bradycardic heart failure seen in these animals that is putatively caused by 
excessive Gs to Gi switching, caused by high βAR activation (Cao et al., 2015).  
 
3.4.5 Effect of silastic capsule implantation on ventricular repolarisation 
 
Much like the effect seen with ovariectomised animals implanted with either an 
estrogen or vehicle minipump, both estrogen and vehicle silastic capsules shortened 
the QT interval in males compared to males with no silastic capsule. As described 
above in relation to this effect in the ovariectomised animals, it seems unlikely that it 
is due to the drugs used at the time of surgery, whereas if animals were studied 12 
hours or 24 hours after surgery then this could be a possibility. As the silastic 
capsule method has only been described using one vehicle, sesame oil, that is what 
was used in these studies.  
 
Sesame oil can act as an antioxidant: in a rat model of lipopolysaccharide-stimulated 
oxidative stress, sesame oil reduced lipid peroxidation, decreased the level of 
superoxide, and increased glutathione levels in the liver, decreasing the amount of 
liver damage the occurred; corn oil or mineral oil failed to have this effect (Hsu and 
Liu, 2004). Similar effects have been found in a rat model of diabetes (Ramesh et al., 
2005) and a rat model of cerebral ischaemia (Ahmad et al., 2006). A stated 
previously, a reduction in oxidative stress could shorten the QT interval, although, 
unlike in ovariectomised animals, in male animals there does not appear to be a 
pathological level of oxidative stress (Baja et al., 2010; Chang et al., 2006; Lehtinen 
et al., 2008). Nevertheless, normal mitochondrial respiration does generate reactive 
oxygen species, and as much as 2% of the O2 used by mitochondria is converted 
into superoxide through the action of complexes I and III (Gustafsson and Gottlieb, 
2008). 
 
There is also some evidence that sesame oil could act to reduce osteoporotic bone 
loss in an ovariectomised rat model of osteoporosis via an estrogenic mechanism as 
rats fed sesame oil showed increased plasma estradiol levels (El Wakf et al., 2014). 
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However, estrogen has been shown to normally lengthen the QT interval (Sedlak et 
al., 2012), primarily through reductions in K+ currents (namely IKr, IKs and IK1) (Berger 
et al., 1997; Tanabe et al., 1999), and therefore this result in male rats, with regard to 
the estrogen silastic capsule group, is confusing and cannot be explained without 
further study. Unlike in the ovariectomised groups, vehicle alone did not reduce 
mortality in the males. As this is a different vehicle, direct comparisons cannot be 
made, and further study is required to elucidate the mechanism of mortality reduction 
in the ovariectomised group, and the reason for the absence of mortality reduction in 
males (e.g. higher ROS level; lower ROS antioxidant of sesame oil versus DMSO 
etc.).  
 
3.4.6 Limitations and further work 
 
The primary limitation with the work presented in this chapter is the presence of a 
pharmacologically-active vehicle: both DMSO and sesame oil act as anti-oxidants, 
and therefore in themselves could be affecting the prevalence of arrhythmia and 
contractile dysfunction after adrenaline bolus. In order to eliminate the effect of 
vehicle, a more inert method to administer estrogen is required: the peroral route is a 
possibility by dissolving the estrogen in Nutella (Ström et al., 2012), or daily 
injections using water-soluble estrogen (estradiol encapsulated in cyclodextrin). 
Without these experiments, we will not be able to ascertain the individual effects of 
estrogen therapy, without the confounding effect of the vehicle.  
 
Due to the high mortality of males, conclusions relating to the effect of silastic 
capsule implantation cannot be reliably drawn, other than the observation that 
mortality does not appear to be reduced after silastic capsule implantation. More 
animals are required to fully assess the contractile response after estrogen therapy, 
and to validate the lack of a difference in mortality.  
 
Sham experiments are required for minipump and silastic capsule implantations, 
alongside paired ECG measurements (i.e. before and after implantation), to fully test 
the effect of the minor surgery on ventricular repolarisation. From these experiments, 
more certain conclusions can be drawn about changes in ECG parameters noted in 
this chapter.  
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Finally, although there was a clear effect of estrogen in the ovariectomised group, a 
lack of major effect in the males requires further testing to ensure that the males are 
receiving a dose of estrogen, and if so, whether that dose is pharmacologically 
relevant in a gender that appears to need a higher level of supplementation to have 
the similar effect in females. An ELISA on extracted plasma would elucidate this and 
validate the lack of mortality reduction after estrogen supplementation if they were 
found to have a sufficient plasma estrogen level.  
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4. Replicating Shao et al.: isoprenaline induction of Takotsubo syndrome 
 
4.1 Introduction 
 
Animal models of human disease often do not fully recapitulate the whole human 
disease, but rather a part or parts of it. Shortly after we published our model of IV 
adrenaline bolus to cause a transient apical dysfunction (Paur et al., 2012), the 
Omerovic research group in Gothenburg, Sweden published a TTS model that 
shared similarities with ours, but also had some key differences (Shao et al., 2013b), 
outlined below (Table 4.1).  
 
Similarities  Differences 
Paur et al. (2012) Shao et al. (2013) 
Dysfunction limited to the 
apical myocardium 
Isoflurane anaesthesia Ketamine-midazolam 
anaesthesia 
Dysfunction inhibited by PTX Transient apical dysfunction 
(resolves within 60 minutes) 
Longer-term apical dysfunction 
(develops within 70 minutes; 
resolves within 7 days) 
Dysfunction inhibited by ICI-
118551 
Segmental contractility 
measured using M-mode 
echocardiography 
Area of akinesia measured 
using ECG-gated B-mode 
echocardiography 
Dysfunction triggered by 
exogenous catecholamines 
Adrenaline used (α and β-
adrenoceptor agonist) 
Isoprenaline used (β-
adrenoceptor agonist) 
 430nmol.kg-1 adrenaline 
administered 
202μmol.kg-1 isoprenaline 
administered (i.e. ~3 orders of 
magnitude greater) 
IV administration IP administration 
 
Table 4.1: The key differences between Paur et al. (2012) and Shao et al. (2013). 
 
One key difference not in the above table is the appearance of the studies’ 
respective echocardiography images on B-mode (i.e. visualising the heart in 2d): 
although in Paur et al. (2012) there was apical dysfunction, this did not manifest itself 
in the same way as in Shao et al. (2013), perhaps due to the fact that the Shao et al. 
(2013) noted akinesia, whereas Paur et al. (2012) noted hypokinesia; Shao et al.’s 
representative B-mode videos look remarkably similar to the human disease. 
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Furthermore, their time course is more similar to the human disease than Paur et al. 
(i.e. days rather than minutes). Therefore, recreating the induction of TTS through IP 
administration of isoprenaline would allow the further delineation of the 
pathophysiology of this disease, especially as the time course gives more 
opportunity for the testing of therapeutic interventions: in Paur et al. (2012) we were 
limited to only giving preventative interventions or interventions concordantly with the 
adrenaline IV bolus.  
 
4.2 Materials and methods 
 
4.2.1 Reagents 
 
(-)-Isoprenaline hydrochloride was obtained from Sigma-Aldrich (UK) and diluted to a 
concentration of x mg.ml-1, where x is the intended dose in mg.kg-1. Isoflurane was 
obtained from Abbot Laboratories. Ketamine was obtained from Zoetis (USA); 
midazolam was obtained from Roche (UK).    
 
4.2.2 Animals 
 
All animal procedures were performed in accordance with Animals (Scientific 
Procedures) Act 1986 and under a personal and project Home Office licence. 
Animals were housed in groups of four and experienced a 12 hour light/dark cycle. 
Male Sprague Dawley rats (Charles River Laboratories, UK) were used for 
experiments in this section. All animals were killed by a Schedule 1 method (cervical 
dislocation) at the end of the procedure.  
 
4.2.3 Anaesthesia protocols 
 
Isoflurane anaesthesia: rats were transferred from a holding cage to a Perspex 
chamber. This was then filled with a 5% isoflurane 95% oxygen gas mixture at a rate 
of 4L.min-1, which caused the loss of the righting reflex typically within two minutes. 
The animal was then transferred to the imaging table, connected to which was a 
Bain co-axial nosecone. Isoflurane was delivered at 2L.min-1 through the nosecone 
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at a concentration of 2.5% (97.5% oxygen). This was continued for the duration of 
the experiment.  
 
Ketamine anaesthesia: rats were removed from a holding cage and restrained in a 
manner so that the torso of the animal was exposed and the animal was vertical, 
cranium superior to caudum. A ketamine-midazolam mixture was injected 
intraperitoneally at a dose of 50mg.kg-1 and 5mg.kg-1, respectively. Loss of righting 
reflex was typically seen 3-4 minutes after injection. Ketamine-midazolam was 
readministered at a dose of 25/2.5mg.kg-1 when the anaesthetic state was seen to 
be ‘light’ (i.e. small movements seen in the animal’s limbs). Animals anaesthetised 
with ketamine-midazolam were not restrained in the dorsal position by their limbs to 
allow for the assessment of anaesthesia depth and due to muscle rigidity caused by 
ketamine. A piece of gauze was placed in to their mouth to remove excess 
secretions.  
 
4.2.4 Echocardiography protocol 
 
Once anaesthetised, the thorax was shaved using electric hair clippers and the 
animal was placed onto a heated echocardiography table (Visualsonics). Hair 
depilatory cream was then applied to the thorax to remove the remaining fur. After 
satisfactory depilation, ultrasound gel was applied to the thorax and the ultrasound 
probe (RMV-716, Visualsonics) positioned to acquire a parasternal long axis view of 
the left ventricle. M-mode images were taken from the apical and basal myocardial 
segments to measure fractional shortening in these regions. Animals were heated by 
the echocardiography table (heated to 50oC) and a homoeothermic blanket 
(Harvard). Body temperature was measured using a rectal probe (Harvard).  
 
4.2.5 Electrocardiography protocol 
 
Needle electrodes were placed subdermally into the left hindlimb (positive electrode) 
and right forelimb (negative electrode) to obtain a Lead II ECG. A Bio Amp (AD 
Instruments) was used to amplify and condition the signal, which was digitised by a 
PowerLab (AD Instruments) and recorded using LabChart 7 (AD Instruments). A 
50Hz mains filter was applied to the signal to reduce electrical noise. ECG traces 
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were analysed automatically using the LabChart 7 ECG Analysis module. All QTc 
values reported are corrected using Bazett’s method (Figure 4.18).  
 
4.2.6 Isoprenaline administration 
 
Isoprenaline was injected intraperitoneally via a 25G needle. Animals injected whilst 
conscious were monitored for signs that indicate distress above and beyond that 
associated with restraint and subsequent IP injection. These animals were then 
anaesthetised as per the isoflurane protocol 3 hours after isoprenaline injection and 
imaged.  
 
4.2.7 Statistical analysis 
 
Unless stated, all echocardiographic and chronotropic data was analysed using two-
way repeated measures  ANOVA calculations with either Tukey’s (for whole 
experiment analysis) or Dunnett’s (individual time-point analysis) post-hoc tests. 
Before and after QTc analysis was carried out using a two-way ANOVA (isoflurane 
experiments) or paired t-test (ketamine-midazolam anaesthesia). One-way ANOVA 
with Sidak’s post-hoc test was used to compare time-points with baseline for 
ketamine-midazolam anaesthetised heart rate measurements.  
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4.3 Results 
 
Figures  Anaesthetic used Dose of isoprenaline 
4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 
4.16, 4.17 
 
Isoflurane  50, 100 or 200mg/kg 
4.7, 4.8, 4.9, 4.10, 4.11 
 Conscious isoprenaline 
injection (isoflurane echo) 
50 or 75 mg/kg 
4.12, 4.13, 4.14, 4.15, 4.16, 
4.17 
 Ketamine-midazolam 50mg/kg 
 
Table 4.2: Experimental conditions for figures presented in this chapter.  
 
4.3.1 50mg.kg-1 isoprenaline did not cause apical dysfunction under isoflurane 
anaesthesia 
 
Shao at al. (2013) uses two protocols to assess the effects of IP isoprenaline: 
monitoring at 5 minute intervals under continuous anaesthesia, and conscious 
administration of isoprenaline IP and imaging under isoflurane anaesthesia two 
hours later. However, for the former they do not specify the methods of anaesthesia. 
Isoflurane (2.5%) was used as this was used previously for echocardiography 
studies and noted to give a sufficient level of anaesthesia. Unlike Shao et al., I found 
that administration of 50mg.kg-1 isoprenaline caused a positive inotropic response in 
both apex and base (Figure 4.1), with no significant difference found between them 
(two-way ANOVA). At all time-points, both apex and base, were significantly different 
to baseline (P<0.05, two-way ANOVA). Out of the 5 animals given 50mg.kg-1, 2 had 
to be excluded from echocardiography analysis due to poor image quality on a large 
number of time points; these animals are still included in the heart rate and QTc 
analyses. Isoprenaline 50mg.kg-1 acted as a positive chronotrope throughout the 100 
minutes, indicating there was not a large desensitisation effect over the experiment 
(Figure 4.3).  
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Figure 4.1: 50mg.kg-1 isoprenaline given immediately after baseline measurement (time 0) 
resulted in a positive inotropic response (n=3). Mean±SEM shown. All points after baseline 
significantly different (P<0.05, two-way ANOVA) to baseline. FS: fractional shortening 
 
24.3.2 100mg.kg-1 or 200mg.kg-1 isoprenaline did not cause apical dysfunction under 
isoflurane anaesthesia 
 
Shao et al. (2013) used a number of doses of isoprenaline, with 50mg.kg-1 being the 
lowest dose to induce apical ballooning; no apical ballooning occurred with a dose of 
25mg.kg-1. Isoprenaline doses of 100 mg.kg-1 and 200mg.kg-1 were tested to ensure 
that the 50mg.kg-1 dose was not inadvertently below the threshold. Neither 
100mg.kg-1 nor 200mg.kg-1 caused apical ballooning (Figure 4.2), and no significant 
differences were present between apex and base or doses (P=0.44, two-way 
repeated measured ANOVA). There was clearly an effect to increase inotropy above 
baseline. However, not all time points were significantly different to baseline: only 
time points 20 minutes and 60 minutes post-isoprenaline were significantly different 
to baseline for 100mg.kg-1 apex, and only 20 minutes and 30 minutes post-
isoprenaline for 100mg.kg-1 base.  For the 200mg.kg-1 dose, all data points except 
the apex at 100 minutes post-isoprenaline were significantly different from baseline.  
 
Both doses were positively chronotropic (Figure 4.3), and 50mg.kg-1 and 100mg.kg-1 
and appear to cause greater heart rates compared to 200mg.kg-1. However, this may 
be due to the lower mean baseline heart rate of the 200mg.kg-1 group (371bpm vs. 
433bpm vs. 396bpm for 200, 100 and 50mg.kg-1, respectively), and therefore 
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comparative statistics were not applied to these results. However, all time-points for 
all doses were significantly different to baseline (P<0.05, two-way ANOVA).  
 
 
Figure 4.2: 100mg.kg-1 and 200mg.kg-1 caused a positive inotropic response in the apex (n=3 
for both doses). No significant differences were found between regions (bases not shown) or 
doses (two-way repeated measures ANOVA).  
 
 
 
Figure 4.3: 50mg.kg-1 100mg.kg-1 and 200mg.kg-1 caused a positive chronotropic response 
(mean±SEM).  
 
 
Although the contractile dysfunction à la Shao et al. (2013) was not seen, the 
experiments did show ST-elevation (Figure 4.4), as reported in their paper. This was 
true for all three doses. There was also a prolongation of QTc at 100 minutes 
compared to baseline for all three doses (Figure 4.5), although there was no 
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significant difference found between doses at the 100 minute time point. 
Furthermore, the dynamics of this prolongation over time showed some variability 
between doses (Figure 4.6).  
 
 
 
 
 
Figure 4.4: Representative lead II ECG traces from before (A) and 10 minutes after (B) 
isoprenaline. Squares = 20ms, 0.1mV.  
 
 
 
Figure 4.5: QTc (Bazett’s corrected) for rats before (0 mins) and after isoprenaline (50, 100 and 
200mg.kg-1) administration (n=3 per dose). *: P<0.05 compared to 0 mins; **: P<0.01 compared 
to 0 mins; ***: P<0.001 compared to 0 mins; two-way ANOVA.  
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Figure 4.6: QTc (Bazett’s corrected) for rats after isoprenaline (50, 100 and 200mg.kg-1) 
administration (0 mins = baseline). Mean±SEM shown.  
 
 
4.3.3 Conscious administration of 50mg.kg-1 isoprenaline resulted no apical 
dysfunction 
 
During another study arm of the paper by Shao et al. (2013), rats were injected IP 
with isoprenaline (50mg.kg-1) and imaged 2 hours later under isoflurane anaesthesia. 
I decided to repeat this protocol but wait 3 hours post injection as the 2 hour time 
point was almost covered by my previous experiments (100 mins) under constant 
anaesthesia and the apical dysfunction described in this paper resolves over days, 
rather than hours. Therefore, I expected to see a higher, or the same, incidence of 
apical ballooning. Animals typically showed decreased locomotor activity after 
isoprenaline, as previously reported, and this was not accompanied by anorexia or 
distress upon handling.  
 
Comparing apical and basal fractional shortening to a mean of the fractional 
shortening in the animals seen in sections 4.3.1 and 4.3.2 before isoprenaline (i.e. a 
mean baseline used as a surrogate for contractility before isoprenaline as these 
animals were not anaesthetised until 3 hours after isoprenaline), the incidence of 
apical to basal contractile disparity with apical dysfunction was 0 (Figure 4.7).  One 
could argue that ISO 1 in Figure 4.7 is showing some apical dysfunction. However, 
when comparing this to the akinesia described in Shao et al., it is clearly not the 
same. Overall I found that apical contraction was not significantly different after 
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isoprenaline than at baseline (Figure 4.8), and that basal contraction was 
significantly (P<0.05) higher than baseline. However, although this result in isolation 
does fit with the recapitulation of a syndrome characterised partly by a hyperkinetic 
base, it is missing the essential hypokinetic apex. 
 
 
Figure 4.7: Apical and basal fractional shortening for 5 rats 3 hours post-isoprenaline 
administration. Mean baseline contraction derived from 9 separate rats before isoprenaline in 
another study arm. Mean±SEM shown.  
 
 
Figure 4.8: Mean±SEM of baseline contractility (taken from different animals) and contractility 
3 hours post-isoprenaline (50mg.kg-1). *: P<0.05, NS: P>0.05; two-way ANOVA. n=9 baseline; 5 
isoprenaline. 
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4.3.4 Conscious administration of 75mg.kg-1 isoprenaline resulted in some cardiac 
dysfunction 
 
One concern was that because Shao et al. (2013) found that 50mg.kg-1 isoprenaline 
was the lower threshold for any apical ballooning to occur, the dose administered in 
these experiments could be inadvertently below that threshold due to differences in 
our rats compared to theirs, small differences in dilution accuracy, weighing accuracy 
or any other of a number of reasons to cause inter-laboratory error. Therefore, 
75mg.kg-1 isoprenaline was attempted, administered whilst conscious and imaged 3 
hours later. This resulted in one animal that showed some level of global dysfunction 
(ISO 1) and some animals showing contractile disparity (ISO 3, 4 & 6) (Figure 4.9). 
However, this is merely a qualitative observation. There were no significant 
differences between mean baseline fractional shortening and mean fractional 
shortening after 75mg.kg-1 isoprenaline in either apex or base (Figure 4.10). 
75mg.kg-1 isoprenaline caused a significant (P<0.01) prolongation of QTc vs 
50mg.kg-1 (Figure 4.11). 
 
 
Figure 4.9: Apical and basal fractional shortening for 8 rats 3 hours post-isoprenaline 
administration. Mean baseline contraction derived from 9 rats before isoprenaline. Mean±SEM 
shown.  
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Figure 4.10: Mean±SEM of baseline contractility (taken from different animals) and contractility 
3 hours post-isoprenaline (75mg.kg-1). NS: P>0.05; two-way ANOVA. n=9 baseline; 8 
isoprenaline. 
 
 
Figure 4.11: Both 75mg.kg-1 isoprenaline and 50mg.kg-1 isoprenaline resulted in a prolonged 
QTc compared to baseline. 75mg.kg-1 resulted in a longer QTc compared to 50mg.kg-1. **: 
P<0.01; ****: P<0.0001, one-way ANOVA (n=11, 5 & 8). 
 
 
 
4.3.5 50mg.kg-1 isoprenaline under constant ketamine-midazolam anaesthesia gave 
a modest, but non-significant, contractile disparity between apex and base. 
 
After making contact with the Omerovic research group and starting a collaboration it 
was made clear that it was not isoflurane that they used during the constant 
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anaesthesia TTS induction, but ketamine-midazolam. Therefore, we switched the 
method of anaesthesia from isoflurane to ketamine-midazolam and repeated the 
50mg.kg-1 dose (initially in PBS, then in water; data was pooled). Measurements at 
the 5 minutes and 10 minutes time points were excluded from the two-way repeated 
ANOVA statistical analysis due to missing values for one of the experiments. Many 
of the time points (20, 30, 40, 50 & 70 mins apex; all time-points base) were 
significantly different (P<0.05, two-way ANOVA) to baseline. The difference between 
apical and basal fractional shortening over the 100 minutes was also near to 
significant (P=0.0738) (Figure 4.12). 50mg.kg-1 isoprenaline under ketamine-
midazolam also caused a significant positive chronotropic response (all points 
P<0.0001 compared to baseline, one-way ANOVA) (Figure 4.13). 
  
Unlike under isoflurane anaesthesia, isoprenaline under ketamine-midazolam 
anaesthesia did not cause a significant (P=0.087) prolongation in QTc at 100 
minutes post-isoprenaline (Figure 4.14). No individual points were significantly 
different to baseline over the 100 minutes (one-way ANOVA) (Figure 4.15). When 
comparing the 100 minute time-point of isoflurane and ketamine-midazolam 
anaesthetised animals, no significant difference was seen in either apex or base 
(Figure 4.16). At 100 minutes post-isoprenaline, animals anaesthetised with 
isoflurane had a significantly longer QTc than those anaesthetised with ketamine-
midazolam (Figure 4.17).  
 
 
Figure 4.12: 50mg.kg-1 isoprenaline under ketamine-midazolam anaesthesia resulted in a 
significant positive inotropic response in both apical and basal myocardial segments, 
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although not for all time-points in the apex. No significant difference was seen between apical 
and basal contractility (n=8). *, ** & ***: P<0.05, 0.01 & 0.001 vs. baseline (apex); ###: P<0.001 
vs. baseline (base).   
 
 
 
 
 
 
 
Figure 4.13: 50mg.kg-1 isoprenaline under ketamine-midazolam anaesthesia resulted in a 
positive chronotropic response (n=8). ****: P<0.0001 compared to 0 mins (baseline), one-way 
ANOVA.   
 
 
 
 
Figure 4.14: QTc is not prolonged at 100 minutes post-isoprenaline under ketamine-midazolam 
anaesthesia (n=8). NS: P>0.05, unpaired t-test. Mean±SEM shown.  
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Figure 4.15: QTc did not significantly change over the course of the experiment after 50mg.kg-1 
isoprenaline administration under ketamine-midazolam anaesthesia (n=8).  
 
 
 
 
 
Figure 4.16: Choice of anaesthetic agent did not influence the change in contractility, relative 
to baseline, in either apical or basal myocardial segments (two-way ANOVA, n=3 & 8).  
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Figure 4.17: At 100 minutes post-isoprenaline, anaesthetic agent affected QTc prolongation, 
with isoflurane exhibiting a longer QTc than those anaesthetised with ketamine-midazolam 
(n=5 & 8). *: P<0.05, unpaired t-test. Mean±SEM shown.  
 
 
4.4 Discussion 
 
Despite TTS being a disease primarily of the post-menopausal female, a number of 
pre-clinical studies have shown TTS-like contractility pathologies in male animals. 
Shao et al. (2013) is no different, and used male Sprague Dawley rats to investigate 
TTS. Therefore, I hoped to also show TTS-like contractility pathologies in a set of 
male Sprague Dawley rats. However, in the initial experiments under isoflurane 
anaesthesia, 50, 100 and 200mg.kg-1 isoprenaline failed to induced TTS-like 
contractility. Furthermore, mimicking another set of experiments by Shao et al. 
(2013) (conscious administration of isoprenaline with echocardiography under 
isoflurane) did not produce TTS-like contractility at 50mg.kg-1 (as used in their 
paper), and infrequently at 75mg.kg-1. Changing anaesthesia from isoflurane to 
ketamine-midazolam (as used by Shao et al. (2013), personal communication, B 
Redfors) still resulted in positive inotropy in both apex and base, with no significant 
difference between the segments.  
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Unlike in Paur et al. (2012), in which the IV adrenaline caused a bradycardia, 
possibly mediated via a reduction in baroreceptor firing due to the increased blood 
pressure, isoprenaline administration always caused a positive chronotropic 
response. There was also an increase in QTc in animals injected with isoprenaline 
under isoflurane anaesthesia and whilst conscious, but not in those injected under 
ketamine-midazolam anaesthesia.  
 
In the animals injected and monitored under constant anaesthesia, there was a 
positive inotropic response in both apex and base. Isoprenaline is a β-adrenoceptor 
agonist, so the administration of isoprenaline activates the Gs pathway, increasing 
levels of cAMP in cardiomyocytes and effecting an increase in contractility. A similar 
pathway is responsible for the increase in heart rate.  
 
4.4.1 Pharmacokinetics of high-dose intraperitoneal isoprenaline 
 
To move these experiments to an in vitro or ex vivo experimental set-up the 
concentration of isoprenaline at the level of the heart would need to be known. To 
further delineate the mechanism of isoprenaline-induced apical hypocontractility, in 
vitro experiments are essential. To date no study has looked at the pharmacokinetics 
of intraperitoneal isoprenaline at a dose of this magnitude, although there was a 
study in 1990 studying the effects of 100mg.kg-1 administered to female Wistar rats 
subcutaneously, with an aim to induce acute heart failure (Hrdina and Kvĕtina, 
1990). This may have been characterised as a model for TTS if the disease was 
more well known at the time (TTS first reported in 1990). However, sadly the paper 
was written in Czech and no translation was available.  
 
The metabolism of isoprenaline has been studied in dogs and humans (Conolly et 
al., 1972), but little work has been carried out directly on its pharmacokinetics in rats. 
Furthermore, the work in dogs and humans assessed IV and oral pharmacokinetics, 
rather than IP. Nonetheless, they found in both humans and dogs that isoprenaline 
has a biphasic excretion profile, with phase I having a half-life of ~5 minutes, and 
phase II having a half life of ~2.5 hours. This was detected through both the change 
in radioactivity of the plasma (3H-tagged isoprenaline was used) and the decrease in 
the positive chronotropic response to IV isoprenaline. However, the paper neglects 
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to report the proportions of plasma isoprenaline that are metabolised in each of the 
phases.  
 
In the study by Conolly et al. (1972) increases of ~50bpm were seen, and within 10 
minutes the increase had dropped to ~25bpm. In the 50mg.kg-1 experiments 
presented in this chapter (figures 4.3 & 4.13) there was an increase of ~100bpm that 
manifested almost immediately after isoprenaline administration and any drop that 
may have been present was modest at best over the 100 minutes: certainly not a 
decrease of 50% of the positive chronotropic response that was seen in ~10 minutes 
in humans. Therefore, three explanations could be proposed: rat pharmacokinetics 
of isoprenaline are somewhat different to humans and dogs; the isoprenaline in the 
peritoneal compartment equilibrates with the rest of the body according to its volume 
of distribution and the high concentration of isoprenaline is overwhelming its 
clearance mechanism (although the study found that IV isoprenaline was mainly 
excreted unchanged in the urine, and therefore should not be a zero order 
clearance); or the IP injection sets up a quasi-depot, whereby there is a high 
concentration of isoprenaline in the peritoneal cavity compared to the plasma, which 
slowly diffuses into the plasma over time, keeping a relatively steady-state plasma 
concentration.  
 
Human doses of isoprenaline for the treatment of shock are in the microgram range, 
whereas here I have used doses in both the tens and low hundreds of milligrams per 
kilogram of body weight, a 10,000 fold increase. The exact volume of distribution is 
not known: The volume of distribution (Vd) in tracheal tissue is 1.9ml.g-1, however 
isoprenaline exhibits a high level of plasma protein binding (~70%) (Kelly and 
McDevitt, 1978). Therefore, calculating a whole-body Vd is mathematically 
challenging, with a number of compartments, each with their own partition 
coefficient. One method of understanding the relative hydrophilicity of a compound is 
to calculate its Log octanol-water partition coefficient (LogPoctanol/water). For 
isoprenaline this can be predicted (Meylan and Howard, 1995) to be 0.21 (data from 
Madison-Qingdao Matabolomics Consortium Database, University of Wisconsin), 
indicating that isoprenaline is approximately equally soluble in lipid and aqueous 
environments. As a comparison, this is somewhat similar to morphine (LogP = 0.89). 
Therefore, as it is not very lipophilic, it is unlikely to have a very high Vd as it will not 
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partition preferentially into the lipid compartments like some general anaesthetics do. 
Intramuscular adrenaline has a Vd of 2.0±1.5L.kg-1 (Simons et al., 1998), and a 
predicted LogPoctanol/water of between -0.81 and 0.256 (Madison-Qingdao 
Matabolomics Consortium Database, University of Wisconsin). I would predict that 
the Vd of isoprenaline is not greater than 10L.kg-1.  
 
If the Vd of isoprenaline was to be 10L.kg-1, and when 50mg.kg-1 isoprenaline was 
administered IP it equilibrated quickly throughout the body, the initial steady drug 
concentration would be 5mg.L-1. The Mr of isoprenaline hydrochloride is 247.72, 
giving a molarity of 20.18uM. In the order of magnitude of 10-5M (10uM) isoprenaline, 
β2 stimulus trafficking is certainly feasible (Heubach et al., 2004). However, as can 
be seen in figures 4.3 and 4.13, there is a sustained positive chronotropic effect. If 
total body equilibration was occurring, there must be some impairment of the 
clearance of isoprenaline as no initial drop in the positive chronotropic response 
occurs as would be expected due to the initial quick clearance of isoprenaline from 
the plasma. This is only the case provided that high-dose isoprenaline does not 
induce release of endogenous catecholamines or that the adrenoceptor system is 
completely saturated (i.e. at the plateau of a dose-response curve), and therefore 
any initial clearance does not bring it back into a zone where changes in 
concentration of the catecholamine do cause changes in response, i.e. back towards 
the steep part of a concentration-response curve. 
 
Alternatively, it could be that the membrane penetration of IP isoprenaline is slow, 
resulting in the formation of a depot inside the peritoneal cavity. However, when 
conducting the experiments the increase in heart rate is almost instantaneous, so 
bioavailability does not appear to be a problem. Isoprenaline is found both free in 
plasma and bound to plasma proteins (Kelly and McDevitt, 1978), so plasma protein 
binding site-availability should not be a limiting factor either.  
 
As can be seen in figure 4.3, the maximum heart rate is approximately the same for 
50, 100 and 200mg.kg-1 (~500-525bpm). Maximum heart rates for rats (albeit Wistar, 
not Sprague Dawley) undergoing maximal exercise are reported to be ~550bpm, and 
~500bpm with isoprenaline infusion (increasing dose until maximum heart rate is 
reached) (Bolter and Atkinson, 1988a). Therefore, it is not possible to use the heart 
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rate response to disprove the equilibration hypothesis: if isoprenaline is fully 
equilibrated and is being excreted as it would be in humans or dogs, the decrease in 
plasma isoprenaline concentration may have little effect on heart rate as it is already 
greatly beyond the concentration required for maximal response with respect to 
chronotropy. To solve the problem of transferability to ex vivo or in vitro experiments, 
an analytical chemistry method such as HPLC is required.  
 
4.4.2 Effects of isoflurane on cardiac function 
 
Isoflurane is a very widely used inhalational anaesthetic in both human and animal 
surgery. In these studies it gave a reliable level of humane restraint to allow for 
precise repeat echocardiographic measurement of LV function. However, it does 
have a number of effects on both the heart and the whole organism that could 
complicate any findings. One such effect is isoflurane’s role as an ischaemic 
preconditioning agent (Cason et al., 1997; Cope et al., 1997) via the activation of the 
KATP channel (Kersten et al., 1997) and the PI3K/Akt pathway (also part of the β2-Gi 
pathway) (Raphael et al., 2005). Although a growing body of evidence shows that 
TTS is a disease not of ischaemic stunning after vasospasm but a direct effect of 
catecholamines on the cardiac complement of adrenoceptors (Tranter et al., 2013), I 
still cannot eliminate the possibility that some aspect of the disease is reliant upon an 
ischaemic response. Therefore, by “treating” the animals with isoflurane before and 
during the isoprenaline administration the non-preconditioned ischaemic response 
would be inhibited.   
 
Research published by the Omerovic group sometime after I carried out these 
experiments showed an inhibition of apical ballooning with isoflurane pre-treatment 
that was not dependent on KATP channel activation (Redfors et al., 2014b). This may 
indicate that isoflurane is acting via a parallel pathway to the ischaemia 
preconditioning pathway. However, KATP is certainly not the only effector of 
isoflurane-induced preconditioning (Belhomme et al., 1999; Raphael et al., 2005). 
Previous studies have used a similar constant isoflurane anaesthesia (Izumi et al., 
2009; Paur et al., 2012), and therefore if isoflurane is able to prevent TTS in the 
isoprenaline model but not other models (both Izumi et al. and Paur et al. are 
adrenaline infusion models), this could point to a critical process that is inhibited by 
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isoflurane and somehow bypassed by adrenaline and not isoprenaline. One such 
process could be a requirement for high afterload: isoflurane is a potent vasodilator 
(Schwinn et al., 1990), whereas adrenaline is a vasopressor through its actions on α1 
adrenoceptors (Penson et al., 2007).  
 
The importance of haemodynamics (and particularly afterload) was investigated by 
the Omerovic group, showing that isoprenaline caused a reduction in afterload, 
leading to predominantly apical dysfunction, whereas catecholamines that caused 
hypertension (e.g. adrenaline) led to basal dysfunction (Redfors et al., 2014a). This 
is a confusing find as we did not see basal dysfunction relative to baseline in the 
adrenaline model (Paur et al., 2012), although there was a reduction in basal 
contractility during the apical dysfunction phase. It implies that a vasodilated state is 
important for apical dysfunction, therefore all but ruling out the vascular effect of 
isoflurane on its inhibition of TTS in the studies presented here. 
 
4.4.3 Absence of apical dysfunction in consciously-injected animals 
 
In studies where rats were injected whilst conscious and imaged 3 hours later, 0/5 
showed apical dysfunction at 50mg.kg-1 (Figure 4.7). At the 75mg.kg-1 dose, 1/8 
showed global hypokinesia and 1/8 showed some level of apical dysfunction with 
basal hyperkinesia (Figure 4.9).  
 
Shao et al. (2013) reports the incidence of TTS at the 50mg.kg-1 dose to be ~65%. 
Therefore, with a probability of 35% per rat of not getting TTS-like contractility, after 
the five rats the probability drops to 0.53% for none of the rats showing TTS-like 
contractility, provided that each is an independent event. Therefore, I suspect that 
something else was a factor during the experiments carried out in Gothenburg.  
 
The consciously-injected experiments were carried out to remove the possibility of 
an unknown source of error during a long period of anaesthesia. IP injections are 
stressful for the animal, often causing visible but transient distress during the 
restraint procedure. Furthermore, during isoflurane anaesthesia body temperature is 
very labile, whereas a rat freely moving around with sufficient nesting material in its 
cage remains endothermic. The 2 out of 13 animals injected whilst conscious that 
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showed some cardiac dysfunction may indicate that an aspect of the Gothenburg 
model was present, but as the prevalence was far lower than reported, something 
else was missing. However, overall in the 50mg.kg-1 isoprenaline study, there was a 
classical positive inotropic response to isoprenaline, mediated via the β1 and β2-Gs 
pathway rather than the proposed TTS pathway of β2-Gi (Lyon et al., 2008). I 
propose that the lack of response to 75mg.kg-1 when a mean of all eight animals was 
compared is a product of a very heterogeneous population of responses, some of 
which were negative (Figure 4.9).  
 
4.4.4 Effects of ketamine-midazolam on cardiac function  
 
After contacting the Omerovic group and clarifying that they were using ketamine-
midazolam, rather than isoflurane, as their continuous anaesthesia method, studies 
were performed to investigate if this was the cause of the difference observed. 
However, no apical dysfunction was present, and both regions showed significant 
positive inotropic responses for much of the 100 minutes (Figure 4.12). Although 
there appears to be some apical-basal disparity present that was not for the 
isoflurane 50mg.kg-1 experiment, this was not significant (P=0.073). Furthermore, an 
analysis of the final time-point (100 mins) did not yield significance, either apex vs. 
base or ketamine-midazolam vs. isoflurane (Figure 4.16).  
 
Compared to isoflurane, in a swine model of shock, ketamine total intravenous 
anaesthesia resulted in a higher mean arterial pressure (Englehart et al., 2008). It is 
also known to increase cardiac output and heart rate in humans (Johnstone, 1976). 
However, ketamine is a poor anaesthetic alone, and is often used in combination 
with agents such as midazolam (a benzodiazepine) or xylazine (α2 adrenoceptor 
agonist). Ketamine alone increases sympathetic activity (Slogoff and Allen, 1974), 
whereas midazolam alone decreases sympathetic activity, as measured through 
heart rate variability spectral analysis (Komatsu et al., 1995). In dogs ketamine-
midazolam anaesthesia as a combination (although at a different dose to these 
studies) caused a reduction in mean arterial pressure and heart rate (Jacobson and 
Hartsfield, 1993).  
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Anecdotally, with the ketamine-midazolam animals it was observed that their body 
temperature was less labile after isoprenaline than those anaesthetised with 
isoflurane. Furthermore, for many ketamine-midazolam animals, external heating 
was reduced after isoprenaline injection to prevent possible hyperthermia, whereas 
those anaesthetised with isoflurane required constant heating to remain euthermic. 
The potential role of body temperature in the induction of TTS will be explored in 
Chapter 5.  
 
4.4.5 Electrocardiographic changes after isoprenaline 
 
Over the experiments presented here, three main ECG changes were observed: 
reduction in R-R interval (indicating an increase in heart rate); prolongation of QT 
interval; and elevation of the ST segment (see Figure 4.4). The increase in heart rate 
seen universally in experiments where the animal was anaesthetised throughout is a 
result of isoprenaline acting as an agonist on β1 and β2 receptors in the sinoatrial 
node, increasing the rate of spontaneous depolarisation (Bolter and Atkinson, 
1988b). ST-segment elevation and QT prolongation are both ECG changes seen in 
TTS (Samuelov-Kinori et al., 2009), although are not specific for TTS. Nonetheless, it 
is promising to see that although the contractility changes were not seen, the 
electrical changes were, and could point to a disconnection between these two 
aspects of the disease.  
 
Prolongation of QT interval is a common ECG finding in TTS patients, often far 
beyond the threshold for the patient to be at risk of torsade de pointes (Wright et al., 
2014). Isoprenaline both under isoflurane anaesthesia and in conscious animals 
resulted in a prolongation of QTc (Figures 4.5 & 4.11). As can be seen in Figure 4.6, 
an increase in QTc could be seen within 5 minutes, although the prolongation to its 
value at 100 minutes took more time. Inherited long QT syndromes have received far 
more research attention than the prolonged QT interval associated with TTS. It is 
well understood from inherited studies that the QT interval becomes prolonged if 
repolarisation is impaired (i.e. a reduction in potassium channel conductivity during 
phase 3) or a depolarising current remains “on” (i.e. a leaky sodium channel) 
(Goldenberg and Moss, 2008). In human studies isoprenaline is known to cause a 
relatively longer QT interval compared to exercise at an equivalent heart rate 
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increase (Magnano et al., 2002). Although a prolonged QT interval is often indicative 
of physiological decreases in repolarisation currents, a prolonged QT interval can 
also be a sign of myocardial damage (Schwartz et al., 1993), which could be 
occurring here with such high doses of isoprenaline, although previous studies show 
isoprenaline-induced cardiac damage after days rather than hours (Heather et al., 
2009).  
 
The correction of QT interval in small mammal studies is controversial: the clinically 
used heart rate-correction methods are based on the longer R-R interval of a human, 
i.e. ~350-700ms; in the rat this could be 120ms or lower. We must correct the QT 
interval according to heart rate in order to take into account the fact that QT naturally 
shortens with a shortening of R-R interval through the process of restitution (Franz, 
2003), i.e. on the cellular level an action potential shortening due to an increase in 
depolarisation rate (Antzelevitch, 2007).  
 
In a study where heart rate is unlikely to change greatly between conditions it may 
be simplest to not correct at all. However, as here there is a potent positive 
chronotropic agent being administered, the heart rate will increase, resulting in an 
increased level of restitution. Therefore, an impairment of restitution if the QT was 
not corrected to heart rate would be seen as a non-changing QT concurrently with an 
increase in heart rate. For this reason, we must correct. Throughout this chapter I 
have used Bazett’s formula (Figure 4.18) (Luo et al., 2004). As the rat R-R interval is 
very short, this results in corrected QT values being ~2 times higher than 
uncorrected. One method proposed to produce QTc values that better represent the 
uncorrected rat QT is shown in Figure 4.19 (Kmecova and Klimas, 2010). However, 
the use of this validated method to correct QT interval does not change the 
mathematical relationship it makes between QTc and RR from Bazett’s formula, but 
rather translates it by a factor of 0.387: a 20% increase in QT interval will still be a 
20% increase, but rather 200ms to 240ms it would be 77.4ms to 92.88ms. Therefore, 
I decided to use the Bazett’s corrected QT as generated by the LabChart software.  
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Figure 4.18: Bazett’s formula for QT correction (Luo et al., 2004) 
 
 
 Figure 4.19: The modified Bazett’s formula for rats (Kmecova and Klimas, 2010). 
 
 
Figure 4.20: The relationship between heart rate and R-R interval.  
 
As can be seen in Figure 4.20, the largest changes in R-R interval occur at lower 
heart rates due to the reciprocal nature of the relationship between R-R interval and 
heart rate; a much greater change in R-R interval would occur between 60 BPM and 
120 BPM (1000ms to 500ms) than between 440 BPM and 500 BPM (136ms to 
120ms). Therefore, by using Bazett’s formula to correct for heart rate I am in fact 
undercorrecting. Therefore, the prolongations in QTc seen in this study in figures 4.5 
and 4.11 are underestimated, and the QTc prolongation in this model may in fact be 
more severe.  
 
ST elevation is another common ECG finding in TTS patients (Bybee et al., 2004), 
and is a primary reason why TTS is often initially misdiagnosed as an acute coronary 
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syndrome. Macroscopically, ST-elevation in a myocardial infarction is due to 
transmural dispersion of repolarisation caused by a full-thickness infarct (Yan and 
Antzelevitch, 1999). After injection of isoprenaline, ST-segment elevation occurred 
within 1 minute, accompanied by a global increase in contractility. Furthermore, post-
mortem hearts were examined and no infarct could be seen. Therefore, I 
hypothesise that the mechanism of ST-segment elevation in these studies is not 
from ischaemia. Brugada syndrome presents with, amongst other signs, ST-segment 
elevation (Brugada et al., 2005; Brugada and Brugada, 1992). The mechanism of 
this is a transmural heterogeneity in action potential morphology, where the 
epicardial cells exhibit a deeply notched action potential and endocardial cells show 
a more normal action potential morphology (Kurita et al., 2002). Ex vivo experiments 
may help to delineate the mechanism of this ECG change. Nonetheless, if 
isoprenaline caused transmural repolarisation heterogeneity, this could manifest on 
the ECG as ST-segment elevation. 
 
4.4.6 Limitations and further work 
 
Clearly the primary limitation in this work is the inability to reproduce consistent 
apical dysfunction after isoprenaline administration: I tried to faithfully reproduce the 
conditions described in Shao et al. (2013) and, although I reproduced the ST-
segment elevation that they observed, I did not observe the TTS phenotype. 
However, the fact I could still observe the ECG changes perhaps indicates to a 
parallel signalling pathway that causes the electrical changes to the pathway that 
causes the contractility changes, rather than, as some have suggested (Madias, 
2013), the dyskinesia is the cause of the ECG changes.  
 
Changes in QT interval after isoprenaline form a major part of the findings of these 
studies. Apart from the limitations associated with QT correction discussed in 4.4.5, 
the use of only one ECG lead could result in other QT changes being missed. Lead II 
was chosen for these studies based on tradition: in previous studies arrhythmia 
analysis, rather than QT analysis was the priority. Therefore, lead II provides a clear 
rhythm strip to analyse ventricular arrhythmias. Post-hoc it was decided to analyse 
QT in these animals from lead II, and although lead V(3) is preferred for QT analysis, 
serendipitously lead II does give the next best QT interval measurement based on 
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the mean QT interval as measured over all twelve leads (Davey, 2000). Ideally it 
would have preferable to have a number of leads, including some pre-cordial leads, 
to analysis parameters such as QT dispersion and attempt to locate the area of 
myocardium that is giving rise to the ST-segment elevation.  
 
Without a knowledge of the plasma concentration of isoprenaline during these 
experiments, it is impossible to plan ex vivo and in vitro experiments to further 
delineate the mechanisms of this model. HPLC or a similar analytical chemistry 
technique will help to solve this. However, experiments with high concentrations of 
isoprenaline on the arrhythmic threshold may be an imperfect substitute.  
 
As with the adrenaline TTS model, testing the same dose in female ovariectomised 
and non-ovariectomised rats would show the effects of female sex hormones on this 
disease as they appear to have a vital role in human TTS based on its prevalence in 
post-menopausal females. Finally, giving a dose of 50mg.kg-1 intravenously rather 
than intraperitoneally would show whether the IP administration is truly equilibrating 
with the rest of the body, or is acting as a depot. 
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5. Hyperthermia and its role in Takotsubo syndrome: discovery and further 
investigations 
 
5.1 Introduction 
 
In Chapter 4, a recreation of the findings of Shao et al. (2013) was attempted: that an 
intraperitoneal injection of 50mg.kg-1 isoprenaline induces apical akinesia within 100 
minutes. Although elements of the human disease were replicated (ST-segment 
elevation, prolonged QT interval), the hallmark of TTS, apical ballooning, was not 
reliably seen, and not at the frequency reported in their paper. This raised a very 
important question: What is the fundamental difference between the experiments 
carried out in London and the experiments carried out in Gothenburg? Ultimately, if 
this could be found, a critical step in TTS pathophysiology could be discovered, and 
perhaps the point of disconnection between the electrophysiological changes seen 
and the contractility changes present in TTS.  
 
One anecdotal finding identified by myself is that after isoprenaline administration, 
when animals are anaesthetised with ketamine-midazolam, there is a sudden 
increase in rectal temperature (Figure 5.1). It is known that beta-adrenoceptor 
agonists can cause hyperthermia (Yamahara et al., 1985), so this finding is not 
unusual. Historically, we recorded body temperature to ensure that animals were not 
becoming hypothermic during extended periods of anaesthesia and, as stated 
previously, under isoflurane anaesthesia an animal’s body temperature is very labile.  
 
To keep experiments comparable when I noticed an increase in body temperature I 
reduced the level of heating that was applied to the animal to keep the animal in its 
approximate euthermic range (37.0 – 38.0oC). However, after observing how the 
experiments were conducted in Gothenburg we quickly realised that body 
temperature may have been difference between the two laboratories’ technique as 
they allow their animals to become hyperthermic in response to isoprenaline.  
 
Hyperthermia causes a very broad range of physiological changes. In rats, 
hyperthermia disrupts the blood-brain barrier (Sharma et al., 2006), can induce 
cardioprotection via heat shock protein upregulation (Patel et al., 2001), and 
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increases blood flow to the tail (O’Leary and Johnson, 1989). In man, much of the 
data we have on hyperthermia comes from studies into heat stroke and malignant 
hyperthermia. In heat stroke, patients often present with hypophosphataemia, 
hyponatraemia and hypocalcaemia, with hypokalaemia and hypomagnesaemia also 
present in some (Nabalawi, 2012). Rhabdomyolysis can also occur, resulting in 
acute renal failure in some patients. Serum creatine kinase, aspartate 
aminotransferase, alanine aminotransferase and lactate dehydrogenase can also be 
raised in heat stroke patients compared to control (Alzeer et al., 1997). Although this 
panel of serum enzymes predominantly shows muscle damage and rhabdolyolysis, 
the presence of a raised serum alanine aminotransferase indicates liver damage, 
which may be due to hyperthermia causing hepatic splanchnic hypoxia (Rowell et al., 
1968). Hyperthermia can also increase sympathetic nerve activity via the rostral 
ventral lateral medulla (Hosking et al., 2009). Furthermore, changes in the enthalpy 
state of the β2AR could change its predisposition for stimulus trafficking (Kim et al., 
2013). However, this final point has yet to be confirmed with respect to small 
changes in temperature. Here I test whether allowing animals to become 
hyperthermic can allow TTS to occur, and if so, when the critical time for 
hyperthermia is.  
 
5.2 Materials and methods 
 
5.2.1 Reagents 
 
(-)-Isoprenaline hydrochloride was obtained from Sigma and diluted to a 
concentration of x mg.ml-1 in 0.9% (w/v) NaCl saline, where x is the intended dose in 
mg.kg-1. Isoflurane was obtained from Abbot Laboratories. Ketamine was obtained 
from . Midazolam was obtained from .    
 
5.2.2 Animals 
 
All animal procedures were performed in accordance with Animals (Scientific 
Procedures) Act 1986 and under a personal and project Home Office licence. 
Animals were housed in groups of four and experienced 12 hour light/dark cycle. 
Male Sprague Dawley rats (Charles River) were used for experiments in this section. 
 132 
All animals were killed by a Schedule 1 method (cervical dislocation) at the end of 
the procedure.  
 
5.2.3 Anaesthesia protocols 
 
Rats were removed from a holding cage and restrained in a manner so that the torso 
of the animal was exposed and the animal was vertical, cranium superior to caudum. 
A ketamine-midazolam mixture was injected intraperitoneally at a dose of 50mg.kg-1 
and 5mg.kg-1, respectively. Loss of righting reflex was typically seen 3-4 minutes 
after injection. Ketamine-midazolam was readministered at a dose of 25/2.5mg.kg-1 
when the anaesthetic state was seen to be ‘light’ (i.e. small co-ordinated movements 
seen in the animal’s limbs). Animals anaesthetised with ketamine-midazolam were 
not restrained in the dorsal position by their limbs to allow for the assessment of 
anaesthesia depth and due to the muscle rigidity caused by ketamine. A piece of 
gauze was placed in to their mouth to remove excess secretions.  
 
5.2.4 Echocardiography protocol 
 
Once anaesthetised, the thorax was shaved using electric hair clippers and the 
animal was placed onto a heated echocardiography table (Visualsonics). Hair 
depilatory cream was then applied to the thorax to remove the remaining fur. After 
satisfactory depilation, ultrasound gel was applied to the thorax and the ultrasound 
probe (RMV-716, Visualsonics) positioned to acquire a parasternal long axis view of 
the left ventricle. M-mode images were taken from the apical and basal myocardial 
segments to measure fractional shortening in these regions. Animals were heated by 
the echocardiography table (heated to 50oC) and a homoeothermic blanket 
(Harvard). Body temperature was measured using a rectal probe (Harvard).  
 
5.2.5 Electrocardiography protocol 
 
Needle electrodes were placed subdermally into the left hindlimb (positive electrode) 
and right forelimb (negative electrode) to obtain a Lead II ECG. A Bio Amp (AD 
Instruments) was used to amplify and condition the signal, which was digitised by a 
PowerLab (AD Instruments) and recorded using LabChart 7 (AD Instruments). A 
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50Hz mains filter was applied to the signal to reduce electrical noise. ECG traces 
were analysed automatically using the LabChart 7 ECG Analysis module. All QTc 
values reported are corrected using the Bazett’s method (Figure 4.18).  
 
5.2.6 Isoprenaline administration 
 
Isoprenaline was injected intraperitoneally via a 25G needle.  
 
5.2.7 Cooling protocol 
 
Cooling was applied in the form of ice and ice packs placed onto the abdomen and 
throat of the animal. All external heating was also removed during the cooling period 
but was reapplied at a lower level when the animal reached the target euthermic 
temperature.  
 
5.2.8 Isoflurane administration 
 
Isoflurane was administered via a Bain co-axial nosecone at a dose of 1.5% in 100% 
O2.  
 
5.2.9 Tail-cuff plethysmography 
 
After the induction of anaesthesia and the acquisition of a baseline echocardiogram, 
a pulse transducer with pressure cuff (AD Instruments) was placed over the base of 
the tail, with the pressure cuff proximal to the pulse transducer. The cuff was then 
inflated to ~220mmHg and deflated slowly. Systolic blood pressure was taken as the 
pressure reading for the pressure cuff when the pulse started to reappear. A reading 
for diastolic pressure was not attempted.  
 
5.2.10 In vitro hyperthermia  
 
Cells isolated using a previously described method (Paur et al., 2012) were 
incubated in a water bath at either 37oC or 41oC for one hour. These cells were then 
transferred to a cell bath mounted on a microscope. After being allowed to adhere to 
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the bottom of the bath for 5 minutes, cells were perfused with Krebs-Henseleit 
solution (1mM Ca2+) at 37-38oC and stimulated at a rate of 0.5Hz.  
 
5.2.11 Statistical analysis 
 
Unless stated, all echocardiographic and chronotropic data was analysed using two-
way repeated measures ANOVA calculations with either Tukey’s (for whole 
experiment analysis) or Dunnett’s (individual time-point analysis) post-hoc tests. 
Before and after QTc analysis was carried out using a two-way ANOVA (isoflurane 
experiments) or paired t-test (ketamine-midazolam anaesthesia). One-way ANOVA 
with Sidak’s post-hoc test was used to compare time-points with baseline for 
ketamine-midazolam anaesthetised heart rate measurements. Mortality was 
analysed using Barnard’s test. Survival curves were analysed using the log-rank test; 
time of death is reported as the next time point at which no ascertainable contractility 
could be seen, or no QRS complexes seen on the ECG. Statistical significance was 
defined as P<0.05.  
 
5.3 Results 
 
5.3.1 50mg.kg-1 isoprenaline under ketamine-midazolam anaesthesia caused a 
significant increase in rectal temperature 
 
After isoprenaline (50mg.kg-1) was administered IP, a significant increase in rectal 
temperature was observed. When the temperature started to rise above the 
euthermic zone (>~38.5oC) heating was removed from the animal until the 
temperature fell back to the euthermic zone. A significant increase in rectal 
temperature was seen for ketamine-midazolam animals for all time points except 5 
minutes post-isoprenaline, compared to baseline. Animals anaesthetised with 
isoflurane did not show a significant increase in rectal temperature at any time-point 
(Figure 5.1).  
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Figure 5.1: After isoprenaline (50mg.kg-1) injection at time 0, rats anaesthetised with ketamine-
midazolam show a significant increase in rectal temperature compared to baseline. *: P<0.05; 
***: P<0.001; ****:P<0.0001, compared to time 0, two-way repeated measured ANOVA. n=5 
(isoflurane) & 8 (ketamine-midazolam). Mean±SEM shown.  
 
5.3.2 Animals under ketamine-midazolam anaesthesia will reach and remain at 
~41oC after isoprenaline (50mg.kg-1) administration if heating is maintained  
 
If heating is maintained until the animal reaches ~41oC and then adjusted to keep 
the animal at ~41oC, the animals’ body temperatures would remain relatively stable 
at ~41oC for the whole experiment and remain significantly increased from baseline 
(Figure 5.2). A subset of animals were allowed to reach 42oC; however, this resulted 
in 3/4 animals dying before 1 hour post-isoprenaline (data not shown).  
 
When animals were allowed to reach 41oC, rather than maintained at ~38oC, 
significant differences were seen between apical and basal contractility changes at 
time points 30, 80 and 90 minutes post-isoprenaline (P<0.05) (Figure 5.3). 
Furthermore, the contractility at time points 80 and 90 minutes post-isoprenaline 
were significantly (P<0.01) negatively inotropic compared to baseline, and all points 
before 70 minutes post-isoprenaline were significantly positively inotropic (P<0.05) in 
the basal myocardium compared to baseline. As a comparison with those animals 
presented in Chapter 4, Figure 5.4 shows a comparison of the apical segments for 
animals anaesthetised with isoflurane and those anaesthetised with ketamine-
midazolam with either a euthermic or hyperthermic rectal temperature. From this it 
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can be clearly seen that only the apex of animals who are hyperthermic show 
negative inotropy relative to baseline. Therefore, based on this finding I hypothesized 
that hyperthermia is critical in the isoprenaline-mediated induction of TTS-like 
contractility patterns in the rat.  
 
 
Figure 5.2: With sustained heating, rectal temperature after isoprenaline (50mg.kg-1) can reach 
and remain at 41oC. ****: P<0.0001 compared to baseline, one-way ANOVA (n=6). Mean±SEM 
shown; dotted line at 41oC.  
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Figure 5.3: After isoprenaline (50mg.kg-1) administration at time 0, the base shows a significant 
positive inotropic response, whereas the apex shows a significant negative inotropic response 
at 80 and 90 minutes post-isoprenaline. For statistical analysis of temperature see Figure 5.2. 
Between lines: *: P<0.05 apex vs. base. Above lines: **: P<0.01 apex vs. baseline; #: P<0.05, 
##: P<0.01, ###: P<0.001, ####: P<0.0001 base vs. baseline, two-way ANOVA (n=6).  
 
 
Figure 5.4: Comparing the apices of animals anaesthetised under isoflurane and under 
ketamine-midazolam anaesthesia (either 38oC or 41oC target temperature), there are significant 
differences present between apical contractility at 41oC vs. both 38oC and isoflurane 
anaesthetised apices. *: p<0.05, **: P<0.01 apex 41 vs. isoflurane; #: P<0.05, ##: P<0.01, ###: 
P<0.001 apex 41 vs. apex 38, two-way ANOVA (n=8, 6 and 3 for 38, 41 and isoflurane, 
respectively).  
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Unlike the euthermic ketamine-midazolam animals presented in Chapter 4, when 
hyperthermic animals showed a significant increase in QTc at 90 minutes compared 
to baseline (baseline vs 90 minutes for 38oC animals was not significant, data not 
shown) (Figure 5.5). There seemed to be a trend for prolongation over time, much 
like the studies shown in this chapter (Figure 5.6). Compared to animals that 
remained euthermic, hyperthermic animals had a significantly longer QTc at 90 
minutes post-isoprenaline (Figure 5.7). As the correction for QT is not perfect in rats, 
this change over time during a period where there is not a large change in heart rate 
indicates that this is a real change in QT, rather than the effect of heart rate on the 
QT correction.  
 
 
Figure 5.5: QTc is significantly prolonged at 90 minutes post isoprenaline (50mg.kg-1) 
compared to baseline. *: P<0.05, paired t-test (n=6). Mean±SEM shown. 
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Figure 5.6: After isoprenaline (50mg.kg-1) there appears to be a gradual increase in QTc over 
time (n=6). Mean±SEM shown.  
 
 
 
Figure 5.7: At 90 minutes post-isoprenaline (50mg.kg-1) hyperthermic animals have a 
significantly longer QTc compared to euthermic animals. *: P<0.05 unpaired t-test (n=8 & 6). 
Mean±SEM shown.  
 
5.3.3 Arterial blood pressure measurements in isoprenaline-treated animals 
 
As previously discussed, other studies have shown that blood pressure (see 4.4.2) 
plays a critical role in the development of apical dysfunction (Redfors et al., 2014a). 
Therefore, I wanted to assess the role of hyperthermia during high exogenous 
catecholamine levels on arterial blood pressure to start to elucidate the reason 
hyperthermia was critical in TTS induction. Unfortunately, due to the anaesthesia 
method, a surgical plane of anaesthesia cannot be reached, and therefore only non-
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invasive methods can be considered. Tail cuff plethysmography has been widely 
used previously for blood pressure studies and is well validated (Kubota et al., 2006). 
However, despite very good baseline recordings, within 20 seconds of the injection 
of 50mg.kg-1 isoprenaline, the detected tail pulse vanished, potentially indicating a 
loss of circulation to the tail. Therefore, attempts to measure the blood pressure in 
these animals were unsuccessful.  
 
5.3.4 Cooling of animals after an initial hyperthermic period did not reverse, or 
exacerbate, the apical dysfunction induced by hyperthermia and isoprenaline  
 
As hyperthermia appears to be essential in the induction of TTS-like contractility, I 
wanted to assess whether hyperthermia was required for the maintenance of the 
apical contraction abnormality. Animals were cooled using external ice packs applied 
to the abdomen of the animal; all heating was removed from the animal during this 
period. Animals could be returned to 37-38oC within 10 minutes from the application 
of cooling (Figure 5.8). However, there was no difference in the change from 
baseline in either of the cooled groups (cooled at 60 minutes post-isoprenaline and 
90 minutes post-isoprenaline) compared to animals that were maintained at ~41oC 
(Figure 5.9).  
 
 
Figure 5.8: Upon application of cooling at the time indicated in the legend, animals rapidly 
returned back to a euthermic rectal temperature (n=3 for maintained, n=4 for both cooled 
groups). Mean±SEM shown.  
 
0 50 100 150
34
36
38
40
42
44
Te
m
p 
(C
)
Time (mins)
Maintained
Cooled 90 mins
Cooled 60 mins
 141 
 
 
Figure 5.9: Cooling animals after the initiation of a Takotsubo-like contractility pattern did not 
cause a change in contractility and did not reverse the apical negative inotropy. No significant 
differences were found between apex groups or base groups, two-way ANOVA (n=3 for 
maintained, 4 for both cooled groups). Error bars are omitted for clarity; for mean±SEM see 
Appendix.  
 
 
5.3.5 Baseline cellular responsiveness after in vitro hyperthermia  
 
In an attempt to determine the link between temperature and TTS-like contractility 
after high-dose catecholamines, isolated rat cardiomyocytes were subjected to 
hyperthermia (41oC; 37oC as control) in a water bath for one hour, with or without the 
presence of a high dose of isoprenaline (100uM) that has been used previously to 
induce in vitro cellular dysfunction (Shao et al., 2013a). Cardiomyocytes were then 
transferred to a cell bath and perfused at 37oC with no catecholamines present. No 
difference was found in baseline contractility between any of the four pre-treatment 
groups (Figure 5.10), showing that hyperthermia is not causing damage to the cells, 
and not changing the basal contractility when catecholamines are not present.  
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Figure 5.10: No significant difference in basal contractility was seen after pre-treatment with 
hyperthermia or hyperthermia and isoprenaline; one-way ANOVA (n=29, 24, 21, 16); Mean±SEM 
shown.  
 
5.3.6 Beta-adrenoceptor responsiveness after hyperthermia pre-treatment 
 
After cells were treated for one hour with a temperature of either 37oC or 41oC, cells 
were then stimulated with 1µM isoprenaline for 10 minutes and cell shortening was 
measured to determine the effects of hyperthermia pre-treatment on catecholamine 
responsiveness. This was followed by a 25 minute washout and then a repeat 
stimulation with isoprenaline in the presence of CGP-20712A, a β1-adrenoceptor 
antagonist. This was to measure any possible Gs to Gi stimulus trafficking that can be 
triggered using this catecholamine pre-stimulation protocol and whether this was 
augmented by hyperthermia. The initial response to isoprenaline was steady-state 
and did not desensitise, whereas the second β2 response often quickly desensitised 
Figure 5.11).  
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Figure 5.11: Representative trace of cell length measurements during the β2 response, with 
the peak and desensitised periods shown in the red ovals. Scale bar: 100s; 25µm.  
 
It was frequently observed that the basal contraction between catecholamine 
stimulations was lower than at the start of the experiment. Therefore, for any ‘fold 
change’ measurements, these are the fold change from the baseline immediately 
previous to the stimulation. There was not a significant difference in the initial beta-
adrenoceptor responsiveness between the two temperatures (Figure 5.12). 
Furthermore, temperature pre-treatment did not affect contractility during the peak or 
steady state (i.e. desensitised) phase of the second isoprenaline treatment (β2 
response) (figures 5.13 & 5.14, respectively).  
 
The time taken for 50% desensitisation (i.e. between peak response and halfway 
between peak and steady-state) of the β2 response was also measured. I found that 
there was not a significant difference between desensitisation kinetics between the 
two pre-treatment temperatures (Figure 5.15). Relaxation to 50% was not 
significantly different between the two temperatures during any part of the 
experiment (Figure 5.16). Relaxation to 90% also showed no significant differences 
between the two temperatures (data not shown).  
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Figure 5.12: Initial beta-adrenoceptor responsiveness was not significantly different between 
37oC and 41oC pre-treatment groups (n=9,9). Mean±SEM shown.  
 
Figure 5.13: Peak β2 response was not changed by hyperthermia pre-treatment (n=9,6). 
Mean±SEM shown.  
 
Figure 5.14: Steady-state (i.e. after desensitisation) β2 response was not changed by 
hyperthermia pre-treatment (n=9,8). Mean±SEM shown.  
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Figure 5.15: Pre-treatment with hyperthermia did not significantly change the time to 50% 
desensitisation of the β2 response (n=9,7). Mean±SEM shown.  
 
Figure 5.16: Cellular relaxation was not significantly different between the two pre-treatment 
temperatures for any of the four experimental conditions (n=9,8). Mean±SEM shown.  
 
5.3.7 Isoflurane administration after Takotsubo induction worsened heart failure 
 
A recent study showed that isoflurane (1.5%) given before the administration of 
catecholamines inhibited the induction of TTS (Redfors et al., 2014b). This was in 
line with the results presented in Chapter 4 of this thesis, although isoflurane was not 
the only anaesthetic present: ketamine was also used. Furthermore, isoflurane 
appeared to have no effect on body temperature. Here I assessed whether 
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isoflurane given after the induction of TTS-like contractility could reverse it, and 
thereby be a possible clinical therapeutic strategy.  
 
However, isoflurane (1.5%) given 120 minutes post-isoprenaline caused no reversal 
of the TTS-like contractility pattern (Figure 5.17). Furthermore, isoflurane did cause a 
sudden and significant bradycardia (figures 5.18) Furthermore, over the 60 minute 
period that isoflurane was administered for, rats treated with isoflurane showed a 
significant level of mortality vs. control (figures 5.19 & 5.20).  
 
 
Figure 5.17: Apical hypokinesia did not improve after the administration of isoflurane (1.5%) 
(n=4-6 for isoflurane due to mortality, n=6 for control). Mean±SEM shown.  
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Figure 5.18: Administration of isoflurane (1.5%) caused a sudden and sustained bradycardia 
compared to control (n=6 for isoflurane until 120 mins, 2-6 after 120 mins due to mortality; 
n=5-6 for control). Mean±SEM shown.  
 
 
 
Figure 5.19: Mortality within 60 minutes of isoflurane (1.5%) administration was significantly 
higher than control (n=6 for both groups). *: P<0.05 Bernard’s exact test.  
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Figure 5.20: Administration of isoflurane (1.5%) caused a significant difference in the survival 
curve compared to control (n=6 for both groups). *: P<0.05 log-rank test.  
 
 
5.4 Discussion 
 
TTS is a syndrome that, according to the current literature, is associated with an 
excess of catecholamines (Wittstein et al., 2005), and pre-clinical models have 
elucidated a link between excess levels of catecholamines delivered from an 
exogenous source and TTS induction (Izumi et al., 2009; Paur et al., 2012; Shao et 
al., 2013b, 2013c). However, as the previous chapter showed, in the case of 
replicating the induction of TTS using high levels of exogenous catecholamines 
(namely isoprenaline), the catecholamine alone was not enough and little, if any, true 
TTS (in an animal model with all the caveats that accompany it) was seen. As a 
result it became clear that something else must be required, at least in this model, to 
allow apical ballooning to manifest itself.  
 
I identified a new element which was missing in the studies presented in Chapter 4, 
namely hyperthermia during the induction phase (i.e. first 60 minutes). Without this 
hyperthermia that spontaneously occurs after isoprenaline administration under 
ketamine-midazolam anaesthesia, no TTS occurred. Therefore, the primary finding 
of this chapter is that hyperthermia, in the isoprenaline-induced rat TTS model, is 
essential, but perhaps not sufficient, to induce TTS in addition to the high 
catecholamine administration. 
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Interestingly, I found that a parameter required for the induction of TTS-like 
contractility is not required shortly after the contractility deficit has established as 
cooling the animals had little effect on contractility. Furthermore, the addition of 
isoflurane, which has been shown to inhibit TTS through a temperature-independent 
mechanism (isoflurane only reduced body temperature by ~3%) (Redfors et al., 
2014b), not only failed to reverse the apical ballooning, but resulted in an increased 
mortality rate due to acute cardiac decompensation. This may have important clinical 
implications if true for the human disease, as treatments may need to be strictly 
delineated into preventative and curative/supportive in order to have any benefit.  
 
Despite the very obvious effects of hyperthermia on in vivo catecholamine 
responsiveness, very little, if any, effect was seen in vitro. Hyperthermia for one hour 
did not reduce basal contractility, even when the cells were incubated with very high 
levels of catecholamines. Further work carried out by a student under my supervision 
showed that altering the temperature during the experiment (i.e. during the IonOptix 
recording) also did not affect cellular contractility or β-adrenoceptor responsiveness 
(Rohan Pancharatnam, personal communication, 22 September 2015). This implies 
that hyperthermia, with or without high levels of catecholamines, does not create a 
contractility deficit on the cellular level in a model that does not have the effects of 
neighbouring cells and their mechanical effects, or the effects of the organism as a 
whole on cardiac function. Therefore, temperature may be acting through a 
mechanism that is beyond the level of the cell, such as through an afterload-
dependent mechanism.  
 
5.4.1 The mechanism of isoprenaline-induced hyperthermia under ketamine-
midazolam anaesthesia 
 
Isoprenaline is known to have a wide range of effects on thermoregulation and may 
cause either an increase or decrease dependent on a number of factors. For 
instance, intracerebroventricular administration of isoprenaline in rabbits causes a 
decrease in body temperature, possibly through the inhibition of a heat generation 
pathway (Jones et al., 1977). Similarly, a peripheral administration of isoprenaline in 
Zucker rats caused a thermolytic effect that was inhibited by propranolol (Carlisle et 
 150 
al., 1993), and by ICI 118,551, indicating a predominantly β2-adrenoceptor pathway 
(Carlisle and Stock, 1992).  
 
Acute stress that would activate the sympathetic nervous system is known to elevate 
body temperature (Marazziti et al., 1992; Renbourn, 1960; Singer et al., 1986). When 
studying the body temperature response to a stressful situation (rats placed in large 
unfamiliar surroundings), cerebral administration of beta-blockers prevents the 
stress-induced hyperthermia, whereas peripheral administration of beta blockers that 
do not cross the blood-brain barrier do not have this effect (Soszynski et al., 1996). 
Further studies by the same group showed that intracerebroventricular 
administration of the β2-adrenoceptor antagonist ICI-118,551 induced hypothermia in 
rats exposed to stress resulted in a decrease in body temperature (Mayfield et al., 
1999). Intracerebroventricular administration of isoprenaline also caused a modest 
hypothermic response. However, in contrast to to my studies presented in this 
chapter, they reported that IP isoprenaline in conscious rats at doses of a similar 
magnitude (10mg.kg-1 & 100mg.kg-1) resulted in no sustained change in body 
temperature over a two hour period.  
 
Ketamine anaesthesia has been shown to also cause hypothermia in a dose-
dependent manner through 5-HT release from the hypothalamus (Fahim et al., 
1973). In order to explain the hyperthermia seen in the experiments presented in this 
chapter there must be some interaction between isoprenaline and ketamine and/or 
midazolam, and much like ketamine, midazolam does not cause hyperthermia. 
Instead it causes a modest attenuation of the stress hyperthermic response through 
its anxiolytic properties (Vinkers et al., 2009). 
 
It has been reported that phaeochromocytoma can present as an acute 
hypermetabolic state, masquerading as malignant hyperthermia if the patient is 
under anaesthesia (Allen and Rosenberg, 1990). Ketamine can inhibit neuronal 
(uptake 1) and extraneural (uptake 2) uptake of sympathetic neurotransmitters 
(Lundy et al., 1986), and uptake 2 is known to be a clearance method for 
isoprenaline in the heart and smooth muscle cells (O’Donnell and Reid, 1984; Picken 
and Jarrott, 1975). Ketamine could therefore be potentiating the effects of 
isoprenaline by increasing its extracellular availability.  
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Isoprenaline can activate thermogenic brown adipose tissue in the rat (Carneheim et 
al., 1984), and therefore, under the correct circumstances, could provide a net 
hyperthermic drive, even though there would be isoprenaline-mediated vasodilation 
to effect heat loss. Furthermore, ketamine has been shown to increase 18F-FDG 
uptake in brown adipose tissue (Tatsumi et al., 2004), a sign of increased metabolic 
activity and thermogenesis (Garcia et al., 2005). Therefore, unlike in previous studies 
showing either ketamine or isoprenaline in isolation caused hypothermia, the 
combination could activate brown fat to increase thermogenesis.  
 
The loss of a pulse in the tail artery almost immediately after isoprenaline (as 
discussed in Section 5.3.3) may indicate a loss of blood flow to the tail, mediated 
through vasoconstriction of the ventral tail artery. The rat tail as a tool for heat 
dissipation was first described in 1942 (Knoppers, 1942), and is now known to 
operate through changes in the blood flow, not in a graded response to heat but 
rather in a binary ON/OFF pattern (Young and Dawson, 1982). Beta-adrenoceptor 
agonists tend to vasodilate rat tail arteries (Rajanayagam et al., 1990), effecting heat 
loss. Therefore, in this model I propose that, despite the strong exogenous drive for 
a vasodilated tail, there must be a stronger central drive to vasoconstrict arteries to 
the tail, indicating the hyperthermia is endogenously driven. Alternatively, there could 
be a steal effect, whereby if there was a body-wide hypotensive effect of 
isoprenaline, the tail could become poorly perfused, which would also cause a loss 
of a detectable pulse.  
 
5.4.2 The mechanism of hyperthermia-induced Takotsubo syndrome-like contractility 
 
Hyperthermia is caused by, and causes, a very wide range of physiological 
responses, although often the direction of these responses is whether the 
hyperthermia is endogenous (i.e. caused by a change in the hypothalamic set-point, 
such as in fever) or exogenous (i.e. heatstroke with no change in the hypothalamic 
set-point). In a endogenous hyperthermia the responses will be effecting the 
increase in body temperature (e.g. increase in metabolic rate, vasoconstriction, 
shivering), whereas with an exogenous hyperthermia the responses will be trying to 
effect a return to euthermic temperatures (sweating, vasodilation, reduction in 
metabolic rate). In this model it is likely that the hyperthermia is endogenously driven 
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(albeit caused by the administration of an exogenous agent) as the same external 
heating was used for animals under isoflurane anaesthesia (see Chapter 5). 
However, as it is may not be driven centrally from the hypothalamus, there could be 
responses such as vasodilation of vessels near to the skin that, when accompanied 
by strong external heating from the heating pad and blanket, cannot overcome the 
increased metabolic rate. Therefore, it is difficult to ascertain exactly what 
homeostatic responses would be occurring. However, regardless of the cause of the 
hyperthermia, there will also be responses simply due to the increased internal 
temperature.  
 
It has been demonstrated that hyperthermic body temperature changes in the rat 
from 38oC to 41oC cause a significant increase in sympathetic nerve discharge rate 
(Kenney et al., 1995). This was accompanied by an increase in mean arterial 
pressure, and indicating that, under hyperthermia, baroreceptor feedback is not 
opposing the increase in mean arterial pressure. However, this point is contentious 
as a previous group (in conscious, rather than anaesthetised animals) showed that 
baroreceptor function did oppose sympathetic-driven increases in mean arterial 
pressure during hyperthermia (Kregel et al., 1990). Furthermore, unpublished data 
has shown that hyperthermia in this model in particular causes hypertension 
compared with normothermia (Björn Redfors, personal communication, 26 
September 2014). However, in general, isoprenaline, which is associated with apical 
dysfunction rather than basal dysfunction, does cause a small reduction (or no 
change) in systolic arterial pressure, whereas agents that cause basal dysfunction 
(e.g. phenylephrine) cause a strong increase in systolic blood pressure (Redfors et 
al., 2014a). Therefore, it is unlikely that hyperthermia is allowing TTS to occur 
through purely a haemodynamic effect.  
 
AMP-activated kinase (AMPK) is an enzyme that is ubiquitously expressed through 
most mammalian tissue, including the heart (Arad et al., 2007). AMPK is activated 
when AMP levels rise, indicating a state of either low levels metabolic substrate or 
an inability to generate ATP through another mechanism, such as the presence of a 
metabolic toxin. Nevertheless, it acts as a metabolic sensor for the cell and can 
coordinate a metabolic response to energy starvation (Beauloye et al., 2011). AMPK 
is indirectly activated by a number of stimuli, including exercise and hypoxia (Arad et 
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al., 2007). When activated, AMPK acts to increase glycolysis and glucose uptake, 
and fatty acid oxidation, to effect a restoration of ATP levels. Activation of AMPK 
may act as an inhibitor of apoptosis, thereby increasing cardiac survival after a pro-
apoptotic insult (Dyck and Lopaschuk, 2006; Zou and Xie, 2013). In the setting of a 
myocardial infarction, AMPK activation with metformin has been shown to increase 
cardioprotection post-MI (Calvert et al., 2008).  
 
The effect of temperature on AMPK activity has been investigated in a number of cell 
types. In cancer cells, hyperthermia may be therapeutic through the activation of 
AMPK (Lee et al., 2014) as AMPK also inhibits protein synthesis in an effort to 
conserve energy (Chan and Dyck, 2005). Unlike in the heart where AMPK activation 
is though to have a protective effect after ischaemia, the opposite seems to be true 
after stroke. It has been shown that acute metformin treatment after experimental 
stroke increases brain damage through its effect on AMPK activity (Li et al., 2010). 
The same group in a later paper showed that hypothermia can provide 
neuroprotection after experimental stroke by reducing AMPK activity (Li et al., 2011). 
Therefore, in the setting of hyperthermia if AMPK activity is increased, this may limit 
the tissue injury by providing a level of cardioprotection, especially as AMPK has 
been shown to offer cardioprotection against catecholamine-induced apoptosis 
(Zhuo et al., 2013). In acute TTS patient biopsies there is an increase in the PI3K/Akt 
cardioprotective signalling pathway (Nef et al., 2009a), which can be activated by 
AMPK (Tao et al., 2010). However, AMPK increases the Ca2+ sensitivity of the 
myofibril and causes increased contractility (Oliveira et al., 2012). If AMPK is a key 
player in the pathophysiology of TTS, this increase in contractility must be 
superseded by a more powerful negative inotropic effect, at least in the apex, 
otherwise TTS would not be a disease of hypocontractility. 
 
Heat shock proteins are a family of cytoprotective proteins in eukaryotes that act as 
molecular chaperones for proteins damaged by a range of environmental stressors, 
one of which is thermal stress (Verghese et al., 2012). In cardiac muscle the heat 
shock protein of primary interest is HSP20 (Fan et al., 2005a). HSP20 has been 
shown to associate with myofibrils after isoprenaline treatment and prevents 
isoprenaline-induced apoptosis (Fan et al., 2004). HSP20 also attenuates 
isoprenaline-mediated cardiac remodelling (Fan et al., 2006) and the ‘activation’ of 
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HSP20, through the phosphorylation of the serine-16 residue by PKA (Beall et al., 
1999), results in increased survival after ischaemic insult (Qian et al., 2009). HSP20 
is a possible candidate for the supposed cardioprotection in this disease if in fact it is 
activated in human TTS.  
 
Thermal stress can also result in phosphorylation at the serine-16 residue, and has 
been shown to cause “force suppression” in vascular smooth muscle (O’Connor and 
Rembold, 2002). However, HSP20 can increase contractility after ischaemia-
reperfusion (Fan et al., 2005b) and increase calcium uptake kinetics (Pipkin et al., 
2003). Therefore, if activated in this model of TTS, HSP20 may be limiting the 
negative inotropy: It is unlikely that HSP20 is a direct critical mediator of TTS-like 
contractility as the apical hypokinesia would be worsened at a euthermic body 
temperature. Nevertheless, it may be important in cell survival against the pro-
apoptotic catecholamine excess.  
 
The Frank-Starling mechanism is the increase in myofilbrillar calcium sensitivity with 
an increase in diastolic length of the sarcomere, thereby increasing inotropy when 
preload increases (Solaro, 2007). Recent studies carried out on computational 
models of the rat heart have shown that a failure of the Frank-Starling mechanism 
significantly increases apical ballooning at end systole (Land et al., 2014). Whole 
body heating has been shown to shift the operating point of the heart to a steeper 
portion of the preload-stroke volume curve (Wilson et al., 2009). This means that a 
small change in preload will have a comparatively larger effect on stroke volume 
compared to normothermia, although the actual changes in core body temperature 
were relatively small in this study (1oC increase). However, in a study that analysed 
the change in the Frank-Starling mechanism in anaesthetised dogs, it was shown 
that hyperthermia in the range of the animals presented in this chapter (40oC-41oC) 
resulted in a significant decrease in the gradient of inotropy change with respect to 
preload, thereby showing a failure of the Frank-Starling mechanism under severe 
hyperthermia (Sagach and Shimanskaya, 1993). Although this is a tempting 
proposition, and certainly fits with a computational model of TTS (Land et al., 2014), 
the critical role of hyperthermia may be multifactorial, affecting enzymatic cascades, 
myofilament responsiveness and whole-body integrated responses.  
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5.4.3 Absence of TTS reversal after cooling 
 
As hyperthermia was essential in the induction of TTS-like contractility, it may be 
possible that its continuation was also dependent on hyperthermia. However, despite 
cooling at 90 minutes and 60 minutes post-isoprenaline, no reversal of TTS was 
seen. A raised body temperature was therefore found not to be essential for the 
disease to continue to occur. This has a very important implication for clinical 
research into TTS: if the need for hyperthermia is true in human TTS, the time 
window in which this may be present only needs to be short (<60 minutes). People 
with TTS can take several hours to present and the hyperthermia may have 
subsided. A small study on 30 patients at Sahlgrenska Hospital, Gothenburg, 
Sweden showed that TTS patients on admission did not show signs of pyrexia (Björn 
Redfors, personal communication, 4 August 2014).  
 
5.4.4 Cause of increased mortality after isoflurane administration 
 
If administered before isoprenaline, isoflurane is thought to inhibit apical dysfunction 
through a temperature- and KATP-independent pathway (Redfors et al., 2014b), and 
the exact mechanism is unknown. Isoflurane has been shown in rats to reduce 
vasodilation mediated by isoprenaline but not by forskolin, indicating a sympatholytic 
property at the level of the receptor or G-protein, rather than a reduction in adenylyl 
cyclase or PKA function (Tanaka and Tsuchida, 1998). In the stimulus trafficking 
hypothesis of TTS, a robust activation of the beta-adrenoceptors is required to 
initiate the phosphorylation of the β2-adrenoceptor by PKA and GRK2 and the 
subsequent switch from Gs to Gi. It is possible that in the presence of a drug (i.e. 
isoflurane) that reduces beta-adrenoceptor activity, the threshold is not met for 
stimulus trafficking and isoprenaline acts as a classical positive inotrope.  
 
However, when applying isoflurane to an animal with already-depressed cardiac 
function (i.e. TTS), it appeared that it did not reduce cardiac contractility. Instead, a 
sudden reduction in heart rate was observed, lowering the cardiac output. The 
mechanism of isoflurane-induced bradycardia is not clear in this situation. However, 
two possibilities arise: isoflurane acts as a sympatholytic to reduce the activity of the 
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injected isoprenaline and endogenous catecholamines on the sino-atrial node; or 
isoflurane enhances Vagal activity.  
 
Isoflurane has been shown to depress baroreflex function (Lee et al., 2002). In an 
acute heart failure scenario, one would expect the blood pressure to be lowered 
compared to normal, and therefore there would be a high sympathetic outflow driven 
by the baroreceptors and coordinated by the nucleus tractus solitarius (NTS). In rats, 
in the presence of 1 MAC (minimum alveolar concentration) isoflurane, sympathetic 
outflow as a result of the baroreflex is eliminated, whereas Vagal tone is present 
(Lee et al., 2002). However, these two possible explanations are in no way mutually 
exclusive, and both, or neither, could be the cause of bradycardia after isoflurane. 
Regardless of the cause, the reduction in heart rate without an increase in 
contractility resulted in a reduction in cardiac output, and 5 out of 6 animals treated 
with isoflurane died within 60 minutes of isoflurane initiation due to acute cardiac 
decompensation.  
 
5.4.5 Limitations and further work 
 
A primary limitation of the work presented in this chapter was the inability to monitor 
the haemodynamics of the rat during TTS induction, either peripherally or centrally 
as haemodynamics have been shown to be critical in this model’s pathophysiology 
(Redfors et al., 2014a). Administration of isoprenaline caused a loss of detectable 
pulse in the tail, preventing the use of tail plethysmography, and ketamine-
midazolam anaesthesia does not give a surgical plane of anaesthesia, preventing 
the use of a central blood pressure transducer. Unfortunately, PV loop data that was 
so informative for the adrenaline bolus TTS model (Paur et al., 2012) could not be 
acquired for this model for the same reason. Further work should be carried out to 
either implant blood pressure telemetry devices or test the use of other anaesthetics 
that do give a surgical plane of anaesthesia to allow for the invasive measurement of 
haemodynamics and a thoracotomy to be performed for the acquisition of PV loop 
data.  
 
As in Chapter 4, the actual plasma concentrations of isoprenaline and the 
endogenous catecholamines are unknown, and therefore translation to ex vivo and 
 157 
in vitro is somewhat challenging. However, use of isoprenaline and adrenaline in 
these experiments just below the arrhythmic threshold should yield useful 
information as almost no tachyarrhythmia of note was seen after isoprenaline 
administration. Modelling the disease on the isolated heart will show the effects of 
high levels of catecholamines on aspects such as mitochondrial function and calcium 
handling, and use of the ‘working heart’, in which the heart is perfused via the left 
atrium and preload and afterload can be adjusted may yield important observations 
regarding the role of haemodynamics in apical dysfunction without the confounding 
effects of the baroreflex and other homeostatic mechanisms.  
 
In the in vitro hyperthermia pre-treatment experiments, there could be a strong 
selection bias post-hyperthermia when assessing contractility as the hyperthermia, 
with or without isoprenaline, may kill the responders to hyperthermia, or simply leave 
a healthier population if it kills the weaker cells that ordinarily would not have been 
excluded according to the exclusion criteria.  
 
Finally, although I have shown that the removal of one important condition after the 
initial phase (hyperthermia) does not cause the reversal of the contractile 
dysfunction, the removal of the other essential condition (isoprenaline) was not 
tested. This could be tested through the administration of a beta blocker, although I 
suspect that, much like isoflurane, it would result in an increase in mortality.  
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6. The effects of catecholamine stress on the ex vivo heart 
 
6.1 Introduction 
 
The ex vivo heart is an important tool in delineating cardiac physiology and 
pathology: without the presence of confounders such as the endocrine system and 
neurohumoural reflexes, the heart’s response to a number of stimuli can be studied 
in isolation (Bell et al., 2011). In vivo, changes in cardiac contractility, for example, 
could result in changes in arterial blood pressure, which could then effect a return 
back to baseline.  
 
The retrograde-perfused heart was developed by Oskar Langendorff over a century 
ago (Langendorff, 1895): it involves the perfusion of the heart via the aorta such that 
the aortic valves close, diverting the perfusate via the aortic sinuses and coronary 
ostia to the coronary arteries. This method leaves the left ventricle empty and 
unloaded, although a balloon can be inserted in the left ventricle and inflated to 
cause isovolumic contraction (Liao et al., 2012). As the perfusate often does not 
contain protein, oedema can gradually build up in the myocardium leading to a 
deterioration of cardiac function over time (Sutherland and Hearse, 2000).  
 
It was hypothesised that TTS is a disease primarily of the myocardium (Lyon et al., 
2008), such that the disease should be able to be replicated without the presence of 
an animal around the heart, i.e. an ex vivo heart. Therefore, the ex vivo heart 
provides a useful tool to establish whether high levels of catecholamines can induce 
cardiac dysfunction without the presence of other effectors. With the isolated heart, 
regional changes in cardiac function can be measured. For instance, the application 
of sonomicrometry crystals allows a measurement of epicardial contractility, whilst 
the use of voltage-sensitive dyes allows for the measurement of epicardial action 
potential duration and morphology. Metabolic dysfunction can be monitored using a 
dye sensitive to changes in mitochondrial membrane potential (Ψm). Here, I assess 
the changes the occur to cardiac function during catecholamine stress in the isolated 
heart in order to characterise possible causes of the dysfunction seen in vivo.  
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6.2 Materials and methods 
 
6.2.1 Reagents 
 
(-)-adrenaline was obtained from Sigma-Aldrich (UK). RH237, Rhod-2 and TMRM 
were obtained from Thermo Fisher Scientific (USA). Blebbistatin was obtained from 
Cayman Chemical (USA).  
  
6.2.2 Animals 
 
All animals (Sprague Dawley rats, Charles River Laboratories, UK) were killed by a 
Schedule 1 method (cervical dislocation after isoflurane sedation), in accordance 
with Animals (Scientific Procedures) Act 1986. Animals were housed in groups of 
four and experienced a 12 hour light/dark cycle. 
 
6.2.3 Heart extraction 
 
After confirmation of death, a cut was made using a pair of scissors to enter the 
peritoneal cavity. The xiphisternum was then gripped and the diaphragm cut to 
expose the heart. Cuts were made superiorly through the lateral aspects of the 
ribcage, followed by a cut to the superior aspect of the ribcage. The heart, lungs and 
thymus were gently gripped and were removed by cutting posteriorly to the organs, 
severing the great vessels and trachea. The organs were then immediately placed 
into ice-cold KH solution with heparin sodium (2 units.ml-1).  
 
6.2.4 Cardiac reperfusion 
 
The heart was dissected away from the other organs in a petri dish filled with ice-
cold KH solution and the ascending aorta was exposed. After gently palpating the 
heart to remove excess blood from the ventricles and any small emboli from the 
aorta, the ascending aorta was held with two Dumont 7 forceps (Fine Scientific 
Tools, UK), lifted onto a cannula, and secured with an artery clip and 2-0 silk suture. 
The artery clip was then removed and a further suture was tied if required. The 
pulmonary artery was then cut to prevent the build-up of perfusate in the right 
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ventricle from the coronary sinuses. Hearts were excluded from experiments 
according to the following exclusion criteria: <200bpm after reestablishment of 
coronary perfusion; >5min-1 premature ventricular contractions; evidence of heart 
block; a clear region of infarction.  
 
6.2.5 Sonomicrometry studies 
 
The heart was perfused with KH using a pressure-driven Langendorff set-up at a 
pressure of 90-100cm.H2O. The perfusate was maintained at 37oC using a thermal 
circulator (Techne Inc., USA). An ECG was taken, with the cathode attached to the 
metal cannula and the anode inserted using a needle electrode (Grass 
Technologies, USA) into the right ventricle. The anode and cathode were connected 
to a BioAmp (AD Instruments, USA).  
 
Piezoelectric crystals (1mm, Sonometrics Inc., Canada) were attached to the left 
ventricular free wall, perpendicular to the interventricular groove using cyanoacrylate 
glue. Wires from the crystals were loosely secured to the water jacket around the 
heart to decrease noise in the signal. Crystals were connected to an Ultrasound 
Dimension Gauge Analogue Sonomicrometer (Sonometrics Inc.). The outputs from 
the sonomicrometry device and the BioAmp were digitised using a PowerLab (AD 
Instruments) at a rate of 1000Hz, low-pass filtered (50Hz), and monitored and 
recorded using LabChart 6 on a MacBook Pro (Apple Inc., USA). Contraction was 
analysed using the Cyclic Measurements function of LabChart 6. Values for 
contraction are reported as the percentage shortening of the distance between the 
crystals relative to the distance during diastole.  
 
6.2.6 Optical mapping studies 
 
The heart was perfused with KH (37oC) at a constant flow rate of 15-17ml.min-1, 
which was maintained by a peristaltic pump (Thermo Scientific, USA), rather than a 
constant hydrostatic pressure column. The perfusate was kept at a constant 
temperature using a thermal circulator (Thermo Scientific). After hanging, the heart 
was chambered inside a KH-filled Perspex box with a quartz window (Cairn 
Research, UK), through which optical recordings could be taken. An ECG was taken 
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(BioAmp to PowerLab: AD Instruments), with the anode was free in the KH-filled 
chamber and the cathode attached to the metal aortic cannula.  
 
Optical images were taken through a microscope (Olympus, Japan) fitted with a 1x 
lens and a 10x body zoom. Imaged light was passed through a dichroic mirror 
(610nm longpass) (Chroma Technology, USA) to split the beam, and then filtered 
(either 565-605nm bandpass or 620nm longpass) (Chroma Technology) to reach 
one of two CCD cameras (SciMeasure, USA), which acquired data at 1000Hz. The 
heart was illuminated using four LED light sets emitting light at a wavelength of 
530nm (Cairn Research). Optical signals were inputted to a computer using a 
custom-made acquisition system (Redshirt Imaging, USA). All images were acquired 
using the Cardioplex software (Redshirt Imaging) at a rate of 1000fps. For calcium 
and voltage recordings, data was taken at baseline and at 5 minute intervals after 
the intervention had started; for Ψm, data was taken every 30 seconds form the start 
of the experiment (i.e. before TMRM was loaded).  
 
6.2.7 Dye loading 
 
After focusing the heart onto the cameras, dyes were loaded into the heart. 150µg of 
Rhod-2 AM (Thermo Fisher Scientific, USA) was mixed with 150µl of 10% w/v 
Pluronic F-127 (Sigma-Aldrich). 1200µl of room temperature KH was added to the 
300µl of Rhod-2 AM and Pluronic F-127: the total volume was injected over 5 
minutes. Signals were acquired ~30 minutes after the Rhod-2 infusion was 
completed. 1.05ml of RH237 solution was made from a 1.25mg.ml-1 in DMSO stock 
by adding 50µl stock RH237 to 1ml KH. This was infused over 5 minutes; signals 
were acquirable immediately.  
 
20µl of 2.5mg.ml-1 TMRM stock was added to 50ml KH to give a final TMRM 
concentration of 2µM. This was infused for 20 minutes at 10% of the infusion rate 
(i.e. 1.5-1.8ml.min-1). After a 20 minute washout period, satisfactory TMRM infusion 
was validated by the presence of a uniform signal across the heart. Experimental 
interventions were then performed.  
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6.2.8 Cardiac paralysis 
 
5mg of blebbistatin (Cayman Chemical, USA) was added to 1.72ml of DMSO and 
mixed. 500µl of this solution was added to 50ml KH and infused at 30% of the flow 
rate (i.e. ~4.8ml.min-1), during which the peristaltic pump rate was reduced by the 
same amount. When the heart was paralysed the flow rate for blebbistatin was 
reduced to 10% of the main pump flow rate (i.e. 1.5-1.8ml.min-1) and the pump rate 
was increased to maintain a constant perfusion rate. A baseline recording was taken 
once the heart rate had re-equilibrated, after which the intervention was started.  
 
6.2.9 Hyperthermia protocol 
 
To induce experimental hyperthermia, the thermal circulator was increased from a 
set temperature of 40.5oC to 44.5oC and allowed to equilibrate for 30 minutes before 
any further experimental interventions were implemented. This corresponded to a 
temperature at the level of the heart of 41oC. For an in vitro determination of the 
effect of hyperthermia on TMRM fluorescence, a 2µM solution of TMRM in KH was 
excited using 530nm light with a previously described fluorometer (Manning et al., 
2008); emission was measured at 585nm.  
 
6.2.10 Optical signal analysis 
 
Data was analysed using Matlab R2014b (Mathworks, USA) using code written by Dr 
Jennifer Simonotto (see Appendix for full code). Voltage and calcium transients were 
detected using a second-order differential method and their duration to 25%, 50%, 
75% and 90% repolarisation for voltage, and 80% decay for calcium, from the peak 
was calculated; a mean was calculated for all the transients for each measurement. 
For TMRM analysis, all changes in TMRM fluorescence after the end were reported 
relative to the TMRM florescence at baseline. The median fluorescence change 
value for all the pixels across the heart was reported for each time point.  
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6.2.11 Statistical analysis 
 
All direct comparisons between two groups were carried out with either a t-test 
(normally distributed data) or a Mann-Whitney U test (non-normally distributed data). 
For comparisons between groups over time, a two-way repeated measures ANOVA 
was used with Dunnett’s post-hoc test for individual time-point comparison. One-way 
ANOVA with Sidak’s post-hoc test was used to compared multiple time-points to 
baseline. Statistical significance was defined as P<0.05.  
 
 
6.3 Results 
 
6.3.1 Validation of sonomicrometry to detect changes in cardiac contractility 
 
Sonomicrometry is the use of a pair of piezoelectric crystals as a transmitter and 
receiver of ultrasound pulses, with the time taken between transmission and 
reception associated with the distance between the crystals. In order to validate this, 
changes in extracellular Ca2+ were used as increases in extracellular Ca2+ are known 
to increase contractility (Comar and Bronner, 2014). Between 0.5mM and 4mM, 
increases in extracellular Ca2+ resulted in a positive inotropic effect in both apex and 
base (data not shown as previously submitted for MRes examination). Therefore, 
increases in contractility during catecholamine stimulation should be detectable.  
 
6.3.2 Absence of cardiac dysfunction with 10-6M adrenaline application 
 
The mechanism of apical dysfunction in the adrenaline bolus model of TTS appears 
to be as a result of stimulus trafficking at the β2AR (Lyon et al., 2008; Paur et al., 
2012). Stimulus trafficking can occur with levels of adrenaline as low as 10-7M (Paur 
et al., 2012), although the level of stimulus trafficking is higher at adrenaline 
concentrations of 10-6M and 10-5M (Heubach et al., 2004). During infusion of 10-6M 
adrenaline, contractile dysfunction was not observed: rather, a positive inotropic 
response was observed in both apex and base, along with a positive chronotropic 
response (data not shown as previously submitted for MRes examination). 
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Therefore, the decision was made to increase the concentration of adrenaline to    
10-5M to assess whether cardiac dysfunction can occur in the isolated heart model.  
 
6.3.3 Absence of cardiac dysfunction with 10-5M adrenaline application 
 
The decision was made to increase the concentration to 10-5M to increase the 
chance of stimulus trafficking occurring. At this concentration, 54.5% of hearts went 
into terminal VF soon after the increase in heart rate was observed. Acutely (during 
the first minute), no difference in apical and basal contraction was observed (figures 
6.1 and 6.2). Furthermore, no difference in contractility between apical and basal 
regions was seen over 60 minutes of 10-5M infusion, and no dysfunction was 
observed in either apex or base on two-way ANOVA; rather, there was a significant 
positive effect on contractility for both over time (P<0.01, two-way repeated 
measures ANOVA) (figure 6.3 and 6.4). Three hearts were studied during my MRes 
year and submitted for that thesis: all other studies were carried out during my PhD.  
 
 
Figure 6.1: Acutely, both apical and basal contractility increase relative to baseline during 10-
5M adrenaline infusion (n=7-11, two-way repeated measures ANOVA, no significant difference), 
mean±SEM shown.  
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Figure 6.2: No difference in mean contractility change over the first 60 seconds was seen 
between apex and base (unpaired t-test, n=7-11). Mean±SEM shown.  
 
 
 
 
 
Figure 6.3: Over one hour, both apical and basal contractility increase relative to baseline 
during 10-5M adrenaline infusion (n=5, two-way repeated measures ANOVA, P<0.01 vs 
baseline), mean±SEM shown.  
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Figure 6.4: No difference in mean contractility change over one hour was seen between apex 
and base (Mann-Whitney U test, n=5). Mean±SEM shown.  
 
6.3.4 Electrophysiological changes during adrenaline application 
 
As dysfunction was not observed with either 10-6M or 10-5M adrenaline, and there 
was a high level of “mortality” with 10-5M adrenaline application, the decision was 
made to use 10-6M adrenaline for optical mapping studies of a “high-level” of 
adrenaline stress, especially as this may still be able to activate stimulus trafficking 
at the level of the β2AR (Heubach et al., 2004).  
 
As the application of 10-6M adrenaline resulted in a positive chronotropic effect, 
comparisons for changes in electrophysiological parameters can only be related to 
the baseline of that heart, rather than a control group, due to the effects of increases 
in heart rate on action potential morphology that would not be present in a non-
adrenaline treated control group that did not exhibit an increase in heart rate.  
 
10-6M adrenaline resulted in a significantly-increased heart rate at 5, 10, 20, 25 and 
30 minutes post-adrenaline (one-way repeated measures ANOVA, n=6) (figure 6.5). 
However, despite this increase in heart rate, all repolarisation parameters 
(repolarisation to 25%, 50%, 75% and 90% of resting membrane potential) were 
significantly prolonged during adrenaline treatment in both apex and base. No 
difference was found between apex and base (two-way repeated measures ANOVA, 
n=6) (figures 6.6, 6.7, 6.8 and 6.9).  
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Figure 6.5: Application of 10-6M adrenaline resulted in a significantly increased heart rate (n=6, 
one-way repeated measures ANOVA). *: P<0.05 vs. 0 minutes; **: P<0.01 vs. 0 minutes. 
Mean±SEM shown.  
 
             
Figure 6.6: Representative recording of epicardial action potentials. Scale bar: 100ms. 
 
 
Figure 6.7: Both apex and base showed significantly prolonged repolarisation duration to 25% 
repolarisation (APD25) after adrenaline (n=6, two-way repeated measures ANOVA). ****: 
P<0.0001 vs. 0 minutes, apex and base. Mean±SEM shown 
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Figure 6.8: Both apex and base showed significantly prolonged repolarisation duration to 50% 
repolarisation after adrenaline (APD50) (n=6, two-way repeated measures ANOVA). ****: 
P<0.0001 vs. 0 minutes, apex and base. Mean±SEM shown.  
 
 
Figure 6.9: Both apex and base showed significantly prolonged repolarisation duration to 75% 
repolarisation after adrenaline (APD75) (n=6, two-way repeated measures ANOVA). ****: 
P<0.0001 vs. 0 minutes, apex and base. Mean±SEM shown.  
 
0 10 20 30
0
10
20
30
40
A
PD
50
 (m
s)
Time (mins)
Base
Apex****
0 10 20 30
0
10
20
30
40
50
60
Time (mins)
A
PD
 7
5 
(m
s)
Base
Apex
****
 170 
 
Figure 6.10: Only the base showed a significantly prolonged repolarisation duration to 90% 
repolarisation after adrenaline (APD90) (n=6, two-way repeated measures ANOVA). *: P<0.05 
base vs. 0 minutes; **: P<0.01 base vs. 0 minutes. Mean±SEM shown. 
 
Unlike voltage, the Ca transient “repolarisation” (i.e. decay) shortened after 10-6M 
adrenaline in both apex and base at 5 and 15 minutes after adrenaline, and at 30 
minutes post-adrenaline for the base only (two-way repeated measures ANOVA, 
n=7) (figure 6.10). Time points 10, 20 and 25 minutes post-adrenaline were excluded 
from statistical analysis to allow the operation of a repeated measures ANOVA on 
the dataset due to missing values. 3/7 hearts were experimented on and analysed 
jointly with a visiting student, Per Nyberg, who worked under my supervision.  
                   
Figure 6.11: Representative recording of epicardial calcium transients. Scale bar: 100ms.  
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Figure 6.12: Calcium transient duration to 80% decay was shortened in both apex and base 
after 10-6M treatment (n=7, two-way repeated measures ANOVA). **: P<0.01 apex vs. 0 minutes; 
###: P<0.001 base vs. 0 minutes. Mean±SEM shown. 
6.3.5 Mitochondrial responsiveness to adrenaline in the ex vivo heart 
 
Although little is known about mitochondrial function during TTS and its role in 
disease pathophysiology, numerous studies have shown signs of metabolic 
disturbances: intracellular lipid accumulation (Shao et al., 2013b); decreases in 
glucose uptake (Bonnemeier et al., 2006; Kurowski et al., 2007); and an increase in 
the level of superoxide (Nef et al., 2008). One may expect that during a disease of 
acute dysfunction, especially in the setting of a hormone that can increase the 
metabolic demand of the heart (Kolwicz et al., 2013), the mitochondria could be an 
interesting part of the cardiomyocyte to assess. Monitoring in vivo metabolic changes 
in response to catecholamines could be greatly affected by endogenous changes in 
circulating factors (e.g. increases in free fatty acids as a result of β3AR-mediated 
lipolysis in adipose tissue), as well as technically challenging (requiring PET 
imaging). The isolated heart on the other hand can give a quick and reliable read-out 
of mitochondrial ‘health’ by using a florescent dye whose change in fluorescence is 
directly related to the change in the inner mitochondrial membrane potential, and 
therefore mitochondrial function (Lyon et al., 2010; Matsumoto-Ida et al., 2006; 
Scaduto and Grotyohann, 1999). 
 
It was found that 10-6M adrenaline application to male hearts resulted in a mild Ψm 
depolarisation compared to control 50 minutes (50 minutes being the last major time 
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point before the loss of two hearts) after the start of continuous infusion (P<0.05, 
unpaired t-test; n=8 per group) (figure 6.11). Over the 60 minutes of infusion, there 
appeared to be a gradual decrease in the fluorescence in both control and 10-6M 
adrenaline infusion, and there was no significant difference found overall between 
the two groups, perhaps indicating that the Ψm depolarisation was limited to the later 
time points (figure 6.12). 
 
Figure 6.13: Adrenaline (10-6M) infusion in male hearts resulted in a significant decrease in Ψm 
compared to control at 50 minutes post-adrenaline infusion commencement (unpaired t-test; 
n=8 per group). *: P<0.05. Mean±SEM shown.  
 
 
 
Figure 6.14: Over the 60 minutes, there was a gradual decline in both control and adrenaline 
(10-6M) infusion (n=8 per group). Mean±SEM shown.  
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6.3.6 Gender differences in mitochondrial responsiveness to adrenaline in the ex 
vivo heart 
 
As females appear to be relatively protected against adrenaline-mediated cardiac 
dysfunction and death (see Chapter 3), the effect of adrenaline on the mitochondria 
of female ex vivo hearts was assessed. Much like hearts from male rats, hearts from 
female rats showed a significant Ψm depolarisation in response to 60 minutes of 10-
6M adrenaline application, compared to control, at the 50 minute time point infusion 
(P<0.001, unpaired t-test; n=7 per group) (figure 6.13). Unlike the males, there was a 
rapid onset of the change in Ψm, and over the 60 minutes there was a significant 
difference between adrenaline (10-6M) infusion and control (P<0.001, two-way 
repeated measures ANOVA; n=7 per group) (figure 6.14). No difference was found 
between male and female hearts at 50 minutes post-adrenaline infusion (n=8 male, 7 
female; unpaired t-test) (figure 6.15).  
 
 
Figure 6.15: Adrenaline (10-6M) infusion in female hearts resulted in a significant decrease in 
Ψm compared to control at 50 minutes post-adrenaline infusion commencement (unpaired t-
test; n=7 per group). ***: P<0.001. Mean±SEM shown. 
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Figure 6.16: There was a significant difference between adrenaline (10-6M) infusion and control 
over the 60 minute infusion period (two-way repeated measures ANOVA; n=7 per group). ***: 
P<0.001. Mean±SEM shown. 
 
 
Figure 6.17: At the 50 minute time point during adrenaline infusion, there was no difference in 
the Ψm depolarisation observed between male and female hearts (n=8 male, 7 female; unpaired 
t-test). Mean±SEM shown.  
 
6.3.7 Effect of temperature on in vitro TMRM fluorescence 
 
As shown previously (Chapter 5), temperature, and particularly hyperthermia, plays a 
key role in the induction of a Takotsubo syndrome-like contractility in rats. Planning 
for experiments to investigate Ψm changes in hyperthermia required validation of 
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530nm wavelength. Fluorescence counts were taken in triplicate after an 
equilibration period of 20 minutes. Fresh TMRM samples were used for each 
temperature between 35oC and 42oC. It was found that TMRM fluorescence showed 
a linear decrease when temperature was increased, with a ~6.5% decrease in 
fluorescence between 37oC and 41oC (figure 6.16).  
 
 
Figure 6.18: TMRM shows a linear decrease in fluorescence with increasing temperature, 
within a physiological range of temperatures. Mean of triplicate values with linear regression 
and its 99% confidence interval shown.  
 
6.3.8 Ex vivo mitochondrial responsiveness to hyperthermia 
 
In order to simulate the hyperthermia required to induce TTS-like contractility (see 
Chapter 5), isolated hearts from male rats were subjected to hyperthermia (41oC for 
30 minutes); tachycardia was often observed shortly after the initiation of 
hyperthermia. At the end of the 30 minute hyperthermia protocol, there was a 
significantly greater Ψm depolarisation in the hyperthermia group compared to the 
control (37oC) group (P<0.05, unpaired t-test; n=12 hyperthermia, 8 control) (figure 
6.17). Looking closely at the data, this corresponded to a ΔΨm of 3.33% for control 
and 7.34% for hyperthermia treated hearts, giving a difference of ~4% (relative to 
baseline). This is similar to the decrease seen in in vitro studies, and therefore I am 
satisfied that, alone, hyperthermia is not causing inner mitochondrial membrane 
potential depolarisation. However there is a clear effect of hyperthermia on TMRM 
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fluorescence that is probably mediated by an effect of hyperthermia on the TMRM 
molecule, rather than its read out of biological function.  
 
Figure 6.19: 30 minutes of hyperthermia results in a significant decrease in TMRM signal 
compared to normothermia (*: P<0.05, unpaired t-test; n=12 hyperthermia, 8 control). 
Mean±SEM shown.  
 
6.3.9 Hyperthermia potentiates the effect of adrenaline on mitochondrial dysfunction 
in male rat hearts 
 
After 30 minutes of hyperthermia, adrenaline (10-6M) was infused for 60 minutes 
using the same protocol as normothermic ex vivo adrenaline infusion, with 
hyperthermia (41oC) present throughout the adrenaline infusion. At 20 minutes after 
the start of the adrenaline infusion, this resulted in a significantly reduced Ψm 
compared to control (at 41oC) (P<0.05, unpaired t-test; n=5 adrenaline, 6 control) 
(figure 6.18). Furthermore, at this same 20 minutes post-adrenaline start time point, 
the presence of hyperthermia caused a greater Ψm depolarisation than when the 
heart was normothermic (P<0.0001, unpaired t-test; n=5 hyperthermic, 8 
normothermic) (figure 6.19). Interestingly, unlike the ΔΨm seen during normothermia, 
during hyperthermia the mitochondrial depolarisation appeared to occur much more 
rapidly. As can be seen in the graph for ΔΨm for the whole experiment, there does 
appear to be a sharp increase in mitochondrial depolarisation after ~50 minutes of 
hyperthermia, as shown in the decrease in control fluorescence (figure 6.20). It is 
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unknown at this time whether this is an effect of hyperthermia on mitochondrial 
physiology or a physical breakdown of TMRM caused by the increased temperature.  
 
  
Figure 6.20: At 41oC, 20 minutes of adrenaline (10-6M) infusion caused a significant inner 
mitochondrial membrane depolarisation (*: P<0.05, unpaired t-test; n=5 adrenaline, 6 control). 
Mean±SEM shown.  
 
 
Figure 6.21: 20 minutes of adrenaline (10-6M) infusion during hyperthermia caused a 
significantly greater inner mitochondrial membrane depolarisation when compared with 
normothermia (****: P<0.0001, unpaired t-test; n=5 hyperthermic, 8 normothermic). Mean±SEM 
shown.  
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Figure 6.22: A graph showing the change in Ψm after hyperthermia (first dotted line from the x-
axis) and 10-6M adrenaline infusion (from the second dotted line from the x-axis). Control 
hearts received hyperthermia but no adrenaline (n=5-6 adrenaline, 6 control). Mean±SEM 
shown.  
 
6.4 Discussion 
 
Application of high-dose adrenaline to the isolated retrograde-perfused heart did not 
elicit apical dysfunction, despite in vitro studies suggesting that it could (Paur et al., 
2012). To the contrary, high-dose adrenaline (10-6M and 10-5M) resulted in a positive 
inotropic response of a similar magnitude in both apex and base. Application of 
10-6M adrenaline to hearts extracted from male rats resulted in a clear increase in 
repolarisation time to 25%, 50% and 75% of baseline in both apical and basal 
epicardial regions, with less effect seen for 90% repolarisation time. In separate 
hearts, calcium transient duration appeared to shorten with 10-6M adrenaline in both 
apex and base, although this was not significant for all time points in the 30 minute 
adrenaline infusion period.  
 
Infusion of 10-6M adrenaline into male hearts resulted in a mild depolarisation of the 
inner mitochondrial membrane, and a similar effect was observed with female hearts. 
Induction of hyperthermia resulted in a decreased in TMRM fluorescence, but this 
was not beyond the decrease seen with in vitro TMRM during cuvette hyperthermia 
studies. However, this hyperthermia did potentiate the inner mitochondrial 
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membrane depolarisation in response to adrenaline, increasing both the speed of 
onset and magnitude.  
 
6.4.1 Contractile response to adrenaline in the ex vivo heart 
 
Previous work has shown that, in rats, the apex of the heart has a greater response 
to β2AR stimulation, and that isolated cardiomyocyte contractility can be reduced via 
a PTX-dependent mechanism as a result of in vitro high-dose adrenaline exposure 
(Paur et al., 2012). Furthermore, stimulus trafficking at the β2AR has been shown to 
be induced by high dose in vitro application of either adrenaline or isoprenaline 
(Gong et al., 2000; Heubach et al., 2004; Liu et al., 2009; Wang et al., 2008). The 
TTS hypothesis of apical dysfunction being dependent on β2AR stimulus trafficking 
was postulated (Lyon et al., 2008), which was later confirmed to be a cause of 
transient apical dysfunction in a rat model of TTS (Paur et al., 2012).  
 
In my studies, high-dose adrenaline application for one hour failed to induce 
dysfunction in either the apex or the base of the isolated heart. Rather, adrenaline 
acted as a classical positive inotrope throughout the one hour infusion and increased 
the contractility in both apex and base. The absence of dysfunction in the isolated 
heart when dysfunction was modelled in isolated cells may be explained due to one 
or many of a number of factors.  
 
One important difference, of many, between the in vivo and Langendorff ex vivo 
heart is afterload: the left ventricle in the Langendorff heart is (almost) completely 
unloaded, whereas the in vivo left ventricle is subject to afterload, which can change 
according to a number of neurohumoural factors, including the drug that is being 
administered. For instance, when adrenaline was administered intravenously, 
afterload increased (Paur et al., 2012), and data published since these experiments 
were carried out has shown that the changes in afterload caused by the 
administration of a Takotsubo-genic pharmacological agent were essential in the 
induction of apical dysfunction (Redfors et al., 2014a).  
 
Another important difference is the lack of the pharmacokinetic processes that occur 
in vivo: due to limitations in the apparatus used for the sonomicrometry studies, any 
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drug that was added to the perfusate could not be “washed out” or diluted to any 
significant level without significantly altering the perfusion pressure, whereas in the 
rat, adrenaline has a half-life of approximately three minutes (Ferreira and Vane, 
1967), and heart failure was shown to occur approximately two half-lives after the 
initial bolus (Paur et al., 2012). Furthermore, as heart failure started (shown by a 
reduction in blood pressure and reduction in cardiac contractility), sympathetic 
afferents may have been activated to compensate for the reduced perfusion 
pressure of organs such as the carotid bodies and kidneys. In order to fully replicate 
the in vivo sympathetic state of the rat during this TTS model, serial plasma 
catecholamine concentrations would need to be measured using a chromatographic 
method. Even with this, the sympathetic nerve input to the heart would not be fully 
known, adding to the complexities when attempting to replicate an in vivo model ex 
vivo.  
 
Importantly, it should be noted that the absence of dysfunction is not related to the 
left ventricle being unloaded and therefore not being able to reduce its contraction: 
experiments were carried out in the presence of 1.85mM Ca2+, and initial tests 
showed that contractility can increase in both the apex and the base between 0.5mM 
Ca2+ and 4mM Ca2+. If dysfunction was to occur in one region, it is known that it 
could reduce down to the level shown at 0.5mM Ca2+. Nevertheless, even though 
dysfunction could not be replicated, this does not mean that the isolated heart cannot 
be used to understand other effects of catecholamines on the heart.  
 
6.4.2 Prolongation of action potentials during adrenaline application 
 
Typically, during an increase in heart rate the action potential will shorten as a result 
of restitution, where the action potential is related to the previous diastolic interval 
(Koller et al., 2005). Changes in the restitution curve (i.e. the relation between 
diastolic interval and subsequent action potential duration) can have important 
effects on the arrhythmogenic properties of the heart: flatter restitution curves appear 
to protect against fibrillation (Riccio et al., 1999), whereas steeper curves can 
promote arrhythmias (Garfinkel et al., 2000).  
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In the experiments presented in this chapter, two elements will be affecting the 
action potential duration and morphology: the positive chronotropic effect of 
adrenaline infusion, acting via restitution; and the direct βAR-mediated 
pharmacological effect of adrenaline on ion currents and calcium transients in the 
cardiomyocyte.  
 
Overall, there was little change in APD90, with no significant change in the APD90 
measured from the apical epicardium over the 30 minute adrenaline infusion, and a 
mild prolongation of the APD90 measured from the basal epicardium at the end of 
the 30 minute adrenaline infusion, despite a very clear increase in heart rate. 
Although restitution is predominantly studied in humans and mammals with more-
humanesque action potential morphology, rat hearts have been shown to exhibit 
restitution in response to a decreased diastolic interval (Hardy et al., 2013). 
Furthermore, catecholamines have been shown to steepen the restitution curve (i.e. 
the same reduction in diastolic interval would cause a shorter APD90 in the presence 
of adrenaline) (Taggart et al., 2003). Therefore, a lack of reduction in the APD90 is 
puzzling, and may be a result of non-canonical action of adrenaline. Catecholamines 
have been shown to increase APD90 in guinea pig hearts in the presence of high 
(>8mM) extracellular K+ (Paterson et al., 1993), primarily thought to be due to an 
increase in Ca2+ conductance. However, in these experiments [K+]o was not raised 
above physiological levels, and therefore does not explain this finding.  
 
TTS is known to present with QT prolongation, and therefore an increased risk of 
torsade de pointes (Wright et al., 2014), which should be the result of the 
prolongation of the action potentials of individual cardiomyocytes (Antzelevitch et al., 
1996). In TTS there is the added connection between a prolonged QT interval and 
myocardial oedema, especially in the apex, causing the authors to hypothesise that 
QT prolongation in TTS could be caused by an increase in intraventricular 
repolarisation dispersion (Perazzolo Marra et al., 2013). In these experiments, 
oedematous changes were not measured, and therefore no comment can be made 
is regard to this connection in the ex vivo catecholamine stress model. Notably 
however, significant differences in APD90 compared to baseline were only found for 
basal measurements, although this could be down to this being underpowered for 
the small changes that may be occurring during adrenaline infusion. 
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Unlike for the APD90, there were very clear increases in both apical and basal 
regions for the APD25, 50 and 75 values. Prolongation of the intermediate parts of 
the action potential without a concordant increase in the overall action potential 
duration (APD90) could indicate an increase the plateau phase of the action 
potential, although as APD75 is also prolonged, this could also indicate a reduction 
in early phase 3 repolarisation currents (such as Iks) (Ziupa et al., 2014). However, 
the contribution of IKs to the phase 3 repolarisation currents in the rat cardiac action 
potential may be negligible as the presence of an IKs blocker did not change 
ventricular action potential electrophysiology (Regan et al., 2005). Nevertheless, 
prolongation in these phases can predispose towards early-afterdepolarisations, 
caused by the reactivation of inward sodium and calcium currents (Volders et al., 
2000),  which can in turn drive torsade de pointes arrhythmias (Hondeghem, 2005), 
a known risk factor for patients during a TTS attack (Ahn et al., 2011).  
 
Around the 50% repolarisation period, the sarcolemma is at ~0mV, where inward 
Ca2+ currents are greatest, and therefore prolongation of this part of the action 
potential could increase the magnitude of calcium entry, thereby increasing the force 
of contraction (Varró et al., 1993). However, as discussed later, attempts to quantify 
the size of the calcium transient were not successful. Nevertheless, increases in 
stimulation frequency have been shown to increase APD50 in rat trabecular muscle 
in order to effect an increase in calcium entry, although the rates used were in the 
order of 1Hz, whereas the intrinsic rate of the isolated rat heart is an order of 
magnitude greater (Tang et al., 1996). A similar experiment carried out on guinea pig 
isolated cardiomyocytes showed that the increase in APD50 was caused by calcium 
facilitation of the inward Ca2+ current (Peineau et al., 1992). Therefore, the 
prolongation seen could be related to the increase in chronotropy.  
 
Contrary to previously-published literature, there was not an apex-base APD 
gradient: basal rat cardiomyocytes have been shown to have longer action potentials 
than apical cardiomyocytes (Watanabe et al., 1983), yet here I found no significant 
difference between apex and base. More experiments are needed to confirm this 
finding as it is an unpaired comparison, and small differences between experimental 
set-up could affect the action potential morphology. Furthermore, as these 
experiments were conducted on a whole heart, whereas the published study was 
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carried out on isolated cardiomyocytes, it could be the cells beyond the epicardium 
that contribute to the apex-base disparity in APD90, especially when cells that are 
known to have longer action potentials (i.e. M cells (Antzelevitch et al., 1991)) are 
included in the analysis. 
 
6.4.3 Shortening of the calcium transient during adrenaline application 
 
One key effect of catecholamines on the heart is to increase the amount of calcium 
in the sarcoplasmic reticulum, which is partly a result of the increased uptake of 
calcium ions by the SERCA2a protein. The activity of SERCA2a is increased during 
βAR activity due to the phosphorylation of its inhibitory protein, phospholamban, by 
protein kinase A at the serine-16 site (Fearnley et al., 2011). The shortening of the 
calcium transient to 80% of baseline is probably due to an increase in uptake, and 
therefore an increase in lusitropy, by SERCA2a, activated by the canonical βAR 
pathway. However, one would expect a larger overall calcium transient if the 
canonical βAR-Gs was activated: the use of a non-ratiometric dye did not allow for 
the quantification of the transient size here, although this would be useful to do in a 
future experiment.  
 
6.4.4 Cause of inner mitochondrial membrane depolarisation during adrenaline 
infusion 
 
The addition of adrenaline to the perfusate will cause the heart to require more ATP: 
even though the left ventricle is unloaded, inotropy does increase, as does 
chronotropy. Therefore, the workload of the heart must have increased, and along 
with it, ATP. Part of this increase in metabolism is facilitated by the increased 
calcium transient size that accompanies βAR-Gs signalling. This increase in 
cytoplasmic calcium leads to increased calcium in the mitochondria: An increase in 
mitochondrial calcium content signals to match ATP production to cardiac workload, 
which is essential to facilitate βAR-mediated increases in contractility (Luongo et al., 
2015; Williams et al., 2015). 
 
It has been shown that, when applied to isolated rat hearts, adrenaline of a similar 
concentration to that used in these studies can increase the rate of glucose oxidation 
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and glycolysis preferentially over the rate of β-oxidation, with a increase in the 
contribution of glucose to ATP production and a decrease in the contribution of fatty 
acids to ATP production (Collins-Nakai et al., 1994). There was however a significant 
increase in H+ production due to some uncoupling between glycolysis and glucose 
oxidation. However, the presence of mild intracellular acidosis can actually protect 
against cell death by acting on the mitochondria (Lemasters et al., 1998), and could 
therefore prevent a deleterious ΔΨm. Furthermore, the increase in intracellular 
calcium during the contraction could signal to increase ATP production by the 
mitochondria by increasing the rate of the Krebs cycle, electron transport chain, and 
the ATP synthase enzyme (Griffiths and Rutter, 2009; Williams et al., 2015). Much 
like the sarcoplasmic reticulum, a pathological level of calcium inside the 
mitochondria can lead to mitochondrial swelling and subsequent opening of the 
mPTP, which could then lead to a dissipation of the Ψm (Zoratti and Szabò, 1995).  
 
It is well known that βAR activation can increase the levels of oxidative stress in 
cardiomyocytes (Sawyer and Colucci, 2000), produced by, at least in the failing 
heart, by complex I of the electron transport chain (Ide et al., 1999). Interestingly, 
oxidative stress can reduce the threshold for the opening of the mPTP by 
mitochondrial calcium (Crompton et al., 1987), and therefore could be causing some 
of the adrenaline-induced ΔΨm seen in the studies presented in this chapter.  
 
6.4.5 Absence of gender difference in mitochondrial response to adrenaline in the ex 
vivo heart 
 
Unlike the significant effects of gender seen in vivo with regard to adrenaline 
responsiveness (see Chapter 3), no difference was seen in the mitochondrial 
response to adrenaline infusion between ex vivo hearts extracted from male and 
female rats. Previous research has shown that the female brain may be somewhat 
protected against oxidative stress (Giordano et al., 2013; Kenchappa et al., 2004; 
Stack et al., 2008), and the female rat heart shows a lower level of hydrogen 
peroxide production compared to male hearts (Colom et al., 2007). Furthermore, the 
discovery of estrogen receptors in the mitochondria indicates a role of estrogen on 
mitochondrial function (Klinge, 2008), including reactive oxygen species formation 
and gene expression (O’Lone et al., 2007). Little is known however about the exact 
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state of the heart when the circulating estrogens have been removed. Although 
estrogen has been shown to change mitochondrial gene expression, more work is 
needed to ascertain the difference between these hearts, in relation to adrenaline 
stress, in the ex vivo state. However, it does appear that the difference in adrenaline 
responsiveness between genders is not caused, at least solely, by differences in 
mitochondrial dysfunction. However, it could still be present in the in vivo model, and 
circulating estrogens could be having an as yet unknown effect. Testing the same 
adrenaline concentration on ovariectomised animals’ hearts would give more 
information regarding this.  
 
6.4.6 Augmentation of adrenaline-induced mitochondrial dysfunction by hyperthermia 
 
As hyperthermia has been shown to be essential in one rat model of TTS (albeit 
isoprenaline-mediated, rather than adrenaline-mediated), the isolated heart is an 
ideal way to assess the role of hyperthermia without the inevitable integrative 
physiological changes that accompany a change in core body temperature. TMRM 
alone in a cuvette showed a clear reduction in fluorescence at the hyperthermic 
temperature, and a reduction beyond this observed in vitro change was not present 
in the isolated heart when exposed to hyperthermia (without catecholamine).  
 
Hyperthermia of a similar magnitude to that used in these studies has been shown to 
increase the permeability of the inner mitochondrial membrane to protons in a non-
specific manner in liver mitochondria (Willis et al., 2000). Furthermore, hyperthermia 
has been shown to increase superoxide production by platelet mitochondria, 
whereas other sources of reactive oxygen species (NADPH oxidase, NOS or 
cyclooxygenase) did not contribute to this increase in ROS (Wang et al., 2013). 
Additionally, temperatures above 40oC have been shown to inhibit oxygen 
consumption in mitochondria in Chinese hamster lung V79 cells (Lepock et al., 1987) 
and can cause dissipation of the Ψm in tumour cells (Yuen et al., 2000). Overall, it 
appears that mitochondria are indeed affected in a deleterious way by hyperthermia, 
although this baseline effect was not observed in these experiments.  
 
It was noticeable that the onset of mitochondrial dysfunction by adrenaline in the 
setting of hyperthermia was more rapid compared with studies at normothermia. 
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There could be a multiplicative effect between adrenaline and hyperthermia to 
induce mitochondrial dysfunction as the decrease appears to be greater than the 
sum of the two parts. If the adrenaline-induced mitochondrial dysfunction was at 
least partially mediated by ROS formation, the addition of another ROS-generating 
stimulus could add to the ROS. As this stimulus is an increase in temperature, there 
should be an additional increase in the chemical rate of reaction, thereby 
exacerbating any chemical processes, provided that the enzymes involved are not 
being denatured. As metabolic processes have been shown to play a potential role in 
TTS, these experiments lend credence to the possibility that catecholamines and 
hyperthermia are combining to cause a metabolic deficit due to mitochondrial 
dysfunction secondary to ROS formation and inner mitochondrial membrane 
depolarisation to cause a predisposition to a contractility deficit.  
 
6.4.7 Limitations and further work 
 
The primary limitation of the work presented in this chapter is the lack of a successful 
recapitulation of the contractility deficit of TTS in the isolated, unloaded heart. 
Furthermore, as the heart is unloaded, the metabolic requirements of the heart are 
far less, increasing the metabolic reserve: if there was a mild metabolic deficit, this 
may be to less effect compared to the in vivo heart exposed to an afterload of 
~80mmHg. Furthermore, as the role of afterload has been shown to be critical in the 
induction of rat TTS (Redfors et al., 2014a), it may be that the contractility reduction 
in the apical myocardium is impossible without an afterload. Nevertheless, as stated 
previously, this method of modelling can still give a somewhat reductionist insight 
into disease pathophysiology. Secondly, as cardiac optical mapping techniques only 
measure the most epicardial of cardiomyocytes, further changes in electrophysiology 
and mitochondrial function could be occurring endocardially to the recording surface, 
and therefore disease processes could be overlooked.  
 
Future work will evaluate the effect of isoprenaline in the setting of hyperthermia, 
after the plasma concentration of the drug after 50mg.kg-1 intraperitoneal injection 
has been ascertained. Additionally, as no effect was seen between male and female 
rat hearts, the use of the hearts of previously-ovariectomised rats, as well as 
ovariectomised rats with estrogen replacement (see Chapter 3), would further 
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delineate the possible role of gender and estrogen on mitochondrial responsiveness 
to catecholamines. Addition of estrogen to the perfusate would help to establish the 
acute effects vs. genomic effects of circulating estrogen of any potential 
mitochondrial protection. Finally, as the working heart preparation has since become 
more established in the research group, the use of sonomicrometry in a more 
physiological isolated heart, and the ability to adjust afterload without regard for the 
normal pressor effect of the drug administered, will be a very useful addition to TTS 
research.  
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7. Final discussion  
 
7.1 Overview 
 
This thesis presents data that supports the ability of high-dose catecholamines to 
induce an apical-specific cardiac dysfunction, and sets out factors that can worsen 
this dysfunction, either through an increase in hypocontractility or through 
arrhythmia. A number of methods were used, although primarily work was carried 
out using whole-animal in vivo experimentation, supplemented with isolated heart 
studies and in vitro cell studies. Gender and estrogen status appear to play a key 
role in the prevention of catecholamine-induced death. Anaesthetic choice also 
appears to be important, as in one model of TTS, use of ketamine, as opposed to 
isoflurane, allows for hyperthermia to develop, as required in this model for apical 
dysfunction to occur. This hyperthermia did not have an effect on contractility in vitro, 
either at baseline or with catecholamine superperfusion. However, ex vivo isolated 
heart studies did show that hyperthermia can increase the mitochondrial dysfunction 
in response to catecholamine stimulation, providing a potential mechanism for its in 
vivo effect.  
 
7.2 Critical role of gender-associated factors in modulating the cardiac 
catecholamine response 
 
As there is a clear predisposition for post-menopausal females, compared to males 
or pre-menopausal females, to suffer from TTS (Schneider et al., 2013a), an 
important analysis to make is the effect of gender, and ovarian failure, on the 
response of the rat TTS model. Previous studies on ovariectomised animals have 
shown that chronic estrogen replacement can reduce contractile dysfunction 
(Ueyama et al., 2007), as well as attenuating haemodynamical changes that could 
predispose to TTS induction in the setting of high emotion stress (Morimoto et al., 
2008). Here, for the first time it has been shown that cardiac dysfunction, either 
arrhythmic or contractile, is worsened by the absence of ovarian function, compared 
to a female with competent ovaries; competent ovary function also reduced cardiac 
dysfunction compared to males.  
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Isolated female mouse hearts, compared to male hearts, have been shown to exhibit 
a blunted contractile response to isoprenaline (particularly at a lower isoprenaline 
concentrations (~1nM)), with the ovariectomised heart’s response between male and 
female (McIntosh et al., 2011). On the other hand, in vivo studies presented here 
perhaps corroborate a reduced catecholamine responsiveness in females vs. males, 
but an increased responsiveness in ovariectomised rats. Where previously the 
Goldilocks hypothesis model of TTS would have stated that females with ovarian 
failure, either through menopause or other causes, were in the “just right” zone of 
catecholamine responsiveness, the ovariectomised rat is, at least in this animal 
model, too responsive, far more than the male was found to be, and the male 
appears to be in this “just right” zone for TTS-like contractility changes to occur (Paur 
et al., 2012). Therefore, it could be possible that the very abrupt cessation of 
estrogen in the ovariectomised rat caused a different physiological response to the 
gradual decline in ovarian function that occurs with the menopause. Alternatively, in 
this particular model, the level of “stress” could be too high, whereas in endogenous 
models of stress (Ueyama et al., 2002), human TTS can be recapitulated, rather 
than predominantly the fatal tachyarrhythmias or fatal acute cardiac decompensation 
as was seen in this thesis’ studies.  
 
In the isolated rat heart, in contrast to previous studies in mouse hearts, males and 
females appeared to show a similar response to catecholamines in terms of their 
mitochondrial dysfunction; testing hearts from ovariectomised rats could give insight 
into the mechanism of the increase in mortality seen, and whether this was also 
associated with an increase in oxidative stress as the ovariectomised state is 
strongly associated with an increase in cardiac ROS (Ribeiro et al., 2013). One may 
expect there to be an increase in mitochondrial dysfunction in the isolated 
ovariectomised heart if the increase in in vivo mortality was due to an increase in 
catecholamine responsiveness.  
 
7.3 Potentiation of TTS induction by hyperthermia 
 
Hyperthermia was a necessary, but not necessarily sufficient, condition for TTS to 
occur in the isoprenaline model. After the induction of TTS, hyperthermia was no 
longer required for the continuation of the apical dysfunction. In vitro studies showed 
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that pre-treatment with hyperthermia exhibited no effect on subsequent 
catecholamine responsiveness, and pre-treatment with hyperthermia, with or without 
concomitant βAR stimulation did not affect basal contractility at normothermic 
temperatures, indicating an absence of damage to the cardiomyocytes by this 
protocol. Therefore, it appears that hyperthermia cannot have long-lasting effects on 
cardiomyocyte function, as measurable by contractility. Furthermore, in work carried 
out by a student under my supervision (Rohan Pancharatnam), hyperthermia at the 
time of catecholamine application also did not affect the change in cellular 
contractility in response to the catecholamine.  
 
However, hyperthermia had a clear effect on the mitochondrial response to 
catecholamines in the ex vivo heart, potentiating the effect adrenaline had at 
normothermic temperatures both with respect to its speed of onset and its 
magnitude. Metabolic changes are heavily implicated in TTS pathophysiology (Nef et 
al., 2007; Shao et al., 2013c), although it is not known whether the metabolic 
dysfunction is causative, contributive, or merely epiphenomenal to the contractile 
dysfunction. As there was not an apical predisposition for mitochondrial dysfunction 
in these hearts, but rather a global dysfunction across the imaged left ventricle wall, I 
propose that metabolic dysfunction is unlikely to be the sole causative factor, but 
rather an exacerbator. In vivo methods to analyse the metabolic state of the heart, 
such as fluorescence-lifetime imaging microscopy (FLIM) to measure the oxidation 
states of metabolic intermediates, would elucidate the temporal and spatial metrics 
associated with hyperthermia- and catecholamine-mediated metabolic dysfunction in 
the heart. However, during these studies the anaesthesia used for the isoprenaline 
TTS model (ketamine-midazolam) did not give a surgical plane of anaesthesia, and 
therefore the obligatory thoracotomy the FLIM requires was not possible. 
Percutaneous FLIM would be an alternative method but would require specific 
hardware to be developed, along with a pericardiectomy to prevent interference from 
extracardiac tissues. If the mechanism through which hyperthermia acts to allow the 
induction of TTS can be found, this would give an essential insight into TTS 
pathophysiology, and could help in the development of possible prophylactic 
measures for at-risk patients, particularly those who suffer from recurrent TTS.  
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When hyperthermia was found to be essential in the isoprenaline TTS model, but not 
the adrenaline TTS model, it raised the question of why this was the case. There are 
clear haemodynamical differences between the two catecholamines used, with 
adrenaline known to increase blood pressure immediately after the bolus (Paur et al., 
2012), whereas isoprenaline can have a hypotensive or neutral effect due to 
unopposed βAR activation (Redfors et al., 2014a). Haemodynamics could not be 
monitored using a non-invasive method due to the loss of a tail pulse, and future 
studies will use an invasive method to assess the changes, if any, that occur during 
the progression to hyperthermia and the induction of cardiac dysfunction. It could be 
that hyperthermia replaces what the αAR agonism of the adrenaline bolus brings to 
the model, or, due to the different temporal dynamics of the two models, 
hyperthermia allows for the continuation of the dysfunction, whereas in the 
adrenaline model the dysfunction is too mild and is rapidly self-correcting.  
 
7.4 Isoflurane as both an aggravator and a mitigator of Takotsubo syndrome 
 
One finding that could be inferred from the studies presented between chapters 4 
and 5 is the ability of isoflurane anaesthesia to prevent apical dysfunction, while still 
allowing isoprenaline to have a clear sympathomimetic effect, thereby blocking some 
key pathway in TTS induction. Shortly after this finding in London, our collaborators 
in Sweden confirmed this in a prospective study (Redfors et al., 2014b). Finding that 
this was not dependent on a change in core body temperature (anecdotally, 
isoflurane anaesthesia results in a very labile core temperature), this provides an 
interesting nucleus for the development of preventative and therapeutic strategies for 
the disease, particularly those who develop cardiogenic shock and require circulatory 
support. However, isoflurane given during the cardiac dysfunction (i.e. after TTS has 
precipitated) worsened outcome through a further reduction in cardiac contractility.  
 
Isoflurane is known to have sympatholytic effects (Seagard et al., 1984), and 
therefore could be reducing the effect of the initial catecholamine surge to prevent 
the reaching of the threshold, above which stimulus trafficking can occur (Lyon et al., 
2008). However, if given during the heart failure phase of TTS, its cardiodepressant 
effects could further decrease the heart’s contractile reserve, resulting in the 
mortality seen in these studies.  
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7.5 Inter-model disparity for TTS induction 
 
One observation from the studies presented in this thesis is the lack of contractile 
dysfunction in some models (i.e. the ex vivo model) yet presence in others (i.e. in 
vivo models). Previous studies have shown that the induction of apical TTS in a rat 
model is somewhat dependent on haemodynamical factors (Redfors et al., 2014a), 
whereas the heart is unloaded in the Langendorff method. When assessing the role 
of hyperthermia in vitro, the lack of load on the isolated cells may prevent any 
dysfunction from becoming apparent, although this remains to be tested. Similarly, 
loading the Langendorff preparation with an intraventricular balloon, or by using the 
working heart preparation, could determine the role of ventricular loading on 
catecholamine-mediated contractile dysfunction. In studies on an in vitro model of 
TTS using adrenaline pre-treatment, a negative inotropic response was not 
observed, but rather a suppression of a positive inotropic response (Paur et al., 
2012). The addition of ventricular loading in vivo may have been the deciding factor 
that tipped the heart into negative inotropy as there was an active force to oppose 
contraction.  
 
One in silico model of TTS has demonstrated that a potential mechanism 
underpinning apical dysfunction is a failure of the Frank-Starling mechanism (Land et 
al., 2014), possibly due to phosphorylation of troponin I, which can attenuate length-
dependent changes in thin filament calcium sensitivity (Kajiwara et al., 2000). 
Although the precise mechanism of the Frank-Starling effect is not known, length-
dependent changes in calcium sensitivity is a primary hypothesis (de Tombe et al., 
2010). With both ex vivo and in vitro modelling techniques already at the lower end 
of a length-tension curve (i.e. short sarcomeric length at end diastole), an acute 
failure of the Frank-Starling mechanism may not be apparent as this mechanism 
does not play a significant role in augmenting contractility in unloaded sarcomeres.  
 
7.6 Clinical relevance of the findings 
 
Perhaps the most relevant finding in relation to clinical therapy is the reduction of 
mortality in the ovariectomised rats after 2 week supplementation with estrogen. 
Previous work has shown that women on hormone replacement therapy may have a 
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better prognosis once TTS has been diagnosed compared to those not on hormone 
replacement therapy (Patel et al., 2013). With regard to hyperthermia, an initial 
analysis of TTS patients at Sahlgrenska Hospital did not show a prevalence of 
hyperthermia (Björn Redfors, personal communication, 26 September 2014), 
although this would have been at the time of admission, rather than at the time of 
trigger or onset. In order to assess the role of hyperthermia in clinical TTS, rather 
than an animal model thereof, serial observations of iatrogenic TTS cases would 
allow for this ultra-acute phase of TTS to be monitored.  
 
7.7 Study limitations 
 
A number of limitations arose when carrying out this set of experiments, particularly 
with regard to the method of administration of pharmacological agents. For instance, 
estrogen was dissolved in either DMSO and glycerol (osmotic minipumps) or 
sesame oil (silastic capsules). Both vehicles can act as anti-oxidants (Hsu and Liu, 
2004; Santos et al., 2003; Zhou et al., 2008), and given the possible importance of 
mitochondrial dysfunction and oxidative stress in the heart’s response to 
catecholamines, as shown in the isolated heart studies.  
 
When isoprenaline was administered, it was given intraperitoneally, and the 
bioavailability of intraperitoneal isoprenaline, especially at these high doses, is 
unknown. At the lowest dose (50mg.kg-1) it did appear to saturate the system in 
some way as higher doses had little additional effect. Nevertheless, this does make 
ex vivo and in vitro simulations of the in vivo model very difficult to be valid. Similarly, 
the use of adrenaline in the isolated heart was not matched to the pharmacokinetics 
of its in vivo metabolism, but rather kept as a constant infusion throughout the 
protocol. After the initial bolus of adrenaline and subsequent hypertension and then 
hypotension (Paur et al., 2012), the endogenous release of catecholamines and 
acetylcholine is unknown. However, this model still stands true as a test-bed for the 
effects of constant catecholamine activity, as would occur during a time of high 
emotional stress.  
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7.8 Future work 
 
Firstly, I would like to understand the concentration of isoprenaline at the level of the 
heart after a 50mg.kg-1 intraperitoneal injection, and how this changes both over 
temporally, and with regard to body temperature. This would allow for more accurate 
modelling of the disease in both ex vivo and in vitro set-ups. Monitoring the 
haemodynamics throughout the experiment would also give critical information about 
the role of this important parameter on the development of cardiac dysfunction, and 
would need to be carried out using an implantable telemetry device. I would also like 
to assess the role of hyperthermia alone on cardiac function, as currently it was not 
possible to induce the level of hyperthermia observed without catecholamine 
injection. Increased levels of external heating may be able to bring the rat’s body 
temperature to 41oC, and if so, would rule out hyperthermia being sufficient to induce 
TTS. 
 
As male and female hearts showed similar levels of mitochondrial dysfunction in 
response to adrenaline ex vivo, and yet they showed very different mortality rates in 
response to adrenaline in vivo, testing hearts from ovariectomised animals would 
give further information about the role, or lack thereof, of mitochondrial dysfunction in 
the gender differences in acute adrenaline-mediated mortality seen in that TTS 
model.  
 
Finally, as TTS is a disease not of hours, but of days and weeks, I aim to induce and 
confirm TTS in rats, using the isoprenaline model, and to follow these rats for 14 
days post-isoprenaline with a number of potential therapeutic agents. Few studies 
have done this before, and as the isoprenaline TTS model perhaps mimics human 
TTS very closely with regard to its timeframe, it would be suitable to assess the 
different possible treatments, such as levosimendan.   
 
7.9 Final conclusion 
 
Takotsubo syndrome is a disease characterised by apical dysfunction with basal 
sparing that precipitates after a period of intense emotional stress. This disease has 
been modelled in a number of species, although the majority have been in rats. Here 
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I present experiments where two models of Takotsubo syndrome were further 
developed, and potential influences on the induction and severity of the disease 
were tested. It was found that an absence of estrogen worsened mortality after 
adrenaline bolus, and replacement of estrogen in ovariectomised rats, but not male 
rats, reduced mortality. In a separate Takotsubo syndrome model using isoprenaline 
as the induction agent, rather than adrenaline, hyperthermia was found to be 
essential in the induction of the apical dysfunction, which was facilitated by 
anaesthesia with ketamine-midazolam. Modelling catecholamine stress in the 
isolated heart, high concentration adrenaline infusion prolongs the action potential, 
even when the heart rate is increased, and can also induce mitochondrial 
dysfunction. Mitochondrial dysfunction in response to adrenaline observed ex vivo 
was potentiated by hyperthermia, potentially indicating a metabolic dysfunction that 
could occur in vivo in the isoprenaline-hyperthermia TTS model. Further work is 
needed to confirm the causative relationships, and could shed light on the currently-
unknown aetiology of this syndrome.   
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Figure 5.9 with error bars included 
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Matlab code to analyse voltage and calcium signals (written by Dr Jennifer 
Simonotto) 
 
%% 
clear all 
close all 
[pname ] = uigetdir('Select folder to process...' ); 
%[pname1 ] = uigetdir('Select folder to save figs to...' ); 
pname1=pname; 
cd(pname) 
d = dir('data*.da') 
%% 
%for  
    %jj = 1:size(d,1) 
jj=2 
time_scale = 130; 
clear CDarkframe VDarkFrame CData VData CDatamean VDatamean CData_demean 
VData_demean Datamask... 
    DummyData Data VData_spavg CData_spavg Datamask_spavg tmrm_spavg 
volt_spavg tweaked_volt ... 
    goodlocs1 goodpks1 goodlocs goodpks pks locs testbefore testafter 
numgoodpks numgoodpks1 ... 
    peaktopeak firstgood heartrate meanpeaktopeak 
fname = d(jj,1).name 
fid = fopen( [ pname,'/', fname ], 'r' ); 
[ Header, count ] = fread( fid, 2560, 'int16' ); 
fname 
Frames = Header( 5 ); 
Columns  = Header( 385 ); 
Rows     = Header( 386 ); 
FrameInterval = Header( 389 ) / 1000.0; 
FramesUsed = floor(Frames); 
SamplingRate=1000/FrameInterval; 
%FramesUsed = input('Enter number of frames you would like to use: '); 
%FrameStart = input('Enter start frame number: '); 
  
DummyData = zeros( Rows*Columns,1 ); 
Data   = zeros( Columns,Rows ); 
VData  = zeros( Rows,Columns/2,FramesUsed); 
CData  = zeros( Rows,Columns/2,FramesUsed); 
  
%% 
%h = waitbar(0,'Reading in data...'); 
%switch back C and V for real camera names!!!!!!!!!!! 
tic 
for k = 1:FramesUsed 
     
    %    waitbar(k/FramesUsed,h) 
    DummyData = fread( fid, Rows*Columns, 'int16' ); 
    Data(:,:) = reshape(DummyData,Columns,Rows); 
    CData(:,:,k) = Data(81:160,:)'; 
    VData(:,:,k) = Data(1:80,:)'; 
end 
  
fclose( fid ); 
%close(h) 
toc 
%% 
tic 
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clear DummyData Data 
  
CDarkframe = squeeze(mean(CData(:,:,3:4),3)); 
VDarkframe = squeeze(mean(VData(:,:,3:4),3)); 
CData =gsubtract(CData,CDarkframe); 
VData = gsubtract(VData,VDarkframe); 
CDatamean=squeeze(mean(CData,3)); 
VDatamean=squeeze(mean(VData,3)); 
CData_demean = gsubtract(CData, CDatamean); 
VData_demean = gsubtract(VData, VDatamean); 
CData = CData(:,:,100:Frames); 
VData = VData(:,:,100:Frames); 
  
plotfig = squeeze(std(CData_demean,[],3)); 
%% 
% roi analysis 
roiplot = 
gdivide(gsubtract(squeeze(CData(:,:,2000)),min(min(squeeze(CData(:,:,25)),[
],2),[],1)),(max(max(squeeze(CData(:,:,2000)),[],2),[],1)-
min(min(squeeze(CData(:,:,2000)),[],1),[],1))); 
figure 
subplot(5,2,[1,3]) 
imagesc(VDatamean);axis equal;axis([1 80 1 128]);colorbar;colormap 
gray;axis xy 
hold on 
title('Voltage Camera image') 
subplot(5,2,[2,4]) 
hold on 
count = 1 
[ROItemp,a,b] = roipoly(flipud(roiplot)); 
ROI_mask{1,count} = mat2cell(ROItemp,[128],[80]); 
xroi{1,count} = mat2cell(a,[length(a)],[1]); 
yroi{1,count} = mat2cell(b,[length(b)],[1]); 
imtemp = imoverlay(flipud(roiplot),cell2mat(ROI_mask{1,count}),[0 1 0]) 
imagesc(imtemp);axis on;axis equal;axis([1 80 1 128]);colorbar;colormap 
gray;axis xy 
  
reply = input('Add new ROI? (y/n) [n]: ','s'); 
  
if isempty(reply) 
    reply = 'n'; 
end 
while reply =='y' 
    count = count+1 
    [ROItemp,a,b] = roipoly(imtemp); 
    ROI_mask{1,count} = mat2cell(ROItemp,[128],[80]); 
    imtemp = imoverlay(imtemp,cell2mat(ROI_mask{1,count}),[0 1 0]) 
    imagesc(imtemp);axis equal;axis([1 80 1 128]);colorbar;colormap 
gray;axis ij; 
    reply = input('Add new ROI? (y/n) [n]: ','s'); 
     
end 
  
for i = 1:count 
    [testx, testy] = find(cell2mat(ROI_mask{1,i})>0); 
     
    for j = 1:length(testx) 
        datatemp1(j,:) = squeeze(VData(testx(j),testy(j),:)); 
        datatemp2(j,:) = squeeze(CData(testx(j),testy(j),:)); 
    end 
    roi_analysis.xdata{1,i} = mat2cell(testx,[length(testx)],[1]); 
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    roi_analysis.ydata{1,i} = mat2cell(testy,[length(testy)],[1]); 
    roi_analysis.data_roi_extract_v{1,i} = 
mat2cell(datatemp1,[size(datatemp1,1)],[size(datatemp1,2)]); 
    roi_analysis.data_roi_extract_c{1,i} = 
mat2cell(datatemp2,[size(datatemp2,1)],[size(datatemp2,2)]); 
     
    roi_analysis.stats_roi_v_mean(i,:) = mean(datatemp1(:,1:end),1); 
    roi_analysis.stats_roi_v_std(i,:) = std(datatemp1(:,1:end),[],1); 
    roi_analysis.stats_roi_c_mean(i,:) = mean(datatemp2(:,1:end),1); 
    roi_analysis.stats_roi_c_std(i,:) = std(datatemp2(:,1:end),[],1); 
end 
hold on 
title('Voltage Camera image') 
hold on 
colorswitch = ['r','b','g','c','m','k','r','g','b','c','m','k']; 
%% 
%Voltage Analysis 
subplot(5,1,4) 
hold off 
clear v_lowestpoint v_risestart v_risestarttemp v_relaxationtime 
v_risetopeak v_transientduration v_t50 v_t75 v_t80 v_t90 v_goodpks 
v_goodlocs 
for j = 1:count 
%things to change 
noise_var = 0.8; 
    tic 
    y = min(squeeze(roi_analysis.stats_roi_v_mean(j,1:end)))-
squeeze(roi_analysis.stats_roi_v_mean(j,1:end)); 
    p = polyfit(1:length(y),y,3); 
    z1 = polyval(p,1:length(y)); 
    z = smooth(y-z1); 
    %volt_sig(j,:)=-detrend(smooth(z-squeeze(calcium_sig(j,:))',3)); 
        volt_sig(j,:)=-detrend(detrend(smooth(z,3))); 
plot(volt_sig(j,:),colorswitch(j));axis tight 
hold on 
end 
%% 
  
j=1 
   
plot((median(volt_sig(j,:))+noise_var*std(volt_sig(j,:)))*ones(1,length(vol
t_sig(j,:))),'k--') 
    [pks,locs]= 
findpeaks(volt_sig(j,:),'MINPEAKHEIGHT',(median(volt_sig(j,:))+noise_var*st
d(volt_sig(j,:))),'MINPEAKDISTANCE',time_scale); 
    testbefore = squeeze(locs>time_scale); 
    testafter = squeeze(locs+100+time_scale<FramesUsed); 
    v_goodlocs(j,:) = locs(testbefore.*testafter>0)'; 
    v_goodpks(j,:) =  pks(testbefore.*testafter>0)'; 
    v_numgoodpks(j,:) = length(v_goodpks(j,:)); 
    plot(v_goodlocs(j,:),v_goodpks(j,:),'rs') 
    v_peaktopeak(j,1:length(v_goodlocs)-1) = diff(v_goodlocs(j,:)); 
    j 
            [a,b] = 
findpeaks(diff(squeeze(volt_sig(j,:))),'MINPEAKDISTANCE',time_scale,'MINPEA
KHEIGHT',(mean(diff(squeeze(volt_sig(j,:))))+1*std(diff(squeeze(volt_sig(j,
:)))))); 
            testbefore1 = ((v_goodlocs(1)-b)<25); 
            %testbefore1 = b>time_scale; 
            testafter1 = b+100+time_scale<FramesUsed; 
            dvdtmaxloc(j,:) = b(testbefore1.*testafter1>0); 
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plot(squeeze(dvdtmaxloc(j,:)),squeeze(volt_sig(j,squeeze(dvdtmaxloc(j,:))))
,'ks') 
%             test = diff(squeeze(volt_sig(j,:))); 
%             diff_detect = 
3+find(test(3:end)>=1*std(diff(squeeze(volt_sig(j,:)))))+1; 
%             diff_detectlocs = diff_detect(find(diff(diff_detect)>1)); 
%             diff_detectpks = squeeze(volt_sig(j,diff_detectlocs)); 
%              
%             %diff_detect_lowlocs(1) = diff_detect(1)-1; 
%             diff_detect_lowlocs = [diff_detect(1)-
4;(diff_detect(find(diff(diff_detect)>1)+1)-4)']; 
%             diff_detect_lowvals = 
squeeze(volt_sig(j,diff_detect_lowlocs)); 
   v_risestart(j,:) = dvdtmaxloc(j,:); 
  
            for k = 1:length(v_goodlocs) 
                %goodlocs1(j) = diff_detectlocs(j); 
                %goodpks1(j) = diff_detectpks(j); 
                v_lowestpoint(j,k) = v_goodlocs(j,k) + 
find(volt_sig(j,v_goodlocs(j,k):v_goodlocs(j,k)+100)<=min(volt_sig(j,v_good
locs(j,k):v_goodlocs(j,k)+100))); 
            end 
%  
% for k = 1:length(v_goodlocs) 
%     v_lowestpoint(j,k) = v_goodlocs(j,k) + 
find(volt_sig(j,v_goodlocs(j,k):v_goodlocs(j,k)+time_scale)<=min(volt_sig(j
,v_goodlocs(j,k):v_goodlocs(j,k)+time_scale))); 
%     v_risestart(j,k) = v_goodlocs(j,k)-time_scale 
+max(find(volt_sig(j,v_goodlocs(j,k)-
time_scale:v_goodlocs(j,k))<=min(volt_sig(j,v_goodlocs(j,k)-
time_scale:v_goodlocs(j,k)))))-3; 
% end 
plot(squeeze(v_lowestpoint(j,:)),volt_sig(j,squeeze(v_lowestpoint(j,:))),'r
*') 
plot(squeeze(v_risestart(j,:))',volt_sig(j,squeeze(v_risestart(j,:))')','c*
') 
v_relaxationtime(j,:) = squeeze(v_lowestpoint(j,:))-
squeeze(v_goodlocs(j,:)); 
v_risetopeak(j,:) = squeeze(v_goodlocs(j,:))-squeeze(v_risestart(j,:)); 
v_transientduration(j,:) = squeeze(v_lowestpoint(j,:))'-
squeeze(v_risestart(j,:))'; 
  
v_valt25(j,:) = 0.75*(v_goodpks(j,:)-
volt_sig(j,v_lowestpoint(j,:)))+volt_sig(j,v_lowestpoint(j,:)); 
v_valt50(j,:) = 0.5*(v_goodpks(j,:)-
volt_sig(j,v_lowestpoint(j,:)))+volt_sig(j,v_lowestpoint(j,:)); 
v_valt75(j,:) = 0.25*(v_goodpks(j,:)-
volt_sig(j,v_lowestpoint(j,:)))+volt_sig(j,v_lowestpoint(j,:)); 
v_valt80(j,:) = 0.20*(v_goodpks(j,:)-
volt_sig(j,v_lowestpoint(j,:)))+volt_sig(j,v_lowestpoint(j,:)); 
v_valt90(j,:) = 0.10*(v_goodpks(j,:)-
volt_sig(j,v_lowestpoint(j,:)))+volt_sig(j,v_lowestpoint(j,:)); 
  
for k = 1:length(v_goodpks) 
    v_t25(j,k) = 
v_goodlocs(j,k)+max(find(volt_sig(j,v_goodlocs(j,k):v_lowestpoint(j,k))>v_v
alt25(j,k))); 
    v_t50(j,k) = 
v_goodlocs(j,k)+max(find(volt_sig(j,v_goodlocs(j,k):v_lowestpoint(j,k))>v_v
alt50(j,k))); 
    v_t75(j,k) = 
v_goodlocs(j,k)+max(find(volt_sig(j,v_goodlocs(j,k):v_lowestpoint(j,k))>v_v
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alt75(j,k))); 
    v_t80(j,k) = 
v_goodlocs(j,k)+max(find(volt_sig(j,v_goodlocs(j,k):v_lowestpoint(j,k))>v_v
alt80(j,k))); 
    v_t90(j,k) = 
v_goodlocs(j,k)+max(find(volt_sig(j,v_goodlocs(j,k):v_lowestpoint(j,k))>v_v
alt90(j,k))); 
end 
plot(v_t25(j,:),v_valt25(j,:)','go') 
plot(v_t50(j,:),v_valt50(j,:)','ko') 
plot(v_t75(j,:),v_valt75(j,:)','mo') 
plot(v_t80(j,:),v_valt80(j,:)','bo') 
plot(v_t90(j,:),v_valt90(j,:)','co') 
  
for j = 2:count 
%end 
  
%end 
%%% 
%hold on 
    
plot((median(volt_sig(j,:))+noise_var*std(volt_sig(j,:)))*ones(1,length(vol
t_sig(j,:))),'k--') 
    [pks,locs]= 
findpeaks(volt_sig(j,:),'MINPEAKHEIGHT',(median(volt_sig(j,:))+noise_var*st
d(volt_sig(j,:))),'MINPEAKDISTANCE',time_scale); 
    testbefore = squeeze(locs>time_scale); 
    testafter = squeeze(locs+100+time_scale<FramesUsed); 
    v_goodlocs(j,:) = locs(testbefore.*testafter>0)'; 
    v_goodpks(j,:) =  pks(testbefore.*testafter>0)'; 
    v_numgoodpks(j,:) = length(v_goodpks(j,:)); 
    plot(v_goodlocs(j,:),v_goodpks(j,:),'rs') 
    v_peaktopeak(j,1:length(v_goodlocs)-1) = diff(v_goodlocs(j,:)); 
    j 
            [a,b] = 
findpeaks(diff(squeeze(volt_sig(j,1:v_goodlocs(j,end)))),'MINPEAKDISTANCE',
time_scale,'MINPEAKHEIGHT',(mean(diff(squeeze(volt_sig(j,:))))+.75*std(diff
(squeeze(volt_sig(j,:)))))); 
            testbefore1 = (squeeze(v_goodlocs(j,1))-
b)<40;%squeeze(b>time_scale); 
            testafter1 = b<max(squeeze(v_goodlocs(j,:))); 
            dvdtmaxloc(j,1:end) = b(testbefore1.*testafter1>0); 
            
plot(squeeze(dvdtmaxloc(j,:)),squeeze(volt_sig(j,squeeze(dvdtmaxloc(j,:))))
,'ks') 
%             test = diff(squeeze(volt_sig(j,:))); 
%             diff_detect = 
3+find(test(3:end)>=1*std(diff(squeeze(volt_sig(j,:)))))+1; 
%             diff_detectlocs = diff_detect(find(diff(diff_detect)>1)); 
%             diff_detectpks = squeeze(volt_sig(j,diff_detectlocs)); 
%              
%             %diff_detect_lowlocs(1) = diff_detect(1)-1; 
%             diff_detect_lowlocs = [diff_detect(1)-
4;(diff_detect(find(diff(diff_detect)>1)+1)-4)']; 
%             diff_detect_lowvals = 
squeeze(volt_sig(j,diff_detect_lowlocs)); 
   v_risestart(j,:) = dvdtmaxloc(j,:); 
  
            for k = 1:length(v_goodlocs) 
                %goodlocs1(j) = diff_detectlocs(j); 
                %goodpks1(j) = diff_detectpks(j); 
                v_lowestpoint(j,k) = v_goodlocs(j,k) + 
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find(volt_sig(j,v_goodlocs(j,k):v_goodlocs(j,k)+100)<=min(volt_sig(j,v_good
locs(j,k):v_goodlocs(j,k)+100))); 
            end 
%  
% for k = 1:length(v_goodlocs) 
%     v_lowestpoint(j,k) = v_goodlocs(j,k) + 
find(volt_sig(j,v_goodlocs(j,k):v_goodlocs(j,k)+time_scale)<=min(volt_sig(j
,v_goodlocs(j,k):v_goodlocs(j,k)+time_scale))); 
%     v_risestart(j,k) = v_goodlocs(j,k)-time_scale 
+max(find(volt_sig(j,v_goodlocs(j,k)-
time_scale:v_goodlocs(j,k))<=min(volt_sig(j,v_goodlocs(j,k)-
time_scale:v_goodlocs(j,k)))))-3; 
% end 
plot(squeeze(v_lowestpoint(j,:)),volt_sig(j,squeeze(v_lowestpoint(j,:))),'r
*') 
plot(squeeze(v_risestart(j,:))',volt_sig(j,squeeze(v_risestart(j,:))')','c*
') 
v_relaxationtime(j,:) = squeeze(v_lowestpoint(j,:))-
squeeze(v_goodlocs(j,:)); 
v_risetopeak(j,:) = squeeze(v_goodlocs(j,:))-squeeze(v_risestart(j,:)); 
v_transientduration(j,:) = squeeze(v_lowestpoint(j,:))'-
squeeze(v_risestart(j,:))'; 
  
v_valt25(j,:) = 0.75*(v_goodpks(j,:)-
volt_sig(j,v_lowestpoint(j,:)))+volt_sig(j,v_lowestpoint(j,:)); 
v_valt50(j,:) = 0.5*(v_goodpks(j,:)-
volt_sig(j,v_lowestpoint(j,:)))+volt_sig(j,v_lowestpoint(j,:)); 
v_valt75(j,:) = 0.25*(v_goodpks(j,:)-
volt_sig(j,v_lowestpoint(j,:)))+volt_sig(j,v_lowestpoint(j,:)); 
v_valt80(j,:) = 0.20*(v_goodpks(j,:)-
volt_sig(j,v_lowestpoint(j,:)))+volt_sig(j,v_lowestpoint(j,:)); 
v_valt90(j,:) = 0.10*(v_goodpks(j,:)-
volt_sig(j,v_lowestpoint(j,:)))+volt_sig(j,v_lowestpoint(j,:)); 
  
for k = 1:length(v_goodpks) 
    v_t25(j,k) = 
v_goodlocs(j,k)+max(find(volt_sig(j,v_goodlocs(j,k):v_lowestpoint(j,k))>v_v
alt25(j,k))); 
    v_t50(j,k) = 
v_goodlocs(j,k)+max(find(volt_sig(j,v_goodlocs(j,k):v_lowestpoint(j,k))>v_v
alt50(j,k))); 
    v_t75(j,k) = 
v_goodlocs(j,k)+max(find(volt_sig(j,v_goodlocs(j,k):v_lowestpoint(j,k))>v_v
alt75(j,k))); 
    v_t80(j,k) = 
v_goodlocs(j,k)+max(find(volt_sig(j,v_goodlocs(j,k):v_lowestpoint(j,k))>v_v
alt80(j,k))); 
    v_t90(j,k) = 
v_goodlocs(j,k)+max(find(volt_sig(j,v_goodlocs(j,k):v_lowestpoint(j,k))>v_v
alt90(j,k))); 
end 
plot(v_t25(j,:),v_valt25(j,:)','go') 
plot(v_t50(j,:),v_valt50(j,:)','ko') 
plot(v_t75(j,:),v_valt75(j,:)','mo') 
plot(v_t80(j,:),v_valt80(j,:)','bo') 
plot(v_t90(j,:),v_valt90(j,:)','co') 
end 
  
%% 
% subplot(5,1,5) 
% hold off 
% plot(-v_goodlocs+c_goodlocs,'ko') 
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% hold on 
% errorbar(mean((-v_goodlocs+c_goodlocs),2),std((-
v_goodlocs+c_goodlocs),[],2),'ro') 
%  
% title ('Mean and Standard Deviation for Calcium-Voltage peak start 
differences, base to apex') 
% %legend('1','2','3','4','5','6') 
  
% 
% figure 
% for j = 1:numgoodpks 
%     datafitrise = z(risestart(j):goodlocs(j)); 
%     datafitfall = z(goodlocs(j):lowestpoint(j)); 
%     fitrise = fit((risestart(j):goodlocs(j))',datafitrise,'poly2') 
%     p1_fitrise(j) = fitrise.p1; 
%     p2_fitrise(j) = fitrise.p2; 
%     p3_fitrise(j) = fitrise.p3; 
%     plot((risestart(j):goodlocs(j))',datafitrise) 
%     hold on 
%     plot(fitrise,'k') 
%     fitfall = fit((goodlocs(j):lowestpoint(j))',datafitfall,'poly2') 
%     p1_fitfall(j) = fitfall.p1; 
%     p2_fitfall(j) = fitfall.p2; 
%     p3_fitfall(j) = fitfall.p3; 
%     plot((goodlocs(j):lowestpoint(j))',datafitfall,'r') 
%     plot(fitfall,'c') 
%     hold off 
%    pause 
% end 
  
  
%  
% m_c_25 = mean(c_t25-c_goodlocs,2)' 
% m_c_50 = mean(c_t50-c_goodlocs,2)' 
% m_c_75 = mean(c_t75-c_goodlocs,2)' 
% m_c_80 = mean(c_t80-c_goodlocs,2)' 
% m_c_90 = mean(c_t90-c_goodlocs,2)' 
% m_c_td = mean(c_transientduration,2)' 
% m_c_rt = mean(c_relaxationtime,2)' 
% m_c_rp = mean(c_risetopeak,2)' 
%  
% s_c_25 = std(c_t25-c_goodlocs,[],2)' 
% s_c_50 = std(c_t50-c_goodlocs,[],2)' 
% s_c_75 = std(c_t75-c_goodlocs,[],2)' 
% s_c_80 = std(c_t80-c_goodlocs,[],2)' 
% s_c_90 = std(c_t90-c_goodlocs,[],2)' 
% s_c_td = std(c_transientduration,[],2)' 
% s_c_rt = std(c_relaxationtime,[],2)' 
% s_c_rp = std(c_risetopeak,[],2)' 
%  
% c_bigmatrix = 
[m_c_25;s_c_25;m_c_50;s_c_50;m_c_75;s_c_75;m_c_80;s_c_80;m_c_90;s_c_90;m_c_
td;s_c_td;m_c_rt;s_c_rt;m_c_rp;s_c_rp;]; 
% save('c_bigmatrix.txt','-ascii','-tabs','c_bigmatrix') 
  
  
  
m_v_25 = mean(v_t25-v_goodlocs,2)' 
m_v_50 = mean(v_t50-v_goodlocs,2)' 
m_v_75 = mean(v_t75-v_goodlocs,2)' 
m_v_80 = mean(v_t80-v_goodlocs,2)' 
m_v_90 = mean(v_t90-v_goodlocs,2)' 
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m_v_td = mean(v_transientduration,2)' 
m_v_rt = mean(v_relaxationtime,2)' 
m_v_rp = mean(v_risetopeak,2)' 
  
s_v_25 = std(v_t25-v_goodlocs,[],2)'; 
s_v_50 = std(v_t50-v_goodlocs,[],2)'; 
s_v_75 = std(v_t75-v_goodlocs,[],2)'; 
s_v_80 = std(v_t80-v_goodlocs,[],2)'; 
s_v_90 = std(v_t90-v_goodlocs,[],2)'; 
s_v_td = std(v_transientduration,[],2)'; 
s_v_rt = std(v_relaxationtime,[],2)'; 
s_v_rp = std(v_risetopeak,[],2)'; 
  
v_bigmatrix = [m_v_25;m_v_50;m_v_75;m_v_80;m_v_90;m_v_td;m_v_rt;m_v_rp;]; 
save('v_bigmatrix.txt','-ascii','-tabs','v_bigmatrix') 
%filename1 = ['workspace_',fname(1:end-4),'_vals.mat'] 
%save(filename1) 
% delay_matrix = [mean((-v_goodlocs+c_goodlocs),2)';std((-
v_goodlocs+c_goodlocs),[],2)'] 
% save('delay_matrix.txt','-ascii','-tabs','delay_matrix') 
% figure 
% 
boxplot([realt50,realt75,realt80,realt90,real_transientduration,real_relaxa
tiontime,real_risetopeak,real_peakvals]) 
% figure 
% boxplot([deltaf]) 
%end 
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Matlab code to analyse TMRM signals (written by Dr Jennifer Simonotto) 
 
clear all 
close all 
clc 
[pname ] = uigetdir('Select folder to process...' ); 
%[pname1 ] = uigetdir('Select folder to save figs to...' ); 
pname1 = pname 
cd(pname) 
d = dir('data*.da') 
for j = 1:size(d,1) 
tic 
fname = d(j,1).name 
fid = fopen( [ pname,'/', fname ], 'r' ); 
[ Header, count ] = fread( fid, 2560, 'int16' ); 
  
Frames = Header( 5 ); 
Columns  = Header( 385 ); 
Rows     = Header( 386 ); 
FrameInterval = Header( 389 ) / 1000.0;  
FramesUsed = floor(Frames); 
SamplingRate=1000/FrameInterval; 
  
DummyData = zeros( Frames*Rows*Columns,1 ); 
Data_temp   = zeros( Frames,Columns*Rows ); 
Data =      zeros(Rows,Columns, Frames); 
VData  = zeros( Rows,Columns/2,FramesUsed); 
CData  = zeros( Rows,Columns/2,FramesUsed); 
dat_tmrm_change = zeros(Rows,Columns/2,size(d,1)); 
%% 
DummyData = fread( fid, Rows*Columns*Frames, 'int16' ); 
Data_temp = reshape(DummyData,Frames,Columns*Rows); 
BNC_Data=reshape(fread(fid,8*Frames,'int16'),Frames,8); 
DarkFrame=reshape(fread(fid,Rows*Columns,'int16'),Columns,Rows)'; 
tic 
%h = waitbar(0,'Reading in data...');  
for k = 1:FramesUsed 
%    waitbar(j/FramesUsed,h) 
    Data(:,:,k) = reshape(squeeze(Data_temp(k,:)),Columns, Rows)'-
DarkFrame; 
    VData(:,:,k) = Data(:,Columns/2+1:Columns,k); 
    CData(:,:,k) = Data(:,1:Columns/2,k);     
end 
  
fclose( fid ); 
%close(h) 
toc 
%% 
clear DummyData Data 
  
CDatamean=squeeze(mean(CData,3)); 
VDatamean=squeeze(mean(VData,3)); 
CData_demean = gsubtract(CData, CDatamean); 
VData_demean = gsubtract(VData, VDatamean); 
plotfig = squeeze(std(CData_demean,[],3)); 
Datamask = squeeze(std(CData,[],3)); 
  
  
%% 
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%  
% subplot(3,1,[1,2]) 
% imagesc(squeeze(CData(:,:,Frames-100)));axis equal;axis([1 80 1 
128]);colorbar;colormap gray;axis xy 
% title('Left Camera image') 
% subplot(3,1,3) 
% plot(squeeze(VData(80,:,:))') 
% title('Left camera image, time series of pixels in row 80') 
  
k = 100; 
  
TMRM_CData_mean(:,:,j) = mean(CData(:,:,Frames-k:end),3); 
  
TMRM_CData_start(:,:,j) = CData(:,:,Frames-k); 
%% 
% figure 
% subplot(3,2,[1,3]) 
% 
imagesc(gdivide(gsubtract(squeeze(CData(:,:,200)),min(min(squeeze(CData(:,:
,25)),[],2),[],1)),(max(max(squeeze(CData(:,:,200)),[],2),[],1)-
min(min(squeeze(CData(:,:,200)),[],1),[],1))));axis equal;axis([1 80 1 
128]);colorbar;colormap gray;axis xy 
% title('TMRM Camera signal') 
% subplot(3,2,[2,4]) 
% contourf(log(max(CData,[],3)-min(CData(:,:,250:300),[],3)));axis 
equal;axis xy;axis tight;colorbar 
% title([string(['\',pname(45:end-1)]),' ',fname]) 
% subplot(3,2,[5,6]) 
% hist(reshape(CData,1,[]),100);axis tight 
% saveas(gcf,[pname1,'/',fname(1:end-3),'_tmrm_decay.fig']) 
 dat_tmrm_change(:,:,j) = max(CData,[],3)-min(CData(:,:,250:300),[],3); 
toc 
end 
  
save workspace_tmrm_readin_rapidacquire 
 
%%% 
  
  
plat = (length(TMRM_CData_mean)-185); 
  
bplat = plat-1; 
  
for j = 2:length(d) 
dat_tmrm_change(:,:,j) = squeeze(TMRM_CData_mean(:,:,j))-
squeeze(TMRM_CData_mean(:,:,plat)); 
                                                                                
dat_tmrm_change_diff(:,:,j) = dat_tmrm_change(:,:,j)-dat_tmrm_change(:,:,j-
1); 
end 
  
  
 
%% 
% normalization from baseline values 
  
Datamask_tmrm = squeeze(TMRM_CData_mean(:,:,plat))>300;   %baseline image 
for datamask: use end of washout 
%dat_tmrm_change_diff_sum_ADR = 
cumsum(dat_tmrm_change_diff(:,:,170:290),3); 
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%timeline = [0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15]*2.67; 
index = plat:5:(plat+185); 
%       start:intervals:end 
  
for j = 1:39 
    mean_TMRM(j) = 
~isnan(nansum(nansum(Datamask_tmrm.*(squeeze(TMRM_CData_mean(:,:,j+bplat)).
/squeeze(TMRM_CData_mean(:,:,plat)))))./nansum(sum(Datamask_tmrm))); 
                                                                                     
%one file before baseline  
                                                                                 
end 
  
mask_sum = sum(sum(Datamask_tmrm)); 
  
for j = plat:(plat+185) 
alldata = 
sort(reshape(squeeze(Datamask_tmrm.*(squeeze(TMRM_CData_mean(:,:,j))-
squeeze(TMRM_CData_mean(:,:,3)))./(squeeze(TMRM_CData_mean(:,:,plat))-
squeeze(TMRM_CData_mean(:,:,3)))),1,[]),'ascend'); 
alldata_nonans(1:length(alldata(~isnan(alldata))),j) = 
alldata(~isnan(alldata)); 
alldata_nozeros(1:mask_sum,j) = squeeze(alldata_nonans((end-
mask_sum+1):end,j)); 
range_good = max(nanstd(alldata_nozeros(:,j),[],1))*3; 
range_dat(j) = nanstd(alldata_nozeros(:,j),[],1); 
median_dat(j) = nanmedian(alldata_nozeros(:,j)); 
%alldata_nozeros(1:mask_sum,j) = 
squeeze(alldata(squeeze(nozeros(1:mask_sum,j)),j)); 
max_F(j) = max(squeeze(alldata_nozeros(:,j))); 
range_F(j) = range(squeeze(alldata_nozeros(:,j))); 
min_F(j) = min(squeeze(alldata_nozeros(:,j))); 
ANF(j) = nansum(squeeze(alldata_nonans(:,j)))/mask_sum; 
pm_F(j) = ((max_F(j)-ANF(j))+(ANF(j)-min_F(j)))/2; 
end 
  
cd (pname) 
%% 
figure(1) 
for j = 1:39 
subplot(7,4,j) 
imagesc(Datamask_tmrm.*(squeeze(TMRM_CData_mean(:,:,index(j)))-
squeeze(TMRM_CData_mean(:,:,3)))./(squeeze(TMRM_CData_mean(:,:,plat))-
squeeze(TMRM_CData_mean(:,:,3))),[0.65,1.2]);colorbar;axis xy;axis 
equal;axis([1 80 1 128]);axis off;colormap jet; 
title(['file no: ', num2str(index(j)), ' ANF: 
',num2str(ANF(index(j))),setstr(177),num2str(pm_F(index(j)))]) 
end 
  
saveas (1,'wholeheart') 
%% 
  
figure(2) 
for j = 1:39 
subplot(7,4,j) 
hist(squeeze(alldata_nozeros(:,index(j))),(median_dat(index(j))-
range_good):.05:(median_dat(index(j))+range_good));xlim ([0 
(median_dat(index(j))+range_good)]); 
title(['file no: ', num2str(index(j)),'median value 
',num2str(median_dat(index(j)))]) 
end 
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%% 
  
saveas (2,'histo2') 
  
figure(3) 
subplot(2,1,1) 
boxplot(alldata_nozeros(:,plat:end),'plotstyle','compact','sym','w'); 
ylim([0 1.5]) 
title('Median and box and whiskers plot of data with baseline 
normalization') 
  
saveas (3,'boxwhisk') 
  
xlswrite('TMRM_median_decay_output_base2.xls',median_dat') 
 
